{"PMC7299136": [["Introduction\u2018Diabetes is a metabolic disease characterised by hyperglycemia resulting from defects in insulin secretion, insulin action or both\u2019 [1].", [["Diabetes", "DISEASE", 13, 21], ["metabolic disease", "DISEASE", 27, 44], ["hyperglycemia", "DISEASE", 62, 75], ["insulin", "GENE_OR_GENE_PRODUCT", 102, 109], ["insulin", "GENE_OR_GENE_PRODUCT", 121, 128], ["Diabetes", "PROBLEM", 13, 21], ["a metabolic disease", "PROBLEM", 25, 44], ["hyperglycemia", "PROBLEM", 62, 75], ["defects in insulin secretion", "PROBLEM", 91, 119], ["insulin action", "TREATMENT", 121, 135], ["hyperglycemia", "OBSERVATION", 62, 75]]], ["With rising pervasiveness globally, diabetes is conceded as a major chronic pandemic disease which does not consider any ethnic background and monetary levels both in developing and developed economies and has also been designated with the status of \u2018public health priority\u2019 in the majority of the countries [2, 3].", [["diabetes", "DISEASE", 36, 44], ["diabetes", "PROBLEM", 36, 44], ["a major chronic pandemic disease", "PROBLEM", 60, 92], ["monetary levels", "PROBLEM", 143, 158], ["rising", "OBSERVATION_MODIFIER", 5, 11], ["pervasiveness", "OBSERVATION", 12, 25], ["diabetes", "OBSERVATION", 36, 44], ["major", "OBSERVATION_MODIFIER", 62, 67], ["chronic", "OBSERVATION_MODIFIER", 68, 75], ["pandemic", "OBSERVATION", 76, 84]]], ["Individuals with diabetes are more susceptible to develop any of the associated complications, viz. macrovascular or microvascular.", [["macrovascular", "ANATOMY", 100, 113], ["microvascular", "ANATOMY", 117, 130], ["diabetes", "DISEASE", 17, 25], ["macrovascular", "DISEASE", 100, 113], ["microvascular", "MULTI-TISSUE_STRUCTURE", 117, 130], ["diabetes", "PROBLEM", 17, 25], ["the associated complications", "PROBLEM", 65, 93], ["diabetes", "OBSERVATION", 17, 25], ["complications", "OBSERVATION", 80, 93], ["microvascular", "ANATOMY", 117, 130]]], ["As a consequence, people experience frequent and exhaustive confrontation with the health care systems [4].", [["people", "ORGANISM", 18, 24], ["people", "SPECIES", 18, 24]]], ["The treatment cost for diabetes and its associated complications exert an enormous economic burden both at the household and national levels [5\u20139].IntroductionIn a developing nation like India, the majority of diabetes patients experience a substantial cost burden from out-of-pocket (OOP).", [["diabetes", "DISEASE", 23, 31], ["diabetes", "DISEASE", 210, 218], ["patients", "ORGANISM", 219, 227], ["patients", "SPECIES", 219, 227], ["The treatment cost", "TREATMENT", 0, 18], ["diabetes", "PROBLEM", 23, 31], ["its associated complications", "PROBLEM", 36, 64], ["an enormous economic burden", "PROBLEM", 71, 98], ["diabetes", "PROBLEM", 210, 218], ["a substantial cost burden", "PROBLEM", 239, 264], ["enormous", "OBSERVATION_MODIFIER", 74, 82], ["economic", "OBSERVATION_MODIFIER", 83, 91], ["burden", "OBSERVATION", 92, 98], ["substantial", "OBSERVATION_MODIFIER", 241, 252], ["cost", "OBSERVATION", 253, 257]]], ["Also, the dearth of insurance schemes and policies escalate the cost of diabetes care [2].", [["diabetes", "DISEASE", 72, 80], ["insurance schemes", "TREATMENT", 20, 37], ["diabetes care", "TREATMENT", 72, 85]]], ["Instantaneous urbanisation and socio-economic transitions, viz. rural to urban migration, low exercise regimen, lifestyle disorder, etc., have resulted in an escalation of diabetes prevalence in India over the last couple of decades [10\u201314].", [["lifestyle disorder", "DISEASE", 112, 130], ["diabetes", "DISEASE", 172, 180], ["Instantaneous urbanisation", "TREATMENT", 0, 26], ["socio-economic transitions", "TREATMENT", 31, 57], ["urban migration", "TREATMENT", 73, 88], ["low exercise regimen", "TREATMENT", 90, 110], ["lifestyle disorder", "PROBLEM", 112, 130], ["diabetes prevalence", "PROBLEM", 172, 191], ["socio-economic transitions", "OBSERVATION", 31, 57], ["urban migration", "OBSERVATION", 73, 88], ["diabetes", "OBSERVATION", 172, 180]]], ["According to the International Diabetes Federation [15], \u2018India is the epicentre of diabetes mellitus and it was found that in 2017 India had the second-largest populace of 73 million diabetic patients, after China.", [["Diabetes", "DISEASE", 31, 39], ["diabetes mellitus", "DISEASE", 84, 101], ["diabetic", "DISEASE", 184, 192], ["patients", "ORGANISM", 193, 201], ["patients", "SPECIES", 193, 201], ["diabetes mellitus", "PROBLEM", 84, 101], ["diabetes", "OBSERVATION", 84, 92], ["largest", "OBSERVATION_MODIFIER", 153, 160]]], ["Considering that fact, the epidemiologic transition of diabetes has a colossal economic burden [16].", [["diabetes", "DISEASE", 55, 63], ["diabetes", "PROBLEM", 55, 63], ["a colossal economic burden", "PROBLEM", 68, 94]]], ["The estimated country-level health care expenditure on diabetes mellitus in India after amending purchasing power difference was 31 billion US dollars in 2017, pushing India in fourth place globally after the USA, China and Germany.", [["diabetes mellitus", "DISEASE", 55, 72], ["diabetes mellitus", "PROBLEM", 55, 72]]], ["Looking at the economic burden, in India, diabetes alone exhausts 5 to 25% share of an average Indian household earning [17\u201319].IntroductionChronic nature and the rising epidemic of diabetes have everlasting consequences on the nation\u2019s economy and health status [20].", [["diabetes", "DISEASE", 42, 50], ["diabetes", "DISEASE", 182, 190], ["diabetes", "PROBLEM", 42, 50], ["diabetes", "PROBLEM", 182, 190], ["economic", "OBSERVATION_MODIFIER", 15, 23], ["burden", "OBSERVATION", 24, 30], ["Chronic", "OBSERVATION_MODIFIER", 140, 147]]], ["Therefore, managing diabetes and its comorbidities is a massive challenge in India due to several issues and stumbling blocks, viz. dearth of awareness regarding diabetes, its risk factors, prevention strategies, health care systems, poverty-stricken economy, non-adherence to medicines, etc. Altogether, these issues and problems remarkably contribute to the economic menace of diabetes in India [20\u201324].IntroductionAfter a perspicuous representation of the economic menace of diabetes in India, policymakers and health experts should provide healthier prospects to enhance the quality of life of millions [19].", [["diabetes", "DISEASE", 20, 28], ["diabetes", "DISEASE", 162, 170], ["diabetes", "DISEASE", 379, 387], ["diabetes", "DISEASE", 478, 486], ["managing diabetes", "PROBLEM", 11, 28], ["its comorbidities", "PROBLEM", 33, 50], ["a massive challenge", "TREATMENT", 54, 73], ["several issues", "PROBLEM", 90, 104], ["stumbling blocks", "PROBLEM", 109, 125], ["diabetes", "PROBLEM", 162, 170], ["medicines", "TREATMENT", 277, 286], ["diabetes", "PROBLEM", 379, 387], ["diabetes", "PROBLEM", 478, 486], ["massive", "OBSERVATION_MODIFIER", 56, 63], ["diabetes", "OBSERVATION", 379, 387], ["economic", "OBSERVATION_MODIFIER", 459, 467], ["menace", "OBSERVATION_MODIFIER", 468, 474], ["diabetes", "OBSERVATION", 478, 486]]], ["Thus, the present study aims at capturing the evidence from the literature on the cost of diabetes mellitus in India, reviewing the materials and methods used to estimate the costs and, lastly, exploring future research area.", [["diabetes mellitus", "DISEASE", 90, 107], ["the present study", "TEST", 6, 23], ["diabetes mellitus", "PROBLEM", 90, 107], ["methods", "TREATMENT", 146, 153]]], ["For the accomplishment of the objective, the paper has been divided into five sections.", [["sections", "ANATOMY", 78, 86]]], ["The \u2018Introduction\u2019 section of the study discusses diabetes and its economic burden.", [["diabetes", "DISEASE", 50, 58], ["the study", "TEST", 30, 39], ["diabetes", "PROBLEM", 50, 58], ["its economic burden", "PROBLEM", 63, 82]]], ["The \u2018Materials and methods\u2019 section deals with materials and methods applied for data extraction and quality assessment.", [["The \u2018Materials", "TREATMENT", 0, 14], ["methods\u2019 section", "TREATMENT", 19, 35], ["data extraction", "TEST", 81, 96], ["quality assessment", "TEST", 101, 119]]], ["The \u2018Results\u2019 section of the present study reports the results of the study.", [["the present study", "TEST", 25, 42], ["the study", "TEST", 66, 75]]], ["The \u2018Discussion\u2019 section concludes the discussion along with policy implications and limitations.Literature search ::: Materials and methodsAn extensive desk search was executed for all published articles and book chapters in relevant databases such as ACADEMIA, NCBI, PubMed, ProQuest, EBSCO, Springer, ResearchGate, Google Scholar, JSTOR and Scopus.", [["An extensive desk search", "PROBLEM", 140, 164], ["extensive", "OBSERVATION_MODIFIER", 143, 152]]], ["For better insight, a literature search was performed on the World Health Organization (WHO) and International Diabetes Federation (IDF) libraries available online.", [["a literature search", "TEST", 20, 39]]], ["\u2018India\u2019, \u2018Diabetes Mellitus or Diabetes\u2019, \u2018Economic Burden\u2019, \u2018Economic Menace\u2019, \u2018Costs of Diabetes\u2019, \u2018Health Care Utilization\u2019, \u2018Cost of Illness\u2019, \u2018Out-of-Pocket Expenditure\u2019, \u2018Diabetes Care\u2019, \u2018Health Economics\u2019, \u2018Direct/Indirect Costs\u2019, \u2018Cost Analysis\u2019, \u2018Hospitalization\u2019, \u2018Diabetic Complications\u2019, \u2018Developing Countries\u2019, \u2018Lifestyle Modification\u2019, \u2018Non-communicable diseases\u2019, \u2018Expenses by patients\u2019, \u2018Comorbidity Burden\u2019 and \u2018Treatment Costs\u2019 were utilised to attain expected results.", [["Diabetes Mellitus", "DISEASE", 10, 27], ["Diabetes\u2019", "DISEASE", 31, 40], ["Diabetes\u2019", "DISEASE", 90, 99], ["Diabetes", "DISEASE", 177, 185], ["Diabetic", "DISEASE", 275, 283], ["communicable diseases", "DISEASE", 355, 376], ["patients", "ORGANISM", 392, 400], ["patients", "SPECIES", 392, 400], ["Diabetes Mellitus", "PROBLEM", 10, 27], ["Diabetes", "PROBLEM", 31, 39], ["Diabetes", "PROBLEM", 90, 98], ["Comorbidity Burden", "PROBLEM", 404, 422]]], ["A total of 412 studies were acquired including duplicates by exercising the desk search criteria.", [["412 studies", "TEST", 11, 22]]], ["Further, a comprehensive analysis of the studies was performed as per the recommendations suggested by Moher et al. [25].", [["a comprehensive analysis", "TEST", 9, 33], ["the studies", "TEST", 37, 48]]], ["Later, 187 articles were identified to be duplicate and removed immediately.Inclusion criterion ::: Materials and methodsOf the total 225 articles, limited studies managed to clear the eligibility criterion based upon the significant elements of the \u2018Patient Intervention Comparison Outcome Study (PICOS)\u2019 procedure [26].", [["limited studies", "TEST", 148, 163]]], ["Title, abstract and keywords of the remaining 225 studies were assessed to determine their relevance.", [["the remaining 225 studies", "TEST", 32, 57]]], ["Thus, the screening procedure facilitated the selection of 32 articles.", [["the screening procedure", "TREATMENT", 6, 29]]], ["Majority of research publications were excluded on the grounds if they (a) did not provide the detailed analysis of how costs were estimated; (b) were conference articles or posters; (c) only presented the costs of diabetes prevention; and (d) were published in non-peer-reviewed journals.Data extraction and quality assessment of included studies ::: Materials and methodsThe exploration includes those articles which highlight the cost burden of diabetes in India.", [["diabetes", "DISEASE", 215, 223], ["diabetes", "DISEASE", 448, 456], ["diabetes prevention", "TREATMENT", 215, 234], ["Data extraction", "TEST", 289, 304], ["quality assessment", "TEST", 309, 327], ["The exploration", "TEST", 373, 388], ["diabetes", "PROBLEM", 448, 456], ["diabetes", "OBSERVATION", 215, 223], ["cost", "OBSERVATION_MODIFIER", 433, 437], ["burden", "OBSERVATION_MODIFIER", 438, 444], ["diabetes", "OBSERVATION", 448, 456]]], ["Whilst performing the analysis, two interdependent excel spreadsheets were developed for data to be summarised.", [["the analysis", "TEST", 18, 30]]], ["In the very first spreadsheet, a predefined category was used, viz. publication title/year, study type, location, diabetes type, methodology and findings.", [["diabetes", "DISEASE", 114, 122]]], ["Relevant information is drawn out and presented in Table 1, highlighting the study characteristics of the included articles.", [["the study", "TEST", 73, 82]]], ["The second excel spreadsheet focuses its attention on the list of technical criteria applied to assess the quality of the articles incorporated in the review process.", [["technical criteria", "TEST", 66, 84]]], ["Copious checklist has been put forward for the quality assessment of the included studies and majority of them emphasise on the economic assessment, viz. cost analysis, cost-benefit analysis (CBA), health care utility analysis, etc. [27, 28].", [["Copious checklist", "TEST", 0, 17], ["the quality assessment", "TEST", 43, 65], ["the included studies", "TEST", 69, 89], ["the economic assessment", "TEST", 124, 147], ["cost analysis", "TEST", 154, 167], ["cost-benefit analysis", "TEST", 169, 190], ["health care utility analysis", "TEST", 198, 226]]], ["Therefore, the quality indicators developed for the present study were grounded on the criterions suggested by prior literature [29\u201332].Data extraction and quality assessment of included studies ::: Materials and methodsA symbol of (\u221a) yes, (\u00d7) no and (\u00b1) moderately available was assigned to individual quality indicator.", [["the present study", "TEST", 48, 65], ["Data extraction", "TEST", 136, 151], ["quality assessment", "TEST", 156, 174]]], ["Each symbol was allocated with a score of 1, which leads to a maximum attainable score of 10 for each study reviewed.", [["each study", "TEST", 97, 107]]], ["Hence, a complete detailed analysis of the parameters utilised is presented in Table 2.Study characteristics ::: ResultsThe characteristics of the included thirty-two studies are presented in Table 1.", [["a complete detailed analysis", "TEST", 7, 35]]], ["A majority of 66% (21) of the studies were published between 2010 and 2019 and the remaining 11 studies (34%) were published in 1999\u20132009.", [["the studies", "TEST", 26, 37], ["the remaining 11 studies", "TEST", 79, 103], ["majority", "OBSERVATION_MODIFIER", 2, 10]]], ["Year of costing was 1999\u20132003 for 5 studies; between 2009 and 2013, 10 studies (31%) were included; and for 2014\u20132019, 12 studies (37%) were included.", [["5 studies", "TEST", 34, 43], ["studies", "TEST", 122, 129]]], ["The cost of diabetes was estimated from various locations such as the south zone (n = 11), followed by the north zone (n = 8), the north-east zone (n = 1) and the west zone (n = 1).", [["diabetes", "DISEASE", 12, 20], ["diabetes", "PROBLEM", 12, 20], ["diabetes", "OBSERVATION", 12, 20]]], ["A large proportion of 11 studies (34%) were defined under India as a whole.Study characteristics ::: ResultsWhilst conducting review studies, it is imperative to initially define the type, study interest, sample size, data source and outlook of the study.", [["11 studies", "TEST", 22, 32], ["review studies", "TEST", 126, 140], ["the study", "TEST", 245, 254], ["large", "OBSERVATION_MODIFIER", 2, 7], ["size", "OBSERVATION_MODIFIER", 212, 216]]], ["The included studies majorly focus on type 2 diabetes (n = 9), followed by both type 1 and type 2 studies (n = 8), 2 studies were identified under type 1 diabetes and only 1 study was acknowledged under gestational/foot ulcer category, whilst the remaining 12 studies did not define any diabetes type (Table 1).", [["foot ulcer", "ANATOMY", 215, 225], ["type 2 diabetes", "DISEASE", 38, 53], ["type 1 diabetes", "DISEASE", 147, 162], ["ulcer", "DISEASE", 220, 225], ["diabetes", "DISEASE", 287, 295], ["foot", "ORGANISM_SUBDIVISION", 215, 219], ["ulcer", "PATHOLOGICAL_FORMATION", 220, 225], ["The included studies", "TEST", 0, 20], ["type 2 diabetes", "PROBLEM", 38, 53], ["2 studies", "TEST", 115, 124], ["type 1 diabetes", "PROBLEM", 147, 162], ["1 study", "TEST", 172, 179], ["gestational/foot ulcer category", "PROBLEM", 203, 234], ["the remaining 12 studies", "TEST", 243, 267], ["diabetes", "OBSERVATION", 154, 162], ["foot", "ANATOMY", 215, 219], ["ulcer", "OBSERVATION", 220, 225]]], ["Of the total 32 studies, 94% of studies focus on general costs and the remaining 2 studies emphasise on foot ulcers and others.", [["foot ulcers", "ANATOMY", 104, 115], ["ulcers", "DISEASE", 109, 115], ["foot", "ORGANISM_SUBDIVISION", 104, 108], ["ulcers", "PATHOLOGICAL_FORMATION", 109, 115], ["the total 32 studies", "TEST", 3, 23], ["studies focus", "TEST", 32, 45], ["general costs", "TREATMENT", 49, 62], ["the remaining 2 studies", "TEST", 67, 90], ["foot ulcers", "PROBLEM", 104, 115], ["foot", "ANATOMY", 104, 108], ["ulcers", "OBSERVATION", 109, 115]]], ["Whilst discussing the cost interests, the complications associated with diabetes were estimated by merely10 studies and the remaining 22 studies (69%) estimated the diabetes cost without any complications.", [["diabetes", "DISEASE", 72, 80], ["diabetes", "DISEASE", 165, 173], ["the complications", "PROBLEM", 38, 55], ["diabetes", "PROBLEM", 72, 80], ["the remaining 22 studies", "TEST", 120, 144], ["the diabetes cost", "PROBLEM", 161, 178], ["any complications", "PROBLEM", 187, 204], ["diabetes", "OBSERVATION", 165, 173]]], ["Defining sample size is the utmost priority of the study, 27 studies (83%) of the total 32 studies have properly identified the sample size to be \u2264 100 respondents, only 2 studies specified the population size to be > 100 respondents and 3 studies (10%) did not define or provide the sample size.Study characteristics ::: ResultsUnder the source of the cost data section, 16 studies (50%) retrieved data on cost from the patients themselves; for 11 studies (34%), source of cost data was obtained from medical institutes; and the remaining 5 studies (16%) acquired the data on cost from publications.", [["patients", "ORGANISM", 421, 429], ["patients", "SPECIES", 421, 429], ["the study", "TEST", 47, 56], ["the total 32 studies", "TEST", 78, 98], ["3 studies", "TEST", 238, 247], ["the cost data section", "TEST", 349, 370], ["16 studies", "TEST", 372, 382], ["11 studies", "TEST", 446, 456], ["cost data", "TEST", 474, 483], ["the remaining 5 studies", "TEST", 526, 549], ["size", "OBSERVATION_MODIFIER", 16, 20], ["size", "OBSERVATION_MODIFIER", 135, 139], ["size", "OBSERVATION_MODIFIER", 205, 209], ["size", "OBSERVATION_MODIFIER", 291, 295]]], ["Studies on the economic burden of illness could be done through several perspectives, viz. household, patient, societal and governmental.", [["illness", "DISEASE", 34, 41], ["patient", "ORGANISM", 102, 109], ["patient", "SPECIES", 102, 109], ["illness", "PROBLEM", 34, 41]]], ["In the particular study, the patient\u2019s perspective was most commonly acknowledged by 19 studies (61%), 9 studies considered societal perspective, followed by government perspective for 7 studies and lastly, household perspective was adopted by 6 studies as highlighted in Table 1.Quality of the reviewed articles ::: ResultsThe quality of the included studies is broadly presented in Table 2.", [["patient", "ORGANISM", 29, 36], ["patient", "SPECIES", 29, 36], ["the particular study", "TEST", 3, 23], ["the included studies", "TEST", 339, 359]]], ["For all 32 studies, research questions and findings were discussed and explained in a very well-defined manner.", [["all 32 studies", "TEST", 4, 18]]], ["It was found that 60% (19) of the studies have comprehensively defined the epidemiological definition such as type of diabetes (type 1 and type 2).", [["diabetes", "DISEASE", 118, 126], ["the studies", "TEST", 30, 41], ["diabetes", "PROBLEM", 118, 126], ["diabetes", "OBSERVATION", 118, 126]]], ["Limitations experienced by the majority of studies that hampered the quality of the reviewed articles were the absence of a broad definition of diabetes and a lack of adequate sample size.", [["diabetes", "DISEASE", 144, 152], ["diabetes", "PROBLEM", 144, 152], ["diabetes", "OBSERVATION", 144, 152], ["size", "OBSERVATION_MODIFIER", 183, 187]]], ["A major proportion of 25 studies (78%) did not extensively define diabetes and 18 studies (56%) moderately considered the sample size.Quality of the reviewed articles ::: ResultsFor most of the reviewed articles, the sampling technique for data collection was addressed and only 1 study did not define the sampling technique.", [["diabetes", "DISEASE", 66, 74], ["25 studies", "TEST", 22, 32], ["diabetes", "PROBLEM", 66, 74], ["18 studies", "TEST", 79, 89], ["the sampling technique", "TEST", 213, 235], ["data collection", "TEST", 240, 255], ["1 study", "TEST", 279, 286], ["the sampling technique", "TEST", 302, 324], ["size", "OBSERVATION_MODIFIER", 129, 133]]], ["However, 56% (18) of studies lucidly defined the tools and technique employed in the reviewed articles and the remaining 14 studies moderately describe the tools and technique.", [["studies", "TEST", 21, 28], ["the remaining 14 studies", "TEST", 107, 131]]], ["A majority of 27 studies (84%) have properly classified the cost of diabetes and the remaining 5 studies defined moderately.", [["diabetes", "DISEASE", 68, 76], ["27 studies", "TEST", 14, 24], ["diabetes", "PROBLEM", 68, 76], ["the remaining 5 studies", "TEST", 81, 104], ["diabetes", "OBSERVATION", 68, 76]]], ["Hence, based on quality index scores, the majority of the studies (n = 11) scored \u20186 Yes\u2019 on a 10-point scale.", [["quality index scores", "TEST", 16, 36], ["the studies", "TEST", 54, 65]]], ["Interestingly, 5 studies attained a marginally higher score of \u20188 Yes\u2019 of the total 32 studies as presented in Table 2.Cost of diabetes ::: ResultsThe economic burden of diabetes mellitus has led to numerous studies on the cost of illness.", [["diabetes", "DISEASE", 127, 135], ["diabetes mellitus", "DISEASE", 170, 187], ["illness", "DISEASE", 231, 238], ["5 studies", "TEST", 15, 24], ["the total 32 studies", "TEST", 74, 94], ["diabetes", "PROBLEM", 127, 135], ["diabetes mellitus", "PROBLEM", 170, 187], ["numerous studies", "TEST", 199, 215], ["illness", "PROBLEM", 231, 238], ["diabetes", "OBSERVATION", 127, 135], ["economic", "OBSERVATION_MODIFIER", 151, 159], ["burden", "OBSERVATION_MODIFIER", 160, 166], ["diabetes mellitus", "OBSERVATION", 170, 187]]], ["The cost exerted by diabetes can be categorised into three groups: direct cost, indirect cost and intangible cost [55, 56].", [["diabetes", "DISEASE", 20, 28], ["diabetes", "PROBLEM", 20, 28], ["diabetes", "OBSERVATION", 20, 28]]], ["Direct cost includes both direct health care costs (diagnosis, treatment, care and prevention) and direct non-health care costs (transport, housekeeping, social service and legal cost) [1, 57].", [["treatment", "TREATMENT", 63, 72]]], ["Indirect cost includes cost for absenteeism, loss of productivity and disability [58, 59].", [["loss of productivity and disability", "DISEASE", 45, 80], ["absenteeism", "PROBLEM", 32, 43], ["loss of productivity", "PROBLEM", 45, 65]]], ["Lastly, intangible costs embrace cost for social isolation and dependence, low socio-economic status, mental health and behavioral disorder and loss of quality of life [56, 60, 61].", [["behavioral disorder", "DISEASE", 120, 139], ["social isolation", "TREATMENT", 42, 58], ["behavioral disorder", "PROBLEM", 120, 139], ["loss of quality of life", "PROBLEM", 144, 167]]], ["All twenty-one reviewed studies put forward data and statistics to evaluate per capita cost of individual/household at zone level and the remaining eleven studies highlighted the cost of diabetes at the national level (Table 3).", [["diabetes", "DISEASE", 187, 195], ["the remaining eleven studies", "TEST", 134, 162], ["diabetes", "PROBLEM", 187, 195]]], ["To have a clear insight on cost, the reviewed articles have been categorised into four different zones, viz. north zone, west zone, south zone and north-east zone.Cost of diabetes ::: ResultsUnder the north zone, 8 studies were included to calculate both direct and indirect costs of diabetes at the individual/household level (Fig. 1).", [["diabetes", "DISEASE", 171, 179], ["diabetes", "DISEASE", 284, 292], ["diabetes", "PROBLEM", 171, 179], ["diabetes", "PROBLEM", 284, 292], ["clear", "OBSERVATION", 10, 15], ["zone", "ANATOMY_MODIFIER", 115, 119], ["north", "ANATOMY_MODIFIER", 147, 152], ["east zone", "ANATOMY_MODIFIER", 153, 162], ["diabetes", "OBSERVATION", 171, 179], ["diabetes", "OBSERVATION", 284, 292]]], ["The median direct cost of diabetes is estimated to be \u20b918,890/- per annum, ranging from \u20b9999/- to \u20b91,09,344/- [19, 35, 39, 44, 46, 48\u201350].", [["diabetes", "DISEASE", 26, 34], ["diabetes", "PROBLEM", 26, 34], ["diabetes", "OBSERVATION", 26, 34]]], ["The most commonly measured costing items under direct cost were expenditure on medicines (7 studies), diagnostic expenses (2 studies), transportation cost (1 study), hospitalisation (2 studies) and consultation fee (3 studies).", [["medicines", "TREATMENT", 79, 88]]], ["The median indirect cost of diabetes for the north zone was evaluated to be \u20b918,146/- per annum, ranging from \u20b94642/- to \u20b998,808/- [19, 35, 46, 49].", [["diabetes", "DISEASE", 28, 36], ["diabetes", "PROBLEM", 28, 36], ["diabetes", "OBSERVATION", 28, 36]]], ["For all indirect cost studies, costing items, viz. wage loss and leisure time forgone, were used majorly.Cost of diabetes ::: ResultsSouth zone includes 11 studies, majorly from Karnataka state (6 studies), followed by Tamil Nadu (4 studies) and Andhra Pradesh (1 study).", [["diabetes", "DISEASE", 113, 121], ["diabetes", "PROBLEM", 113, 121], ["ResultsSouth zone", "TEST", 126, 143], ["diabetes", "OBSERVATION", 113, 121]]], ["The median indirect cost of diabetes was \u20b91198/- per annum, ranging from \u20b9462/- to \u20b93572/- per annum with major cost items such as monitoring cost (1 study), absenteeism (3 studies) and impairment (1 study) [7\u20139, 33, 37].Cost of diabetes ::: ResultsUnder the north-east and west zone, only one-one study was observed, to evaluate the direct and indirect cost of diabetes at the individual/household level [47, 51].", [["diabetes", "DISEASE", 28, 36], ["diabetes", "DISEASE", 229, 237], ["diabetes", "DISEASE", 362, 370], ["diabetes", "PROBLEM", 28, 36], ["monitoring cost (1 study", "TEST", 131, 155], ["absenteeism (3 studies", "TEST", 158, 180], ["diabetes", "PROBLEM", 229, 237], ["one study", "TEST", 294, 303], ["diabetes", "PROBLEM", 362, 370], ["diabetes", "OBSERVATION", 28, 36], ["diabetes", "OBSERVATION", 229, 237], ["diabetes", "OBSERVATION", 362, 370]]], ["The median direct cost of diabetes for north-east was evaluated to be \u20b945,792/- per annum and \u20b98822/- per annum was observed for the west zone (Fig. 1).", [["diabetes", "DISEASE", 26, 34], ["diabetes", "PROBLEM", 26, 34], ["diabetes", "OBSERVATION", 26, 34]]], ["Commonly estimated costing items were surgical procedures, expenditure on drugs/medicines, clinical fees, etc. The median indirect cost estimated for the north-east zone was \u20b918,707/- per annum and \u20b93949/- per annum was analysed for the west zone.", [["surgical procedures", "TREATMENT", 38, 57], ["drugs", "TREATMENT", 74, 79], ["medicines", "TREATMENT", 80, 89]]], ["Indirect costing items identified for both reviewed studies were loss of wage, spendings on health class, travelling expenditure and spendings on diet control.", [["diet control", "TREATMENT", 146, 158]]], ["Lastly, 11 studies were incorporated to estimate the cost of diabetes for India as a whole at the individual/household level [5, 20, 22\u201324, 34, 36, 43, 51\u201353].", [["diabetes", "DISEASE", 61, 69], ["11 studies", "TEST", 8, 18], ["diabetes", "PROBLEM", 61, 69]]], ["The median direct cost of diabetes for India as a whole was \u20b99996/- per annum, ranging from \u20b94724/- to \u20b925,391/- per annum.", [["diabetes", "DISEASE", 26, 34], ["diabetes", "PROBLEM", 26, 34], ["diabetes", "OBSERVATION", 26, 34]]], ["Also, the median indirect cost of diabetes at the individual/household level was estimated to be \u20b95237/- per annum, ranging from \u20b92435/- to \u20b912,756/- annually (Figs.", [["diabetes", "DISEASE", 34, 42], ["diabetes", "PROBLEM", 34, 42], ["diabetes", "OBSERVATION", 34, 42]]], ["1 and 2).Complications ::: ResultsDiabetes mellitus is associated with a large number of serious and chronic complications, which act as a major cause of hospitalisation, morbidity and premature mortality in diabetic patients [2, 7, 8, 42].", [["ResultsDiabetes mellitus", "DISEASE", 27, 51], ["diabetic", "DISEASE", 208, 216], ["patients", "ORGANISM", 217, 225], ["patients", "SPECIES", 217, 225], ["ResultsDiabetes mellitus", "PROBLEM", 27, 51], ["serious and chronic complications", "PROBLEM", 89, 122], ["morbidity", "PROBLEM", 171, 180], ["premature mortality in diabetic patients", "PROBLEM", 185, 225], ["mellitus", "OBSERVATION", 43, 51], ["large", "OBSERVATION_MODIFIER", 73, 78], ["serious", "OBSERVATION_MODIFIER", 89, 96], ["chronic", "OBSERVATION_MODIFIER", 101, 108], ["complications", "OBSERVATION", 109, 122]]], ["Diabetes mellitus is commonly associated with chronic complications both macrovascular and microvascular origin [2, 3].", [["macrovascular", "ANATOMY", 73, 86], ["microvascular", "ANATOMY", 91, 104], ["Diabetes mellitus", "DISEASE", 0, 17], ["microvascular", "TISSUE", 91, 104], ["Diabetes mellitus", "PROBLEM", 0, 17], ["chronic complications both macrovascular and microvascular origin", "PROBLEM", 46, 111], ["mellitus", "OBSERVATION", 9, 17], ["chronic", "OBSERVATION_MODIFIER", 46, 53], ["complications", "OBSERVATION", 54, 67], ["macrovascular", "ANATOMY", 73, 86], ["microvascular origin", "ANATOMY", 91, 111]]], ["Microvascular complications of diabetes mellitus include retinopathy, autonomic neuropathy, peripheral neuropathy and nephropathy [3, 53].", [["Microvascular", "ANATOMY", 0, 13], ["diabetes mellitus", "DISEASE", 31, 48], ["retinopathy", "DISEASE", 57, 68], ["autonomic neuropathy", "DISEASE", 70, 90], ["peripheral neuropathy", "DISEASE", 92, 113], ["nephropathy", "DISEASE", 118, 129], ["Microvascular", "TISSUE", 0, 13], ["Microvascular complications", "PROBLEM", 0, 27], ["diabetes mellitus", "PROBLEM", 31, 48], ["retinopathy", "PROBLEM", 57, 68], ["autonomic neuropathy", "PROBLEM", 70, 90], ["peripheral neuropathy", "PROBLEM", 92, 113], ["nephropathy", "PROBLEM", 118, 129], ["complications", "OBSERVATION", 14, 27], ["diabetes", "OBSERVATION", 31, 39], ["retinopathy", "OBSERVATION", 57, 68], ["autonomic neuropathy", "OBSERVATION", 70, 90], ["peripheral", "ANATOMY_MODIFIER", 92, 102], ["neuropathy", "OBSERVATION", 103, 113], ["nephropathy", "OBSERVATION", 118, 129]]], ["The macrovascular complication of diabetes mellitus broadly includes coronary and peripheral arterial disease [2, 7].", [["macrovascular", "ANATOMY", 4, 17], ["coronary", "ANATOMY", 69, 77], ["peripheral arterial", "ANATOMY", 82, 101], ["diabetes mellitus", "DISEASE", 34, 51], ["coronary and peripheral arterial disease", "DISEASE", 69, 109], ["coronary", "MULTI-TISSUE_STRUCTURE", 69, 77], ["peripheral arterial", "MULTI-TISSUE_STRUCTURE", 82, 101], ["The macrovascular complication", "PROBLEM", 0, 30], ["diabetes mellitus", "PROBLEM", 34, 51], ["coronary and peripheral arterial disease", "PROBLEM", 69, 109], ["macrovascular", "OBSERVATION_MODIFIER", 4, 17], ["complication", "OBSERVATION", 18, 30], ["diabetes", "OBSERVATION", 34, 42], ["coronary", "ANATOMY", 69, 77], ["peripheral", "ANATOMY_MODIFIER", 82, 92], ["arterial", "ANATOMY", 93, 101], ["disease", "OBSERVATION", 102, 109]]], ["Of the total reviewed studies, only 10 studies estimated the cost of complications associated with diabetes (Table 3).", [["diabetes", "DISEASE", 99, 107], ["10 studies", "TEST", 36, 46], ["complications", "PROBLEM", 69, 82], ["diabetes", "PROBLEM", 99, 107]]], ["A couple of studies on diabetes assessed the cost of illness to be 1.4 times higher for individuals with complications as exhibited in Table 3 [8, 52].", [["diabetes", "DISEASE", 23, 31], ["illness", "DISEASE", 53, 60], ["diabetes", "PROBLEM", 23, 31], ["illness", "PROBLEM", 53, 60], ["complications", "PROBLEM", 105, 118]]], ["A similar study by Sachidananda et al. [42] concluded that the cost of diabetes is 1.8 times higher for complicated non-hospitalised patients and 2.4 times higher for complicated hospitalised patients.", [["diabetes", "DISEASE", 71, 79], ["patients", "ORGANISM", 133, 141], ["patients", "ORGANISM", 192, 200], ["patients", "SPECIES", 133, 141], ["patients", "SPECIES", 192, 200], ["A similar study", "TEST", 0, 15], ["diabetes", "PROBLEM", 71, 79], ["diabetes", "OBSERVATION", 71, 79]]], ["Kapur [38] inferred that individuals with three or more comorbidities encounter 48% more cost of care, amounting to \u20b910,593/- annually.", [["individuals", "ORGANISM", 25, 36]]], ["According to Cavanagh et al. [5], India is the most expensive country for a patient with a complex diabetic foot ulcer, where 68.8 months of income was required to pay for treatment.", [["foot ulcer", "ANATOMY", 108, 118], ["diabetic foot ulcer", "DISEASE", 99, 118], ["patient", "ORGANISM", 76, 83], ["foot", "ORGANISM_SUBDIVISION", 108, 112], ["ulcer", "PATHOLOGICAL_FORMATION", 113, 118], ["patient", "SPECIES", 76, 83], ["a complex diabetic foot ulcer", "PROBLEM", 89, 118], ["treatment", "TREATMENT", 172, 181], ["complex", "OBSERVATION_MODIFIER", 91, 98], ["diabetic", "OBSERVATION_MODIFIER", 99, 107], ["foot", "ANATOMY", 108, 112], ["ulcer", "OBSERVATION", 113, 118]]], ["Three reviewed studies incorporated in the study estimated the cost of individual/household with both macrovascular and microvascular complications [2, 7, 53].", [["macrovascular", "ANATOMY", 102, 115], ["microvascular", "ANATOMY", 120, 133], ["macrovascular and microvascular complications", "DISEASE", 102, 147], ["microvascular", "MULTI-TISSUE_STRUCTURE", 120, 133], ["Three reviewed studies", "TEST", 0, 22], ["the study", "TEST", 39, 48], ["both macrovascular and microvascular complications", "PROBLEM", 97, 147], ["macrovascular", "ANATOMY", 102, 115], ["microvascular", "ANATOMY", 120, 133], ["complications", "OBSERVATION", 134, 147]]], ["Of these 3 reviewed articles, a couple of them primarily concentrate on the cost of illness prompted by renal (kidney) complication [2, 53].", [["renal", "ANATOMY", 104, 109], ["kidney", "ANATOMY", 111, 117], ["illness", "DISEASE", 84, 91], ["renal (kidney) complication", "DISEASE", 104, 131], ["renal", "ORGAN", 104, 109], ["kidney", "ORGAN", 111, 117], ["illness", "PROBLEM", 84, 91], ["renal", "ANATOMY", 104, 109], ["kidney", "ANATOMY", 111, 117]]], ["Lastly, Eshwari et al. [9] estimated the total cost for the treatment of diabetes with comorbidities was \u20b99133/- annually.", [["diabetes", "DISEASE", 73, 81], ["diabetes", "PROBLEM", 73, 81], ["comorbidities", "PROBLEM", 87, 100], ["diabetes", "OBSERVATION", 73, 81]]], ["Direct cost with complications was \u20b98185/- per annum and indirect cost amounts to be \u20b9508/- annually.DiscussionRising menace of diabetes has been a major concern for India.", [["diabetes", "DISEASE", 128, 136], ["complications", "PROBLEM", 17, 30], ["diabetes", "PROBLEM", 128, 136], ["diabetes", "OBSERVATION", 128, 136]]], ["With a frightening increase in population with diabetes, India is soon going to be crowned as \u2018diabetes capital\u2019 of the world.", [["diabetes", "DISEASE", 47, 55], ["diabetes", "DISEASE", 95, 103], ["a frightening increase", "PROBLEM", 5, 27], ["diabetes", "PROBLEM", 47, 55], ["frightening", "OBSERVATION_MODIFIER", 7, 18], ["increase", "OBSERVATION_MODIFIER", 19, 27], ["population", "OBSERVATION_MODIFIER", 31, 41], ["diabetes", "OBSERVATION", 47, 55]]], ["A swift cultural and social alteration, viz. rising age, diet modification, rapid urbanisation, lack of regular exercise regimen, obesity and a sedentary lifestyle, will result in the continuous incidence of diabetes in India.", [["obesity", "DISEASE", 130, 137], ["diabetes", "DISEASE", 208, 216], ["diet modification", "TREATMENT", 57, 74], ["rapid urbanisation", "TREATMENT", 76, 94], ["regular exercise regimen", "TREATMENT", 104, 128], ["obesity", "PROBLEM", 130, 137], ["diabetes", "PROBLEM", 208, 216], ["obesity", "OBSERVATION", 130, 137], ["diabetes", "OBSERVATION", 208, 216]]], ["The primary objective of this article is to detect and capture the evidence from published literature on the per capita cost at the individual/household level for both direct and indirect costs of diabetes in India which are available and published since 1999.", [["diabetes", "DISEASE", 197, 205], ["diabetes", "PROBLEM", 197, 205], ["diabetes", "OBSERVATION", 197, 205]]], ["Of the total 412 records, 32 studies were identified to meet the inclusion criterion.", [["32 studies", "TEST", 26, 36]]], ["Therefore, the findings of the present study suggest that per annum median direct and indirect cost of diabetes at the individual/household level is very colossal in India.DiscussionA large proportion of health care cost is confronted by the patients themselves, which affects the fulfilment of health care because of financial restraints [62].", [["diabetes", "DISEASE", 103, 111], ["patients", "ORGANISM", 242, 250], ["patients", "SPECIES", 242, 250], ["the present study", "TEST", 27, 44], ["diabetes", "PROBLEM", 103, 111], ["financial restraints", "TREATMENT", 318, 338]]], ["Hence, financing and delivering health care facilities in India is majorly catered by the private sector for more than 70% of diseases in both rural and urban areas [24].DiscussionDirect cost items (expenditure on medicines, diagnostic expenses, transportation cost, hospitalisation and consultation fee) and indirect cost items (loss of wage, spendings on health class and travelling expenditure) were most commonly reported costing items in the present study [8, 9, 19, 37, 46, 48].", [["diseases", "PROBLEM", 126, 134], ["medicines", "TREATMENT", 214, 223]]], ["Most of the reviewed studies on the cost of diabetes highlighted expenditure on drugs/medicine as the foremost costing item which accounts for a significant share of all direct costs.", [["diabetes", "DISEASE", 44, 52], ["the reviewed studies", "TEST", 8, 28], ["diabetes", "PROBLEM", 44, 52], ["drugs", "TREATMENT", 80, 85], ["medicine", "TREATMENT", 86, 94]]], ["The finding of the present study is consistent with Yesudian et al. [62], \u2018cost on drugs constitutes 50% of the total direct costs\u2019.", [["the present study", "TEST", 15, 32], ["drugs", "TREATMENT", 83, 88], ["consistent with", "UNCERTAINTY", 36, 51]]], ["The majority of the reviewed articles included in the study justify that the primary cause for such abnormal costs of medicines is the common practice adopted by physicians to prescribe brand-named medicines, rather than generic medicines.DiscussionIn context to the quality of tools and techniques incorporated by the included studies, a large number of articles (56%) witnessed to acknowledge the standards of tools and techniques.", [["the study", "TEST", 50, 59], ["such abnormal costs of medicines", "PROBLEM", 95, 127], ["brand-named medicines", "TREATMENT", 186, 207], ["generic medicines", "TREATMENT", 221, 238], ["large", "OBSERVATION_MODIFIER", 339, 344]]], ["Similarly, the classification of the cost of diabetes was also determined by the majority of reviewed articles (27 articles).", [["diabetes", "DISEASE", 45, 53], ["diabetes", "PROBLEM", 45, 53], ["diabetes", "OBSERVATION", 45, 53]]], ["But the absence of a comprehensive definition of diabetes and a small size of individuals/households produce dubiousness about the standards or quality of the study.", [["diabetes", "DISEASE", 49, 57], ["diabetes", "PROBLEM", 49, 57], ["the study", "TEST", 155, 164], ["diabetes", "OBSERVATION", 49, 57], ["small", "OBSERVATION_MODIFIER", 64, 69], ["size", "OBSERVATION_MODIFIER", 70, 74]]], ["Hence, the limitations experienced by the majority of reviewed articles hampered the quality of the present study.", [["the present study", "TEST", 96, 113]]], ["Thus, it is beneficial to develop and suggest standard procedures and framework to conduct a comprehensive and exhaustive study on the cost of diabetes.Limitations of the studyThe present study holds few limitations.", [["diabetes", "DISEASE", 143, 151], ["standard procedures", "TREATMENT", 46, 65], ["exhaustive study", "TEST", 111, 127], ["diabetes", "PROBLEM", 143, 151], ["the study", "TEST", 167, 176], ["The present study", "TEST", 176, 193], ["few", "OBSERVATION_MODIFIER", 200, 203]]], ["Primarily the exclusion of the relevant articles presented as conference papers and those studies published under non-peer-reviewed journals.", [["those studies", "TEST", 84, 97]]], ["Furthermore, the major limitation of the present study is the non-availability of published articles under the central and east zone of India.", [["the present study", "TEST", 37, 54], ["central", "ANATOMY_MODIFIER", 111, 118]]], ["Also, the studies published under the north-east zone and west zone were only one.", [["the studies", "TEST", 6, 17]]], ["Lastly, the heterogeneity in material and methodology used in cost estimation are not analogous.", [["the heterogeneity in material", "PROBLEM", 8, 37], ["cost estimation", "TEST", 62, 77], ["heterogeneity", "OBSERVATION_MODIFIER", 12, 25]]], ["As a consequence, conducting a meta-analysis is not feasible.ConclusionThe above discussion highlighted a huge economic burden of diabetes in India and variations were recorded in the different zones.", [["diabetes", "DISEASE", 130, 138], ["diabetes", "PROBLEM", 130, 138], ["huge", "OBSERVATION_MODIFIER", 106, 110], ["economic", "OBSERVATION_MODIFIER", 111, 119], ["burden", "OBSERVATION_MODIFIER", 120, 126], ["diabetes", "OBSERVATION", 130, 138], ["different", "ANATOMY_MODIFIER", 184, 193], ["zones", "ANATOMY_MODIFIER", 194, 199]]], ["It was observed that the cost of drugs/medicines accounts for a major burden of the cost of diabetes.", [["diabetes", "DISEASE", 92, 100], ["drugs", "TREATMENT", 33, 38], ["medicines", "TREATMENT", 39, 48], ["diabetes", "PROBLEM", 92, 100], ["diabetes", "OBSERVATION", 92, 100]]], ["The study suggested few policy interventions to cope with the high economic burden of diabetes.", [["diabetes", "DISEASE", 86, 94], ["The study", "TEST", 0, 9], ["policy interventions", "TREATMENT", 24, 44], ["diabetes", "PROBLEM", 86, 94], ["few", "OBSERVATION_MODIFIER", 20, 23], ["diabetes", "OBSERVATION", 86, 94]]], ["There is a dire need in the country to arrange awareness programmes on diabetes and associated risk factors.", [["diabetes", "DISEASE", 71, 79], ["diabetes", "PROBLEM", 71, 79], ["associated risk factors", "PROBLEM", 84, 107]]], ["The menace of diabetes can be controlled by devising new health care policies, introducing new generic medicines and taxing alcohol/tobacco.", [["diabetes", "DISEASE", 14, 22], ["alcohol", "CHEMICAL", 124, 131], ["alcohol", "CHEMICAL", 124, 131], ["alcohol", "SIMPLE_CHEMICAL", 124, 131], ["tobacco", "ORGANISM", 132, 139], ["tobacco", "SPECIES", 132, 139], ["diabetes", "PROBLEM", 14, 22], ["new generic medicines", "TREATMENT", 91, 112], ["menace", "OBSERVATION_MODIFIER", 4, 10], ["diabetes", "OBSERVATION", 14, 22]]], ["Diabetes is a lifestyle disease so along with the above measures, a change in dietary habits, physical activity, beliefs and behavior can reduce its economic burden.", [["Diabetes", "DISEASE", 0, 8], ["Diabetes", "PROBLEM", 0, 8], ["a lifestyle disease", "PROBLEM", 12, 31], ["the above measures", "TREATMENT", 46, 64], ["a change in dietary habits", "PROBLEM", 66, 92], ["its economic burden", "PROBLEM", 145, 164]]]], "PMC7384784": [["In 2019, approximately 3.5 billion people\u201445% of the world\u2019s population\u2014used some form of social media, which represented a 9% increase since 2018.", [["people", "ORGANISM", 35, 41], ["people", "SPECIES", 35, 41]]], ["The United States has seen an especially dramatic rise in the use of social media, from 7% of the population in 2005 to 70% in 2019 (1, 2,2).", [["social media", "TREATMENT", 69, 81], ["especially", "OBSERVATION_MODIFIER", 30, 40], ["dramatic", "OBSERVATION_MODIFIER", 41, 49], ["rise", "OBSERVATION_MODIFIER", 50, 54]]]], "09c8917c3a94284fff227cc7a5ea4aefece810fa": [["Introduction SARS-CoV-2, which causes COVID-19, is the third novel coronavirus in 17 years [1] , first reported in Wuhan, China, on 31 December 2019 [2] .", [["coronavirus", "DISEASE", 67, 78], ["SARS-CoV-2", "ORGANISM", 13, 23], ["SARS-CoV", "SPECIES", 13, 21], ["COVID", "TEST", 38, 43]]], ["It has since spread globally, with the World Health Organization (WHO) declaring it a Public Health Emergency of International Concern on 30 January 2020 and a pandemic on 11 March 2020.", [["spread", "OBSERVATION_MODIFIER", 13, 19], ["globally", "OBSERVATION_MODIFIER", 20, 28]]], ["With its basic reproduction number close to or higher than SARS-CoV [3, 4] and MERS-CoV [5] , COVID-19 represents a potentially higher pandemic risk than the SARS outbreak in 2003 [6] .", [["COVID-19", "CHEMICAL", 94, 102], ["SARS", "DISEASE", 158, 162], ["SARS-CoV", "GENE_OR_GENE_PRODUCT", 59, 67], ["MERS-CoV", "GENE_OR_GENE_PRODUCT", 79, 87], ["SARS-CoV", "SPECIES", 59, 67], ["MERS-CoV", "SPECIES", 79, 87], ["COVID", "TEST", 94, 99]]], ["Initial cases of zoonotic transmission from bats [7] have since evolved into human-to-human transmission through droplets, fomites [8] , fecal material [9] , and tears [10] .", [["droplets", "ANATOMY", 113, 121], ["human", "ORGANISM", 77, 82], ["human", "ORGANISM", 86, 91], ["human", "SPECIES", 77, 82], ["human", "SPECIES", 86, 91], ["human", "SPECIES", 77, 82], ["human", "SPECIES", 86, 91], ["fecal material", "TEST", 137, 151], ["tears", "PROBLEM", 162, 167]]], ["Detection of SARS-CoV-2 in tears and conjunctival secretions of infected patients with conjunctivitis [10] , similar to findings during the 2003 SARS outbreak [11] , suggests a unique risk to the ophthalmology department.", [["tears", "ANATOMY", 27, 32], ["conjunctival secretions", "ANATOMY", 37, 60], ["conjunctivitis", "DISEASE", 87, 101], ["SARS", "DISEASE", 145, 149], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 13, 23], ["tears", "TISSUE", 27, 32], ["conjunctival secretions", "ORGAN", 37, 60], ["patients", "ORGANISM", 73, 81], ["patients", "SPECIES", 73, 81], ["SARS-CoV", "SPECIES", 13, 21], ["SARS", "PROBLEM", 13, 17], ["CoV", "TEST", 18, 21], ["tears", "PROBLEM", 27, 32], ["conjunctival secretions", "PROBLEM", 37, 60], ["conjunctivitis", "PROBLEM", 87, 101], ["conjunctival", "ANATOMY", 37, 49]]]], "PMC7502155": [["IntroductionToxoplasma gondii is an obligate intracellular pathogen that has been estimated to chronically infect approximately one-third of the world\u2019s population (Dubey 2010).", [["intracellular", "ANATOMY", 45, 58], ["Toxoplasma gondii", "DISEASE", 12, 29], ["Toxoplasma gondii", "ORGANISM", 12, 29], ["intracellular", "IMMATERIAL_ANATOMICAL_ENTITY", 45, 58], ["Toxoplasma gondii", "SPECIES", 12, 29], ["Toxoplasma gondii", "SPECIES", 12, 29], ["IntroductionToxoplasma gondii", "PROBLEM", 0, 29], ["an obligate intracellular pathogen", "PROBLEM", 33, 67]]], ["However, T. gondii causes severe diseases in prenatally infected children and in immunocompromised individuals (Hohlfeld et al. 1989; Luft and Remington 1992).", [["T. gondii", "DISEASE", 9, 18], ["prenatally infected", "DISEASE", 45, 64], ["T. gondii", "ORGANISM", 9, 18], ["children", "ORGANISM", 65, 73], ["T. gondii", "SPECIES", 9, 18], ["children", "SPECIES", 65, 73], ["T. gondii", "SPECIES", 9, 18], ["severe diseases", "PROBLEM", 26, 41], ["severe", "OBSERVATION_MODIFIER", 26, 32], ["diseases", "OBSERVATION", 33, 41], ["infected", "OBSERVATION_MODIFIER", 56, 64]]], ["Although T. gondii has a wide range of intermediate hosts, felids are the only definitive host of this parasite.", [["T. gondii", "ORGANISM", 9, 18], ["felids", "ORGANISM", 59, 65], ["T. gondii", "SPECIES", 9, 18], ["T. gondii", "SPECIES", 9, 18], ["T. gondii", "PROBLEM", 9, 18]]], ["Cats play an important role in spreading of T. gondii, and one infected cat can discharge millions of oocysts in the feces (/Dubey 2001).", [["feces", "ANATOMY", 117, 122], ["Cats", "GENE_OR_GENE_PRODUCT", 0, 4], ["T. gondii", "ORGANISM", 44, 53], ["cat", "ORGANISM", 72, 75], ["feces", "ORGANISM_SUBDIVISION", 117, 122], ["T. gondii", "SPECIES", 44, 53], ["cat", "SPECIES", 72, 75], ["T. gondii", "SPECIES", 44, 53], ["T. gondii", "PROBLEM", 44, 53], ["oocysts", "OBSERVATION", 102, 109], ["feces", "ANATOMY", 117, 122]]], ["The ability of T. gondii to enter and sexually differentiate within intestinal epithelial cells into oocysts constitutes a fundamental step in the biology and transmission of this parasite.", [["intestinal epithelial cells", "ANATOMY", 68, 95], ["T. gondii", "ORGANISM", 15, 24], ["intestinal epithelial cells", "CELL", 68, 95], ["intestinal epithelial cells", "CELL_TYPE", 68, 95], ["T. gondii", "SPECIES", 15, 24], ["T. gondii", "SPECIES", 15, 24], ["T. gondii", "PROBLEM", 15, 24], ["this parasite", "PROBLEM", 175, 188], ["intestinal", "ANATOMY", 68, 78], ["epithelial cells", "OBSERVATION", 79, 95]]], ["A deeper understanding of the molecular events that shape the interaction of T. gondii with the feline intestine is therefore important for developing new intervention to interrupt the production of oocysts, which in turn may reduce the spread of infection to other hosts.IntroductionProtein acetylation was firstly discovered in 1964 (Allfrey et al. 1964) and participated in multiple cellular processes such as gene regulation, protein degradation, cellular metabolism, and cellular stress response (Lee and Gu 2013; Lima et al. 2011; Sang et al. 2017).", [["intestine", "ANATOMY", 103, 112], ["oocysts", "ANATOMY", 199, 206], ["cellular", "ANATOMY", 386, 394], ["cellular", "ANATOMY", 451, 459], ["cellular", "ANATOMY", 476, 484], ["infection", "DISEASE", 247, 256], ["T. gondii", "ORGANISM", 77, 86], ["feline", "ORGANISM", 96, 102], ["intestine", "ORGAN", 103, 112], ["cellular", "CELL", 386, 394], ["cellular", "CELL", 451, 459], ["cellular", "CELL", 476, 484], ["T. gondii", "SPECIES", 77, 86], ["feline", "SPECIES", 96, 102], ["T. gondii", "SPECIES", 77, 86], ["new intervention", "TREATMENT", 151, 167], ["oocysts", "PROBLEM", 199, 206], ["infection", "PROBLEM", 247, 256], ["IntroductionProtein acetylation", "TREATMENT", 272, 303], ["multiple cellular processes", "PROBLEM", 377, 404], ["gene regulation", "TREATMENT", 413, 428], ["protein degradation", "PROBLEM", 430, 449], ["cellular metabolism", "PROBLEM", 451, 470], ["cellular stress response", "PROBLEM", 476, 500], ["oocysts", "OBSERVATION", 199, 206], ["infection", "OBSERVATION", 247, 256], ["cellular processes", "OBSERVATION", 386, 404], ["cellular metabolism", "OBSERVATION", 451, 470]]], ["Protein lysine acetylation (LysAc) has been reported in bacteria [e.g. Escherichia coli (Zhang et al. 2009), Bacillus subtilis (Kim et al. 2013)], parasites [e.g. Plasmodium falciparum (Miao et al. 2013)], insect [e.g. Drosophila melanogaster (Weinert et al. 2011)], and mammals [e.g. Mus musculus (Lundby et al. 2012) and Homo sapiens (Choudhary et al. 2009)].", [["lysine", "CHEMICAL", 8, 14], ["LysAc", "CHEMICAL", 28, 33], ["Plasmodium falciparum", "DISEASE", 163, 184], ["lysine", "CHEMICAL", 8, 14], ["Protein lysine acetylation", "GENE_OR_GENE_PRODUCT", 0, 26], ["LysAc", "GENE_OR_GENE_PRODUCT", 28, 33], ["Escherichia coli", "ORGANISM", 71, 87], ["Bacillus subtilis", "ORGANISM", 109, 126], ["Plasmodium falciparum", "ORGANISM", 163, 184], ["Drosophila melanogaster", "ORGANISM", 219, 242], ["Mus musculus", "ORGANISM", 285, 297], ["Homo sapiens", "ORGANISM", 323, 335], ["LysAc", "PROTEIN", 28, 33], ["Escherichia coli", "SPECIES", 71, 87], ["Bacillus subtilis", "SPECIES", 109, 126], ["Plasmodium falciparum", "SPECIES", 163, 184], ["Drosophila melanogaster", "SPECIES", 219, 242], ["Mus musculus", "SPECIES", 285, 297], ["Homo sapiens", "SPECIES", 323, 335], ["Escherichia coli", "SPECIES", 71, 87], ["Bacillus subtilis (Kim et al. 2013)", "SPECIES", 109, 144], ["Plasmodium falciparum", "SPECIES", 163, 184], ["Drosophila melanogaster", "SPECIES", 219, 242], ["Mus musculus", "SPECIES", 285, 297], ["Homo sapiens", "SPECIES", 323, 335], ["Protein lysine acetylation (LysAc", "TREATMENT", 0, 33], ["bacteria", "PROBLEM", 56, 64], ["Escherichia coli", "PROBLEM", 71, 87], ["Bacillus subtilis", "PROBLEM", 109, 126], ["parasites", "PROBLEM", 147, 156], ["Plasmodium falciparum", "PROBLEM", 163, 184], ["lysine acetylation", "OBSERVATION", 8, 26], ["Escherichia coli", "OBSERVATION", 71, 87]]], ["These studies showed that acetylated proteins can influence a broad variety of cellular processes.IntroductionAcetylation of protein was found to play a role in regulation of the interaction between host and pathogen (Husain and Cheung 2014).", [["cellular", "ANATOMY", 79, 87], ["cellular", "CELL", 79, 87], ["acetylated proteins", "PROTEIN", 26, 45], ["These studies", "TEST", 0, 13], ["acetylated proteins", "PROBLEM", 26, 45], ["IntroductionAcetylation of protein", "TREATMENT", 98, 132], ["broad", "OBSERVATION_MODIFIER", 62, 67], ["cellular processes", "OBSERVATION", 79, 97]]], ["A genome-wide acetylation analysis identified many acetylated proteins involved in diverse cellular processes and different localizations in T. gondii, suggesting potential of the parasite to modulate host cell acetylome (Jeffers and Sullivan, 2012).", [["cellular", "ANATOMY", 91, 99], ["cell", "ANATOMY", 206, 210], ["cellular", "CELL", 91, 99], ["T. gondii", "ORGANISM", 141, 150], ["host cell", "CELL", 201, 210], ["acetylated proteins", "PROTEIN", 51, 70], ["T. gondii", "SPECIES", 141, 150], ["T. gondii", "SPECIES", 141, 150], ["A genome-wide acetylation analysis", "TEST", 0, 34], ["many acetylated proteins", "PROBLEM", 46, 70], ["different localizations in T. gondii", "PROBLEM", 114, 150], ["the parasite", "PROBLEM", 176, 188], ["acetylated proteins", "OBSERVATION", 51, 70], ["diverse", "OBSERVATION_MODIFIER", 83, 90], ["cellular processes", "OBSERVATION", 91, 109], ["host cell acetylome", "OBSERVATION", 201, 220]]], ["Lysine acetylation has also been studied in different genotype of T. gondii and was found to correlate with the virulence of the parasite strains (Wang et al. 2019).", [["Lysine", "CHEMICAL", 0, 6], ["Lysine", "CHEMICAL", 0, 6], ["Lysine", "AMINO_ACID", 0, 6], ["T. gondii", "ORGANISM", 66, 75], ["T. gondii", "SPECIES", 66, 75], ["T. gondii", "SPECIES", 66, 75], ["Lysine acetylation", "TREATMENT", 0, 18], ["T. gondii", "TEST", 66, 75], ["the parasite strains", "PROBLEM", 125, 145]]], ["However, to what extent does T. gondii influence the cat intestine acetylome remains unknown.IntroductionIn the present study, a quantitative analysis of the acetylome of cat small intestine infected by T. gondii was performed.", [["intestine", "ANATOMY", 57, 66], ["small intestine", "ANATOMY", 175, 190], ["T. gondii", "ORGANISM", 29, 38], ["cat", "ORGANISM", 53, 56], ["intestine", "ORGAN", 57, 66], ["cat", "ORGANISM", 171, 174], ["small intestine", "ORGAN", 175, 190], ["T. gondii", "ORGANISM", 203, 212], ["T. gondii", "SPECIES", 29, 38], ["T. gondii", "SPECIES", 203, 212], ["T. gondii", "SPECIES", 29, 38], ["T. gondii", "SPECIES", 203, 212], ["the present study", "TEST", 108, 125], ["a quantitative analysis", "TEST", 127, 150], ["the acetylome of cat small intestine infected", "PROBLEM", 154, 199], ["T. gondii", "TEST", 203, 212], ["intestine", "ANATOMY", 181, 190]]], ["To our knowledge, this is the first study to profile the acetylome alteration of feline small intestine following T. gondii infection.Animals ::: Materials and methodsSix domestic cats (7- to 9-month-old) of the Chinese Li Hua breed were purchased from a local breeder and housed in a controlled environment.", [["small intestine", "ANATOMY", 88, 103], ["T. gondii infection", "DISEASE", 114, 133], ["Li", "CHEMICAL", 220, 222], ["feline", "ORGANISM", 81, 87], ["small intestine", "ORGAN", 88, 103], ["T. gondii", "ORGANISM", 114, 123], ["cats", "ORGANISM", 180, 184], ["feline", "SPECIES", 81, 87], ["T. gondii", "SPECIES", 114, 123], ["cats", "SPECIES", 180, 184], ["T. gondii", "SPECIES", 114, 123], ["the first study", "TEST", 26, 41], ["feline small intestine", "PROBLEM", 81, 103], ["T. gondii infection", "PROBLEM", 114, 133], ["intestine", "ANATOMY", 94, 103], ["gondii infection", "OBSERVATION", 117, 133], ["Hua", "ANATOMY", 223, 226]]], ["Prior to the experiment, sera of all cats were tested using a modified agglutination test (MAT) to confirm that the cats were negative for T. gondii antibodies.", [["sera", "ANATOMY", 25, 29], ["sera", "ORGANISM_SUBSTANCE", 25, 29], ["cats", "ORGANISM", 37, 41], ["cats", "ORGANISM", 116, 120], ["T. gondii", "ORGANISM", 139, 148], ["T. gondii antibodies", "PROTEIN", 139, 159], ["cats", "SPECIES", 37, 41], ["cats", "SPECIES", 116, 120], ["T. gondii", "SPECIES", 139, 148], ["T. gondii", "SPECIES", 139, 148], ["a modified agglutination test", "TEST", 60, 89], ["the cats", "TEST", 112, 120], ["T. gondii antibodies", "PROBLEM", 139, 159]]], ["Commercial ELISA Kits (NuoYuan, Shanghai, China) were used to confirm that the cats used in the study were free of four viral infections (feline immunodeficiency virus, feline parvovirus, feline coronavirus, and feline leukemia virus).", [["viral infections", "DISEASE", 120, 136], ["feline immunodeficiency virus", "DISEASE", 138, 167], ["feline parvovirus", "DISEASE", 169, 186], ["feline coronavirus", "DISEASE", 188, 206], ["feline leukemia virus", "DISEASE", 212, 233], ["cats", "ORGANISM", 79, 83], ["feline immunodeficiency virus", "ORGANISM", 138, 167], ["feline parvovirus", "ORGANISM", 169, 186], ["feline coronavirus", "ORGANISM", 188, 206], ["feline leukemia virus", "ORGANISM", 212, 233], ["cats", "SPECIES", 79, 83], ["feline immunodeficiency virus", "SPECIES", 138, 167], ["feline parvovirus", "SPECIES", 169, 186], ["feline coronavirus", "SPECIES", 188, 206], ["feline leukemia virus", "SPECIES", 212, 233], ["feline immunodeficiency virus", "SPECIES", 138, 167], ["feline parvovirus", "SPECIES", 169, 186], ["feline coronavirus", "SPECIES", 188, 206], ["feline leukemia virus", "SPECIES", 212, 233], ["the study", "TEST", 92, 101], ["four viral infections (feline immunodeficiency virus", "PROBLEM", 115, 167], ["feline parvovirus", "PROBLEM", 169, 186], ["feline coronavirus", "PROBLEM", 188, 206], ["feline leukemia virus", "PROBLEM", 212, 233], ["feline leukemia virus", "OBSERVATION", 212, 233]]], ["All cats had access to commercial diet and water ad libitum.Parasite infection and sample collection ::: Materials and methodsPRU strain (genotype II) of T. gondii was used in the present study.", [["sample", "ANATOMY", 83, 89], ["Parasite infection", "DISEASE", 60, 78], ["cats", "ORGANISM", 4, 8], ["T. gondii", "ORGANISM", 154, 163], ["cats", "SPECIES", 4, 8], ["T. gondii", "SPECIES", 154, 163], ["T. gondii", "SPECIES", 154, 163], ["Parasite infection", "PROBLEM", 60, 78], ["methodsPRU strain (genotype II) of T. gondii", "PROBLEM", 119, 163], ["the present study", "TEST", 176, 193], ["infection", "OBSERVATION", 69, 78]]], ["The parasite tissue cysts were collected from the brains of Kunming mice infected by PRU strain and counted microscopically.", [["tissue cysts", "ANATOMY", 13, 25], ["brains", "ANATOMY", 50, 56], ["parasite tissue cysts", "ORGANISM_SUBSTANCE", 4, 25], ["brains", "ORGANISM_SUBDIVISION", 50, 56], ["mice", "ORGANISM", 68, 72], ["mice", "SPECIES", 68, 72], ["mice", "SPECIES", 68, 72], ["The parasite tissue cysts", "PROBLEM", 0, 25], ["parasite tissue", "OBSERVATION_MODIFIER", 4, 19], ["cysts", "OBSERVATION", 20, 25], ["PRU strain", "OBSERVATION", 85, 95]]], ["Six cats were randomly allocated to 2 groups (3 cats per group).", [["cats", "ORGANISM", 4, 8], ["cats", "ORGANISM", 48, 52], ["cats", "SPECIES", 4, 8]]], ["Each cat in the infected group was orally inoculated with 100 cysts suspended in 1 ml of sterile phosphate buffer saline (PBS), whereas cats of the control (noninfected) group received 1 ml of sterile PBS only.", [["cysts", "ANATOMY", 62, 67], ["phosphate", "CHEMICAL", 97, 106], ["phosphate", "CHEMICAL", 97, 106], ["cat", "ORGANISM", 5, 8], ["phosphate buffer saline", "SIMPLE_CHEMICAL", 97, 120], ["cats", "ORGANISM", 136, 140], ["cat", "SPECIES", 5, 8], ["cats", "SPECIES", 136, 140], ["sterile phosphate buffer saline (PBS", "TREATMENT", 89, 125], ["sterile PBS", "TREATMENT", 193, 204], ["infected", "OBSERVATION_MODIFIER", 16, 24]]], ["Ten days postinfection, cats were euthanized, and their small intestines were collected followed by several washes using PBS to remove the intestinal contents.", [["intestines", "ANATOMY", 62, 72], ["intestinal", "ANATOMY", 139, 149], ["cats", "ORGANISM", 24, 28], ["intestines", "ORGAN", 62, 72], ["intestinal", "ORGAN", 139, 149], ["cats", "SPECIES", 24, 28], ["PBS", "TREATMENT", 121, 124], ["small intestines", "ANATOMY", 56, 72], ["intestinal", "ANATOMY", 139, 149], ["contents", "OBSERVATION", 150, 158]]], ["The collected intestinal samples were frozen immediately in liquid nitrogen and stored at \u2013 80 \u00b0C until use.Confirmation of T. gondii infection in the intestines ::: Materials and methodsGenomic DNA of harvested small intestine was extracted using TIANamp Genomic DNA Kit (TianGenTM, Beijing, China).", [["intestinal samples", "ANATOMY", 14, 32], ["intestines", "ANATOMY", 151, 161], ["small intestine", "ANATOMY", 212, 227], ["T. gondii infection", "DISEASE", 124, 143], ["nitrogen", "CHEMICAL", 67, 75], ["intestinal samples", "CANCER", 14, 32], ["T. gondii", "ORGANISM", 124, 133], ["intestines", "ORGAN", 151, 161], ["DNA", "CELLULAR_COMPONENT", 195, 198], ["small intestine", "ORGAN", 212, 227], ["T. gondii", "SPECIES", 124, 133], ["T. gondii", "SPECIES", 124, 133], ["The collected intestinal samples", "TEST", 0, 32], ["liquid nitrogen", "TREATMENT", 60, 75], ["T. gondii infection", "PROBLEM", 124, 143], ["Materials", "TREATMENT", 166, 175], ["harvested small intestine", "PROBLEM", 202, 227], ["TIANamp", "TREATMENT", 248, 255], ["intestinal", "ANATOMY", 14, 24], ["gondii infection", "OBSERVATION", 127, 143], ["intestines", "ANATOMY", 151, 161], ["harvested", "OBSERVATION_MODIFIER", 202, 211], ["small", "OBSERVATION_MODIFIER", 212, 217], ["intestine", "ANATOMY", 218, 227]]], ["A nested PCR was used to detect T. gondii infection in cat intestine tissues as described previously (Lin et al. 2000).", [["intestine tissues", "ANATOMY", 59, 76], ["T. gondii infection", "DISEASE", 32, 51], ["T. gondii", "ORGANISM", 32, 41], ["cat", "ORGANISM", 55, 58], ["intestine tissues", "TISSUE", 59, 76], ["T. gondii", "SPECIES", 32, 41], ["T. gondii", "SPECIES", 32, 41], ["cat", "SPECIES", 55, 58], ["A nested PCR", "TEST", 0, 12], ["T. gondii infection in cat intestine tissues", "PROBLEM", 32, 76], ["infection", "OBSERVATION", 42, 51], ["intestine tissues", "ANATOMY", 59, 76]]], ["In the first round of the nested PCR, the following primers were used: TOXO1: 5'-GGAACTGCATCCGTTCATGAG-3' and TOXO2: 5'-TCTTTAAAGCGTTCGTGGTC-3'.", [["5'-GGAACTGCATCCGTTCATGAG-3", "GENE_OR_GENE_PRODUCT", 78, 104], ["the nested PCR", "TEST", 22, 36], ["the following primers", "TREATMENT", 38, 59], ["GGAACTGCATCCGTTCATGAG", "TEST", 81, 102], ["TOXO2", "TEST", 110, 115], ["TCTTTAAAGCGTTCGTGGTC", "TEST", 120, 140]]], ["PCR conditions included an initial denaturation step at 94 \u00b0C for 10 min, followed by 30 PCR cycles of 94 \u00b0C for 1 min, 60 \u00b0C for 15 s, and 72 \u00b0C for 45 s.", [["PCR conditions", "TEST", 0, 14], ["an initial denaturation step", "PROBLEM", 24, 52], ["PCR cycles", "TEST", 89, 99]]], ["In the second round of nested PCR, 1 \u03bcl PCR product (~ 193 bp) of first round was used as PCR template and the same protocol used in first round was followed, but with using primer TOXO 3 (5'-TGCATAGGTTGCAGTCACTG-3') instead of the primer TOXO 1 with anticipated amplicon size of 131 bp.", [["PCR template", "DNA", 90, 102], ["primer TOXO 3", "DNA", 174, 187], ["primer TOXO 1", "DNA", 232, 245], ["nested PCR", "TEST", 23, 33], ["bp", "TEST", 59, 61], ["PCR template", "TREATMENT", 90, 102], ["the same protocol", "TREATMENT", 107, 124], ["primer TOXO", "TEST", 174, 185], ["TGCATAGGTTGCAGTCACTG", "TEST", 192, 212], ["the primer TOXO", "TEST", 228, 243], ["anticipated amplicon size", "TEST", 251, 276], ["bp", "TEST", 284, 286]]], ["The PCR products were electrophoresed on 1% agarose-Tris-acetate-EDTA gel that was stained with ethidium bromide.", [["agarose-Tris-acetate-EDTA", "CHEMICAL", 44, 69], ["ethidium bromide", "CHEMICAL", 96, 112], ["agarose-Tris-acetate-EDTA gel", "CHEMICAL", 44, 73], ["ethidium bromide", "CHEMICAL", 96, 112], ["agarose-Tris-acetate-EDTA", "SIMPLE_CHEMICAL", 44, 69], ["ethidium bromide", "SIMPLE_CHEMICAL", 96, 112], ["The PCR products", "TREATMENT", 0, 16], ["1% agarose-Tris-acetate-EDTA gel", "TREATMENT", 41, 73], ["ethidium bromide", "TREATMENT", 96, 112]]], ["The PCR products were purified and sequenced.", [["PCR products", "DNA", 4, 16], ["The PCR products", "TREATMENT", 0, 16]]], ["Also, fecal samples were collected daily and examined using flotation method to monitor the shedding of T. gondii oocysts.Protein extraction ::: Materials and methodsThe appropriate amount of lysis buffer (containing 8 M urea and protease inhibitor) was added to each sample followed by sonication on ice for 5 min.", [["fecal samples", "ANATOMY", 6, 19], ["sample", "ANATOMY", 268, 274], ["urea", "CHEMICAL", 221, 225], ["urea", "CHEMICAL", 221, 225], ["fecal samples", "ORGANISM_SUBSTANCE", 6, 19], ["T. gondii", "ORGANISM", 104, 113], ["oocysts", "ORGANISM", 114, 121], ["urea", "SIMPLE_CHEMICAL", 221, 225], ["T. gondii", "SPECIES", 104, 113], ["T. gondii", "SPECIES", 104, 113], ["fecal samples", "TEST", 6, 19], ["flotation method", "TREATMENT", 60, 76], ["the shedding of T. gondii oocysts", "PROBLEM", 88, 121], ["lysis buffer", "TREATMENT", 192, 204], ["8 M urea and protease inhibitor", "TREATMENT", 217, 248], ["fecal", "ANATOMY", 6, 11], ["gondii oocysts", "OBSERVATION", 107, 121], ["appropriate", "OBSERVATION_MODIFIER", 170, 181], ["amount", "OBSERVATION_MODIFIER", 182, 188], ["lysis", "OBSERVATION", 192, 197]]], ["Then, samples were centrifuged at 25,000g for 20 min at 4 \u00b0C, and the supernatant was collected.", [["samples", "ANATOMY", 6, 13], ["supernatant", "ANATOMY", 70, 81], ["samples", "TEST", 6, 13], ["the supernatant", "TREATMENT", 66, 81]]], ["Dithiothreitol (DTT) was added to the supernatant at a final concentration of 10 mM, and the samples were incubated at 56 \u00b0C for 1 h in a water bath.", [["supernatant", "ANATOMY", 38, 49], ["samples", "ANATOMY", 93, 100], ["Dithiothreitol", "CHEMICAL", 0, 14], ["DTT", "CHEMICAL", 16, 19], ["Dithiothreitol", "CHEMICAL", 0, 14], ["DTT", "CHEMICAL", 16, 19], ["Dithiothreitol", "SIMPLE_CHEMICAL", 0, 14], ["DTT", "SIMPLE_CHEMICAL", 16, 19], ["Dithiothreitol (DTT)", "TREATMENT", 0, 20], ["a water bath", "TREATMENT", 136, 148]]], ["The deacetylase inhibitor (55 mM IAM) was added followed by incubation in the dark for 45 min at room temperature.", [["The deacetylase inhibitor", "TREATMENT", 0, 25]]], ["Finally, protein concentration of each protein sample was determined by using the Bradford assay.Trypsin digestion and affinity enrichment of acetylated peptides ::: Materials and methodsFrom each sample, 5 mg of extracted protein were diluted with 30 mM HEPES until the final concentration of urea reached < 2 M. Then, trypsin was added at protein to trypsin mass ratio of 50:1 and digested at 37 \u00b0C for overnight.", [["urea", "CHEMICAL", 294, 298], ["HEPES", "CHEMICAL", 255, 260], ["urea", "CHEMICAL", 294, 298], ["Trypsin", "GENE_OR_GENE_PRODUCT", 97, 104], ["urea", "SIMPLE_CHEMICAL", 294, 298], ["trypsin", "GENE_OR_GENE_PRODUCT", 320, 327], ["trypsin", "SIMPLE_CHEMICAL", 352, 359], ["trypsin", "PROTEIN", 320, 327], ["trypsin", "PROTEIN", 352, 359], ["protein concentration", "TEST", 9, 30], ["each protein sample", "TEST", 34, 53], ["the Bradford assay", "TEST", 78, 96], ["Trypsin digestion", "PROBLEM", 97, 114], ["extracted protein", "TREATMENT", 213, 230], ["30 mM HEPES", "TREATMENT", 249, 260], ["urea", "TEST", 294, 298], ["trypsin", "TREATMENT", 320, 327], ["trypsin mass ratio", "TEST", 352, 370]]], ["The digested peptides were desalted using Sep-Pac C18 column and vacuum dried.", [["Sep-Pac C18", "CHEMICAL", 42, 53], ["The digested peptides", "TREATMENT", 0, 21], ["Sep-Pac C18 column", "TREATMENT", 42, 60], ["vacuum dried", "TREATMENT", 65, 77], ["C18 column", "OBSERVATION", 50, 60], ["vacuum dried", "OBSERVATION", 65, 77]]], ["The tryptic peptides were dissolved in IAP buffer and mixed with the coupled acetylated antibody beads at 4 \u00b0C overnight with gentle shaking.", [["The tryptic peptides", "TREATMENT", 0, 20], ["IAP buffer", "TREATMENT", 39, 49], ["the coupled acetylated antibody beads", "TREATMENT", 65, 102], ["gentle shaking", "PROBLEM", 126, 140], ["acetylated antibody beads", "OBSERVATION", 77, 102]]], ["The sample was centrifuged at 2000g and 4 \u00b0C for 4 s, and the supernatant was discarded.", [["sample", "ANATOMY", 4, 10], ["supernatant", "ANATOMY", 62, 73], ["The sample", "TEST", 0, 10], ["the supernatant", "TREATMENT", 58, 73]]], ["The sediment was washed twice with 1 ml IPA buffer followed by washing three times with precooled double distilled H2O.", [["IPA", "CHEMICAL", 40, 43], ["H2O", "CHEMICAL", 115, 118], ["H2O", "CHEMICAL", 115, 118], ["1 ml IPA buffer", "TREATMENT", 35, 50], ["precooled double distilled H2O", "TREATMENT", 88, 118], ["sediment", "OBSERVATION", 4, 12]]], ["After adding 200 \u03bcl 0.15% trifluoroacetic acid (TFA) and incubation for 10 min at room temperature, the sample was centrifuged at 2000g and 4 \u00b0C for 4 s, and the supernatant was collected.", [["sample", "ANATOMY", 104, 110], ["supernatant", "ANATOMY", 162, 173], ["trifluoroacetic acid", "CHEMICAL", 26, 46], ["TFA", "CHEMICAL", 48, 51], ["trifluoroacetic acid", "CHEMICAL", 26, 46], ["TFA", "CHEMICAL", 48, 51], ["trifluoroacetic acid", "SIMPLE_CHEMICAL", 26, 46], ["TFA", "SIMPLE_CHEMICAL", 48, 51], ["200 \u03bcl 0.15% trifluoroacetic acid (TFA", "TREATMENT", 13, 51]]], ["Finally, the peptides in the supernatant were dried using a vacuum centrifuge.HPLC fractionation and LC-MS/MS analysis ::: Materials and methodsThe dried peptides were reconstituted in double distilled H2O with 2% ACN and 0.1% FA.", [["supernatant", "ANATOMY", 29, 40], ["H2O", "CHEMICAL", 202, 205], ["ACN", "CHEMICAL", 214, 217], ["FA", "CHEMICAL", 227, 229], ["H2O", "CHEMICAL", 202, 205], ["ACN", "CHEMICAL", 214, 217], ["ACN", "SIMPLE_CHEMICAL", 214, 217], ["FA", "SIMPLE_CHEMICAL", 227, 229], ["the peptides", "TREATMENT", 9, 21], ["a vacuum centrifuge", "TREATMENT", 58, 77], ["HPLC fractionation", "TEST", 78, 96], ["LC", "TEST", 101, 103], ["MS analysis", "TEST", 107, 118], ["The dried peptides", "TREATMENT", 144, 162], ["double distilled H2O", "TREATMENT", 185, 205], ["2% ACN", "TREATMENT", 211, 217], ["vacuum centrifuge", "OBSERVATION", 60, 77]]], ["Then, the dissolved peptides were separated by UHPLC (UltiMate 3000, Thermo) using the HPLC gradient elution settings described in Table S1.", [["the dissolved peptides", "TREATMENT", 6, 28], ["the HPLC gradient elution settings", "TREATMENT", 83, 117]]], ["Peptide segments were ionized by nanoESI source and then detected by tandem mass spectrometer Q-Exactive HF (Thermo Fisher Scientific, San Jose, CA) with DDA (data-dependent acquisition) detection mode.", [["DDA", "CHEMICAL", 154, 157], ["segments", "ANATOMY_MODIFIER", 8, 16], ["ionized", "OBSERVATION", 22, 29]]], ["The m/z scan range was 350 to 1500 for full scan, and intact peptides were detected in the orbitrap at a resolution of 120,000.", [["The m/z scan range", "TEST", 0, 18], ["full scan", "TEST", 39, 48], ["the orbitrap", "TEST", 87, 99]]], ["The analyses of the MS/MS data, including identification, normalization, and differential analysis, were processed using MaxQuant (v.1.5.3.30) search engine (Cox and Mann 2008).", [["the MS/MS data", "TEST", 16, 30], ["identification", "TEST", 42, 56], ["differential analysis", "TEST", 77, 98]]], ["Tandem mass spectra were searched against UniProt database for protein identification.", [["Tandem mass spectra", "PROBLEM", 0, 19], ["protein identification", "TEST", 63, 85], ["mass", "OBSERVATION", 7, 11]]], ["Trypsin/P was specified as cleavage enzyme allowing up to 4 missing cleavages.", [["Trypsin", "GENE_OR_GENE_PRODUCT", 0, 7], ["P", "DNA", 8, 9], ["cleavage enzyme", "PROTEIN", 27, 42], ["cleavage enzyme", "TEST", 27, 42]]], ["The mass tolerance for precursor ions was set as 20 ppm and 0.05 Da for fragment ions.", [["The mass tolerance", "PROBLEM", 0, 18], ["precursor ions", "TREATMENT", 23, 37], ["fragment ions", "PROBLEM", 72, 85], ["mass", "OBSERVATION", 4, 8], ["fragment ions", "OBSERVATION", 72, 85]]], ["Carbamidomethylation of cysteine was considered as a fixed modification.", [["Carbamidomethylation of cysteine", "CHEMICAL", 0, 32], ["cysteine", "CHEMICAL", 24, 32], ["cysteine", "AMINO_ACID", 24, 32], ["Carbamidomethylation of cysteine", "TREATMENT", 0, 32], ["a fixed modification", "TREATMENT", 51, 71]]], ["Methionine oxidation, acetylation on lysine, and acetylation on protein N-terminal were designated as variable modifications.", [["Methionine", "CHEMICAL", 0, 10], ["lysine", "CHEMICAL", 37, 43], ["Methionine", "CHEMICAL", 0, 10], ["lysine", "CHEMICAL", 37, 43], ["N", "CHEMICAL", 72, 73], ["Methionine", "SIMPLE_CHEMICAL", 0, 10], ["lysine", "AMINO_ACID", 37, 43], ["protein N-terminal", "PROTEIN", 64, 82], ["Methionine oxidation", "TREATMENT", 0, 20], ["acetylation on lysine", "TREATMENT", 22, 43], ["acetylation", "TREATMENT", 49, 60]]], ["The threshold of differentially acetylated peptides (DAPs) was P < 0.05.Bioinformatics analysis ::: Materials and methodsGene ontology (GO) analysis was performed to identify the enriched acetylated proteins among the proteins with differentially acetylated peptides (PDAPs) by using ToxoDB 11.0 and UniProt-GOA database, and acetylated proteins were classed into three categories: molecular function (MF), biological process (BP), and cellular component (CC).", [["cellular", "ANATOMY", 436, 444], ["CC", "CHEMICAL", 456, 458], ["PDAPs", "GENE_OR_GENE_PRODUCT", 268, 273], ["cellular", "CELL", 436, 444], ["acetylated proteins", "PROTEIN", 188, 207], ["acetylated proteins", "PROTEIN", 326, 345], ["BP", "PROTEIN", 427, 429], ["differentially acetylated peptides", "TREATMENT", 17, 51], ["Bioinformatics analysis", "TEST", 72, 95], ["analysis", "TEST", 140, 148], ["differentially acetylated peptides", "TREATMENT", 232, 266], ["ToxoDB", "TEST", 284, 290], ["UniProt", "TEST", 300, 307], ["GOA database", "TEST", 308, 320], ["acetylated proteins", "TREATMENT", 326, 345], ["BP", "TEST", 427, 429], ["acetylated peptides", "OBSERVATION", 32, 51], ["cellular", "OBSERVATION_MODIFIER", 436, 444], ["component", "OBSERVATION_MODIFIER", 445, 454]]], ["The orthologous proteins were classified by using orthologous groups of proteins (COG) database (Tatusov et al. 2000).", [["orthologous proteins", "PROTEIN", 4, 24], ["COG", "PROTEIN", 82, 85], ["The orthologous proteins", "TEST", 0, 24]]], ["Functional enrichment analysis was performed to identify the enriched pathways using Kyoto Encyclopedia of Genes and Genomes (KEGG) database (Kanehisa 2008).", [["Kyoto Encyclopedia of Genes", "DNA", 85, 112], ["Functional enrichment analysis", "TEST", 0, 30]]], ["KEGG pathways were considered significant at a P value of < 0.05.", [["KEGG pathways", "TEST", 0, 13], ["a P value", "TEST", 45, 54]]], ["WoLF PSORT algorithm was applied to predict the subcellular locations of the PDAPs (Horton et al. 2007).", [["subcellular", "ANATOMY", 48, 59], ["WoLF PSORT algorithm", "TEST", 0, 20]]], ["For motif analysis, the 11-mers amino acid (\u00b1 5 amino acids residues around the lysine acetylation site) of sequences of all DAPs was analyzed using Motif-x software.", [["amino acid", "CHEMICAL", 32, 42], ["amino acids", "CHEMICAL", 48, 59], ["amino acid", "CHEMICAL", 32, 42], ["amino acids", "CHEMICAL", 48, 59], ["lysine", "CHEMICAL", 80, 86], ["amino acid", "AMINO_ACID", 32, 42], ["amino acids", "AMINO_ACID", 48, 59], ["lysine", "AMINO_ACID", 80, 86], ["lysine acetylation site", "PROTEIN", 80, 103], ["DAPs", "PROTEIN", 125, 129], ["motif analysis", "TEST", 4, 18], ["the 11-mers amino acid (\u00b1 5 amino acids residues", "TREATMENT", 20, 68], ["the lysine acetylation site", "TREATMENT", 76, 103], ["all DAPs", "TEST", 121, 129]]], ["All protein sequences were used as background and other parameters were set to the default values.Confirmation of T. gondii infection and overall features of the differentially acetylated peptides ::: ResultsDaily fecal examination detected T. gondii oocysts in feline feces at 7 dpi.", [["fecal", "ANATOMY", 214, 219], ["feces", "ANATOMY", 269, 274], ["T. gondii infection", "DISEASE", 114, 133], ["T. gondii oocysts", "DISEASE", 241, 258], ["T. gondii", "ORGANISM", 114, 123], ["fecal", "ORGANISM_SUBSTANCE", 214, 219], ["T. gondii", "ORGANISM", 241, 250], ["oocysts", "ORGANISM_SUBSTANCE", 251, 258], ["feline", "ORGANISM", 262, 268], ["feces", "ORGANISM_SUBDIVISION", 269, 274], ["T. gondii", "SPECIES", 114, 123], ["T. gondii", "SPECIES", 241, 250], ["feline", "SPECIES", 262, 268], ["T. gondii", "SPECIES", 114, 123], ["T. gondii", "SPECIES", 241, 250], ["All protein sequences", "TEST", 0, 21], ["T. gondii infection", "PROBLEM", 114, 133], ["fecal examination", "TEST", 214, 231], ["T. gondii oocysts in feline feces", "PROBLEM", 241, 274], ["gondii infection", "OBSERVATION", 117, 133], ["fecal", "ANATOMY", 214, 219]]], ["All feline small intestines were PCR positive (Figure S1), and our DNA sequencing confirmed that the PCR product was B1 gene of T. gondii.", [["intestines", "ANATOMY", 17, 27], ["feline", "ORGANISM", 4, 10], ["small intestines", "ORGAN", 11, 27], ["DNA", "CELLULAR_COMPONENT", 67, 70], ["B1", "GENE_OR_GENE_PRODUCT", 117, 119], ["T. gondii", "ORGANISM", 128, 137], ["B1 gene", "DNA", 117, 124], ["T. gondii", "SPECIES", 128, 137], ["T. gondii", "SPECIES", 128, 137], ["PCR", "TEST", 33, 36], ["our DNA sequencing", "TEST", 63, 81], ["the PCR product", "TEST", 97, 112], ["T. gondii", "PROBLEM", 128, 137], ["small", "OBSERVATION_MODIFIER", 11, 16], ["intestines", "ANATOMY", 17, 27]]], ["In high-resolution immunoaffinity LC-MS/MS analysis, the mass errors were less than 6 ppm, and the majority were close to zero (Fig. 1a), showing the accuracy of the data obtained in the present study.", [["MS analysis", "TEST", 40, 51], ["the mass errors", "PROBLEM", 53, 68], ["the present study", "TEST", 183, 200], ["mass", "OBSERVATION", 57, 61]]], ["A total of 2606 unique acetylation sites of 1357 proteins were identified (Table S2).", [["2606 unique acetylation sites", "DNA", 11, 40]]], ["Acetylated peptides with P value < 0.05 were deemed as differentially regulated.", [["Acetylated peptides", "TREATMENT", 0, 19], ["P value", "TEST", 25, 32]]], ["In this study, the acetylation of 334 peptides was decreased in the infected small intestine, whereas acetylation of 82 peptides was increased (Fig. 1b and Table S3).", [["small intestine", "ANATOMY", 77, 92], ["small intestine", "ORGAN", 77, 92], ["this study", "TEST", 3, 13], ["the infected small intestine", "PROBLEM", 64, 92], ["infected", "OBSERVATION_MODIFIER", 68, 76], ["small intestine", "ANATOMY", 77, 92]]], ["About 65% acetylated proteins had only one acetylated site, 17% acetylated proteins contained two acetylated site, 10% acetylated proteins contained three or four acetylated sites, and 8% acetylated proteins contained five or more acetylated sites (Fig. 1c).", [["acetylated proteins", "PROTEIN", 10, 29], ["acetylated proteins", "PROTEIN", 64, 83], ["acetylated site", "PROTEIN", 98, 113], ["acetylated proteins", "PROTEIN", 119, 138], ["acetylated sites", "PROTEIN", 163, 179], ["acetylated proteins", "PROTEIN", 188, 207], ["acetylated sites", "PROTEIN", 231, 247], ["acetylated proteins", "TEST", 10, 29], ["10% acetylated proteins", "TREATMENT", 115, 138], ["8% acetylated proteins", "TREATMENT", 185, 207], ["acetylated site", "OBSERVATION", 98, 113], ["acetylated sites", "OBSERVATION", 163, 179], ["acetylated sites", "OBSERVATION", 231, 247]]], ["To identify the motif of DAPs in feline small intestine, the character of the amino acid sequence adjacent to acetylation sites was analyzed.", [["small intestine", "ANATOMY", 40, 55], ["amino acid", "CHEMICAL", 78, 88], ["amino acid", "CHEMICAL", 78, 88], ["DAPs", "GENE_OR_GENE_PRODUCT", 25, 29], ["feline", "ORGANISM", 33, 39], ["small intestine", "ORGAN", 40, 55], ["amino acid", "AMINO_ACID", 78, 88], ["DAPs", "PROTEIN", 25, 29], ["amino acid sequence", "PROTEIN", 78, 97], ["acetylation sites", "PROTEIN", 110, 127], ["feline", "SPECIES", 33, 39], ["DAPs in feline small intestine", "PROBLEM", 25, 55], ["the amino acid sequence", "TEST", 74, 97], ["acetylation sites", "TREATMENT", 110, 127], ["small intestine", "ANATOMY", 40, 55]]], ["As shown in Fig. 1d, no clear acetylation motif was detected.Functional classification and subcellular localization of the proteins with differentially acetylated peptides ::: ResultsTo elucidate the functions of PDAPs altered by T. gondii infection in the small intestine, subcellular localization, GO, KEGG, and COG classification analyses were performed.", [["subcellular", "ANATOMY", 91, 102], ["small intestine", "ANATOMY", 257, 272], ["subcellular", "ANATOMY", 274, 285], ["T. gondii infection", "DISEASE", 230, 249], ["PDAPs", "GENE_OR_GENE_PRODUCT", 213, 218], ["T. gondii", "ORGANISM", 230, 239], ["small intestine", "MULTI-TISSUE_STRUCTURE", 257, 272], ["PDAPs", "PROTEIN", 213, 218], ["T. gondii", "SPECIES", 230, 239], ["T. gondii", "SPECIES", 230, 239], ["clear acetylation motif", "PROBLEM", 24, 47], ["T. gondii infection in the small intestine", "PROBLEM", 230, 272], ["subcellular localization", "TEST", 274, 298], ["KEGG", "TEST", 304, 308], ["COG classification analyses", "TEST", 314, 341], ["no", "UNCERTAINTY", 21, 23], ["clear", "OBSERVATION_MODIFIER", 24, 29], ["acetylation motif", "OBSERVATION", 30, 47], ["gondii infection", "OBSERVATION", 233, 249], ["small intestine", "ANATOMY", 257, 272]]], ["Analysis of subcellular localization of PDAPs indicated that most PDAPs were localized in the cytoplasm (32%), nucleus (29%), mitochondria (18%), extracellular (8%), cyto-nucl (3%), and endoplasmic reticulum (2%) (Fig. 2a).Functional classification and subcellular localization of the proteins with differentially acetylated peptides ::: ResultsCOG analysis showed that PDAPs were classified into 24 functional groups.", [["subcellular", "ANATOMY", 12, 23], ["cytoplasm", "ANATOMY", 94, 103], ["nucleus", "ANATOMY", 111, 118], ["mitochondria", "ANATOMY", 126, 138], ["extracellular", "ANATOMY", 146, 159], ["cyto-nucl", "ANATOMY", 166, 175], ["endoplasmic reticulum", "ANATOMY", 186, 207], ["subcellular", "ANATOMY", 253, 264], ["PDAPs", "GENE_OR_GENE_PRODUCT", 40, 45], ["PDAPs", "GENE_OR_GENE_PRODUCT", 66, 71], ["cytoplasm", "ORGANISM_SUBSTANCE", 94, 103], ["nucleus", "CELLULAR_COMPONENT", 111, 118], ["mitochondria", "CELLULAR_COMPONENT", 126, 138], ["extracellular", "CELLULAR_COMPONENT", 146, 159], ["cyto-nucl", "GENE_OR_GENE_PRODUCT", 166, 175], ["endoplasmic reticulum", "CELLULAR_COMPONENT", 186, 207], ["PDAPs", "SIMPLE_CHEMICAL", 370, 375], ["PDAPs", "PROTEIN", 40, 45], ["PDAPs", "PROTEIN", 66, 71], ["cyto-nucl", "PROTEIN", 166, 175], ["subcellular localization of PDAPs", "TEST", 12, 45], ["nucleus", "TEST", 111, 118], ["mitochondria", "TEST", 126, 138], ["extracellular", "TEST", 146, 159], ["cyto-nucl", "TEST", 166, 175], ["endoplasmic reticulum", "TEST", 186, 207], ["ResultsCOG analysis", "TEST", 338, 357], ["PDAPs", "PROBLEM", 370, 375], ["cytoplasm", "ANATOMY_MODIFIER", 94, 103], ["nucleus", "ANATOMY", 111, 118], ["endoplasmic reticulum", "ANATOMY", 186, 207]]], ["The proteins involved in translation, ribosomal structure and biogenesis, posttranslational modification, protein turnover, and chaperones account for a large proportion of the PDAPs (Fig. 2b).", [["ribosomal", "ANATOMY", 38, 47], ["ribosomal", "CELLULAR_COMPONENT", 38, 47], ["chaperones", "PROTEIN", 128, 138], ["PDAPs", "PROTEIN", 177, 182], ["posttranslational modification", "TREATMENT", 74, 104], ["protein turnover", "PROBLEM", 106, 122], ["ribosomal structure", "OBSERVATION", 38, 57], ["posttranslational modification", "OBSERVATION", 74, 104], ["large", "OBSERVATION_MODIFIER", 153, 158]]], ["According to COG annotations, a number of metabolically related enzymes were identified as acetylated proteins, including acyl-coenzyme A oxidase 3, aconitate hydratase, malate dehydrogenase, isocitrate dehydrogenase, dihydrolipoyl dehydrogenase, fumarate hydratase, and citrate synthase.Functional classification and subcellular localization of the proteins with differentially acetylated peptides ::: ResultsTo further identify intestinal biological changes that may have been influenced by PDAPs induced by T. gondii, we performed GO and KEGG pathway enrichment analyses with all PDAPs.", [["subcellular", "ANATOMY", 318, 329], ["intestinal", "ANATOMY", 430, 440], ["malate", "CHEMICAL", 170, 176], ["isocitrate", "CHEMICAL", 192, 202], ["dihydrolipoyl", "CHEMICAL", 218, 231], ["fumarate", "CHEMICAL", 247, 255], ["citrate", "CHEMICAL", 271, 278], ["acyl", "CHEMICAL", 122, 126], ["aconitate", "CHEMICAL", 149, 158], ["malate", "CHEMICAL", 170, 176], ["isocitrate", "CHEMICAL", 192, 202], ["dihydrolipoyl", "CHEMICAL", 218, 231], ["fumarate", "CHEMICAL", 247, 255], ["citrate", "CHEMICAL", 271, 278], ["acyl-coenzyme A oxidase 3", "GENE_OR_GENE_PRODUCT", 122, 147], ["aconitate hydratase", "GENE_OR_GENE_PRODUCT", 149, 168], ["malate dehydrogenase", "GENE_OR_GENE_PRODUCT", 170, 190], ["isocitrate dehydrogenase", "GENE_OR_GENE_PRODUCT", 192, 216], ["dihydrolipoyl dehydrogenase", "GENE_OR_GENE_PRODUCT", 218, 245], ["fumarate hydratase", "GENE_OR_GENE_PRODUCT", 247, 265], ["citrate synthase", "GENE_OR_GENE_PRODUCT", 271, 287], ["intestinal", "ORGAN", 430, 440], ["PDAPs", "GENE_OR_GENE_PRODUCT", 493, 498], ["T. gondii", "ORGANISM", 510, 519], ["PDAPs", "PATHOLOGICAL_FORMATION", 583, 588], ["enzymes", "PROTEIN", 64, 71], ["acetylated proteins", "PROTEIN", 91, 110], ["acyl-coenzyme A oxidase 3", "PROTEIN", 122, 147], ["aconitate hydratase", "PROTEIN", 149, 168], ["malate dehydrogenase", "PROTEIN", 170, 190], ["isocitrate dehydrogenase", "PROTEIN", 192, 216], ["dihydrolipoyl dehydrogenase", "PROTEIN", 218, 245], ["fumarate hydratase", "PROTEIN", 247, 265], ["citrate synthase", "PROTEIN", 271, 287], ["PDAPs", "PROTEIN", 493, 498], ["T. gondii", "SPECIES", 510, 519], ["T. gondii", "SPECIES", 510, 519], ["metabolically related enzymes", "PROBLEM", 42, 71], ["acetylated proteins", "TREATMENT", 91, 110], ["acyl-coenzyme A oxidase", "TREATMENT", 122, 145], ["aconitate hydratase", "TREATMENT", 149, 168], ["malate dehydrogenase", "TREATMENT", 170, 190], ["isocitrate dehydrogenase", "TREATMENT", 192, 216], ["dihydrolipoyl dehydrogenase", "TREATMENT", 218, 245], ["fumarate hydratase", "TREATMENT", 247, 265], ["citrate synthase", "TREATMENT", 271, 287], ["intestinal biological changes", "PROBLEM", 430, 459], ["all PDAPs", "TREATMENT", 579, 588], ["intestinal", "ANATOMY", 430, 440]]], ["GO enrichment identified several PDAPs involved in mitochondrial matrix (6.92%), mitochondrion (6.11%), and organelle part (3.52%).", [["mitochondrial matrix", "ANATOMY", 51, 71], ["mitochondrion", "ANATOMY", 81, 94], ["organelle", "ANATOMY", 108, 117], ["PDAPs", "GENE_OR_GENE_PRODUCT", 33, 38], ["mitochondrial matrix", "CELLULAR_COMPONENT", 51, 71], ["mitochondrion", "CELLULAR_COMPONENT", 81, 94], ["organelle", "CELLULAR_COMPONENT", 108, 117], ["PDAPs", "PROTEIN", 33, 38], ["mitochondrial matrix", "TEST", 51, 71], ["mitochondrion", "TEST", 81, 94], ["organelle part", "TEST", 108, 122], ["several", "OBSERVATION_MODIFIER", 25, 32], ["mitochondrial matrix", "ANATOMY", 51, 71]]], ["This result was consistent with that of WoLF PSORT prediction.", [["PSORT", "PROTEIN", 45, 50], ["consistent with", "UNCERTAINTY", 16, 31]]], ["Also, a variety of molecular functions were enriched, such as actin-dependent ATPase activity (3.22%), cysteine-type endopeptidase activity (2.88%), anion channel activity (2.66%), and oxidoreductase activity (2.54%), which were involved in oxidation-reduction process (4.55%) and various metabolic process (\u2265 2.98%) (Fig. 3a and Table S4).", [["cysteine", "CHEMICAL", 103, 111], ["cysteine", "CHEMICAL", 103, 111], ["ATPase", "GENE_OR_GENE_PRODUCT", 78, 84], ["cysteine-type endopeptidase", "GENE_OR_GENE_PRODUCT", 103, 130], ["anion", "SIMPLE_CHEMICAL", 149, 154], ["oxidoreductase", "GENE_OR_GENE_PRODUCT", 185, 199], ["actin-dependent ATPase", "PROTEIN", 62, 84], ["cysteine-type endopeptidase", "PROTEIN", 103, 130], ["oxidoreductase", "PROTEIN", 185, 199], ["actin-dependent ATPase activity", "TEST", 62, 93], ["cysteine-type endopeptidase activity", "TREATMENT", 103, 139], ["anion channel activity", "TREATMENT", 149, 171], ["variety", "OBSERVATION_MODIFIER", 8, 15]]], ["According to the KEGG enrichment analysis, a majority of the PDAPs were related to microbial metabolism, carbon metabolism, fatty acid metabolism, and degradation (Fig. 3b).Functional classification and subcellular localization of the proteins with differentially acetylated peptides ::: ResultsFor proteins with upregulated acetylated peptides (Fig. 4a), DNA binding, zinc ion binding, and protein binding were the top 3 GO terms in the MF category.", [["subcellular", "ANATOMY", 203, 214], ["fatty acid", "CHEMICAL", 124, 134], ["zinc", "CHEMICAL", 369, 373], ["carbon", "CHEMICAL", 105, 111], ["fatty acid", "CHEMICAL", 124, 134], ["zinc", "CHEMICAL", 369, 373], ["PDAPs", "GENE_OR_GENE_PRODUCT", 61, 66], ["carbon", "SIMPLE_CHEMICAL", 105, 111], ["fatty acid", "SIMPLE_CHEMICAL", 124, 134], ["DNA", "CELLULAR_COMPONENT", 356, 359], ["zinc", "SIMPLE_CHEMICAL", 369, 373], ["PDAPs", "DNA", 61, 66], ["the KEGG enrichment analysis", "TEST", 13, 41], ["the PDAPs", "PROBLEM", 57, 66], ["microbial metabolism", "PROBLEM", 83, 103], ["carbon metabolism", "TEST", 105, 122], ["fatty acid metabolism", "PROBLEM", 124, 145], ["proteins", "TEST", 299, 307], ["upregulated acetylated peptides", "TREATMENT", 313, 344], ["DNA binding", "PROBLEM", 356, 367], ["zinc ion binding", "PROBLEM", 369, 385], ["protein binding", "PROBLEM", 391, 406], ["microbial metabolism", "OBSERVATION", 83, 103], ["carbon metabolism", "OBSERVATION", 105, 122]]], ["In the CC category, most proteins with upregulated acetylated peptides were enriched in nuclear and nucleolar.", [["nuclear", "ANATOMY", 88, 95], ["nucleolar", "ANATOMY", 100, 109], ["CC", "CHEMICAL", 7, 9], ["nuclear", "CELLULAR_COMPONENT", 88, 95], ["nucleolar", "CELLULAR_COMPONENT", 100, 109], ["upregulated acetylated peptides", "PROBLEM", 39, 70], ["acetylated peptides", "OBSERVATION", 51, 70]]], ["The positive regulation of nucleosome assembly and apoptosis in the BP category corresponds to a relatively large number of proteins with upregulated acetylated peptides.", [["nucleosome", "ANATOMY", 27, 37], ["nucleosome", "CELLULAR_COMPONENT", 27, 37], ["apoptosis", "PROBLEM", 51, 60], ["the BP category", "TEST", 64, 79], ["upregulated acetylated peptides", "TREATMENT", 138, 169], ["positive", "OBSERVATION_MODIFIER", 4, 12], ["nucleosome assembly", "OBSERVATION", 27, 46], ["large", "OBSERVATION_MODIFIER", 108, 113], ["acetylated peptides", "OBSERVATION", 150, 169]]], ["Regarding the proteins with downregulated acetylated peptides (Fig. 4b), the results of MF indicated that the largest group was ATP-binding protein, and the second largest group was protein-binding protein.", [["ATP", "CHEMICAL", 128, 131], ["ATP", "CHEMICAL", 128, 131], ["ATP", "SIMPLE_CHEMICAL", 128, 131], ["ATP-binding protein", "PROTEIN", 128, 147], ["protein-binding protein", "PROTEIN", 182, 205], ["downregulated acetylated peptides", "TREATMENT", 28, 61], ["ATP-binding protein", "TEST", 128, 147], ["acetylated peptides", "OBSERVATION", 42, 61], ["largest", "OBSERVATION_MODIFIER", 110, 117]]], ["For the CC category, most proteins with downregulated acetylated peptides correspond to cytoplasm and mitochondria.", [["cytoplasm", "ANATOMY", 88, 97], ["mitochondria", "ANATOMY", 102, 114], ["CC", "CHEMICAL", 8, 10], ["cytoplasm", "ORGANISM_SUBSTANCE", 88, 97], ["mitochondria", "CELLULAR_COMPONENT", 102, 114], ["the CC category", "TEST", 4, 19], ["downregulated acetylated peptides", "TREATMENT", 40, 73], ["cytoplasm and mitochondria", "PROBLEM", 88, 114], ["acetylated peptides", "OBSERVATION", 54, 73]]], ["In the BP category, the redox process and the ATP decomposition process were the top two protein groups enriched by the proteins with downregulated acetylated peptides.Identification of acetylated proteins of T. gondii ::: ResultsIn the present study, we identified 40 acetylated proteins of T. gondii, including 64 acetylated peptides (Table S3).", [["ATP", "CHEMICAL", 46, 49], ["ATP", "CHEMICAL", 46, 49], ["ATP", "SIMPLE_CHEMICAL", 46, 49], ["T. gondii", "ORGANISM", 209, 218], ["T. gondii", "ORGANISM", 292, 301], ["acetylated proteins", "PROTEIN", 186, 205], ["acetylated proteins", "PROTEIN", 269, 288], ["T. gondii", "SPECIES", 209, 218], ["T. gondii", "SPECIES", 292, 301], ["T. gondii", "SPECIES", 209, 218], ["T. gondii", "SPECIES", 292, 301], ["the BP category", "TEST", 3, 18], ["the redox process", "PROBLEM", 20, 37], ["the ATP decomposition process", "PROBLEM", 42, 71], ["downregulated acetylated peptides", "TREATMENT", 134, 167], ["the present study", "TEST", 233, 250], ["T. gondii", "TEST", 292, 301], ["64 acetylated peptides", "TREATMENT", 313, 335], ["redox process", "OBSERVATION", 24, 37], ["ATP decomposition", "OBSERVATION", 46, 63], ["acetylated peptides", "OBSERVATION", 148, 167], ["acetylated proteins", "OBSERVATION", 186, 205]]], ["These proteins mainly included histones and heat shock proteins.", [["heat shock proteins", "GENE_OR_GENE_PRODUCT", 44, 63], ["histones", "PROTEIN", 31, 39], ["heat shock proteins", "PROTEIN", 44, 63], ["histones", "PROBLEM", 31, 39], ["heat shock proteins", "PROBLEM", 44, 63]]], ["In total, we found 21 novel acetylated proteins that have not been identified previously (Wang et al. 2019).", [["acetylated proteins", "PROTEIN", 28, 47], ["21 novel acetylated proteins", "PROBLEM", 19, 47], ["acetylated proteins", "OBSERVATION", 28, 47]]], ["These novel acetylated proteins included TGME49_286470, TGME49_206430, TGME49_214260, TGME49_313830, TGME49_306240, TGME49_213770, TGME49_300612, TGME49_207770, TGME49_305240, TGME49_245530, TGME49_268380, TGME49_211890, TGME49_241300, TGME49_207100, TGME49_254050, TGME49_286470, TGME49_231815, TGME49_217220, TGME49_253360, TGME49_282210, and TGME49_201640.", [["TGME49_286470", "CHEMICAL", 41, 54], ["TGME49_206430", "CHEMICAL", 56, 69], ["TGME49_214260", "CHEMICAL", 71, 84], ["TGME49_313830", "CHEMICAL", 86, 99], ["TGME49_306240", "CHEMICAL", 101, 114], ["TGME49_213770", "CHEMICAL", 116, 129], ["TGME49_300612", "CHEMICAL", 131, 144], ["TGME49_207770", "CHEMICAL", 146, 159], ["TGME49_305240", "CHEMICAL", 161, 174], ["TGME49_245530", "CHEMICAL", 176, 189], ["TGME49_268380", "CHEMICAL", 191, 204], ["TGME49_211890", "CHEMICAL", 206, 219], ["TGME49_241300", "CHEMICAL", 221, 234], ["TGME49_207100", "CHEMICAL", 236, 249], ["TGME49_254050", "CHEMICAL", 251, 264], ["TGME49_286470", "CHEMICAL", 266, 279], ["TGME49_231815", "CHEMICAL", 281, 294], ["TGME49_201640", "CHEMICAL", 345, 358], ["TGME49_286470", "GENE_OR_GENE_PRODUCT", 41, 54], ["acetylated proteins", "PROTEIN", 12, 31], ["TGME49_201640", "PROTEIN", 345, 358]]], ["Among these novel acetylated proteins, the acetylated hypothetical protein TGME49_201640 is only expressed in the oocyst and feline enterocyte stage.", [["oocyst", "ANATOMY", 114, 120], ["enterocyte", "ANATOMY", 132, 142], ["TGME49_201640", "GENE_OR_GENE_PRODUCT", 75, 88], ["feline", "ORGANISM", 125, 131], ["acetylated proteins", "PROTEIN", 18, 37], ["acetylated hypothetical protein", "PROTEIN", 43, 74], ["TGME49_201640", "PROTEIN", 75, 88], ["feline", "SPECIES", 125, 131], ["the acetylated hypothetical protein TGME49_201640", "TREATMENT", 39, 88], ["oocyst", "OBSERVATION", 114, 120], ["feline enterocyte stage", "OBSERVATION", 125, 148]]], ["The function of TGME49_201640 remains unknown; however, the protein has one signal peptide at N-terminal.", [["TGME49_201640", "CHEMICAL", 16, 29], ["TGME49_201640", "CHEMICAL", 16, 29], ["TGME49_201640", "GENE_OR_GENE_PRODUCT", 16, 29], ["TGME49_201640", "PROTEIN", 16, 29], ["the protein", "TEST", 56, 67]]], ["WoLF PSORT prediction showed that the protein is a secretory protein.DiscussionThe aim of this study was to analyze the effect of T. gondii infection on lysine acetylation profile of small intestinal protein in cats.", [["intestinal", "ANATOMY", 189, 199], ["T. gondii infection", "DISEASE", 130, 149], ["lysine", "CHEMICAL", 153, 159], ["lysine", "CHEMICAL", 153, 159], ["WoLF", "GENE_OR_GENE_PRODUCT", 0, 4], ["T. gondii", "ORGANISM", 130, 139], ["lysine", "AMINO_ACID", 153, 159], ["small intestinal", "ORGAN", 183, 199], ["cats", "ORGANISM", 211, 215], ["PSORT", "PROTEIN", 5, 10], ["secretory protein", "PROTEIN", 51, 68], ["small intestinal protein", "PROTEIN", 183, 207], ["T. gondii", "SPECIES", 130, 139], ["cats", "SPECIES", 211, 215], ["T. gondii", "SPECIES", 130, 139], ["WoLF PSORT prediction", "TEST", 0, 21], ["the protein", "TEST", 34, 45], ["this study", "TEST", 90, 100], ["T. gondii infection", "PROBLEM", 130, 149], ["lysine acetylation profile", "TREATMENT", 153, 179], ["small intestinal protein in cats", "PROBLEM", 183, 215], ["infection", "OBSERVATION", 140, 149], ["small", "OBSERVATION_MODIFIER", 183, 188], ["intestinal protein", "ANATOMY", 189, 207]]], ["Compared with the control (uninfected) cats, a total of 2606 unique acetylated sites in 1357 proteins were detected in the feline small intestine attributed to the T. gondii infection.", [["small intestine", "ANATOMY", 130, 145], ["T. gondii infection", "DISEASE", 164, 183], ["cats", "ORGANISM", 39, 43], ["feline", "ORGANISM", 123, 129], ["small intestine", "ORGAN", 130, 145], ["T. gondii", "ORGANISM", 164, 173], ["1357 proteins", "PROTEIN", 88, 101], ["cats", "SPECIES", 39, 43], ["feline", "SPECIES", 123, 129], ["T. gondii", "SPECIES", 164, 173], ["T. gondii", "SPECIES", 164, 173], ["a total of 2606 unique acetylated sites", "TREATMENT", 45, 84], ["the T. gondii infection", "PROBLEM", 160, 183], ["intestine", "ANATOMY", 136, 145], ["gondii infection", "OBSERVATION", 167, 183]]], ["Most of these proteins have only a single lysine acetylation site.", [["lysine", "CHEMICAL", 42, 48], ["lysine acetylation site", "PROTEIN", 42, 65], ["a single lysine acetylation site", "TREATMENT", 33, 65], ["acetylation site", "OBSERVATION", 49, 65]]], ["T. gondii infection can alter the expression of genes involved in protein modification processes in feline small intestine (Cong et al. 2018; Wang et al. 2018).", [["small intestine", "ANATOMY", 107, 122], ["T. gondii infection", "DISEASE", 0, 19], ["T. gondii", "ORGANISM", 0, 9], ["feline", "ORGANISM", 100, 106], ["small intestine", "ORGAN", 107, 122], ["T. gondii", "SPECIES", 0, 9], ["feline", "SPECIES", 100, 106], ["T. gondii", "SPECIES", 0, 9], ["T. gondii infection", "PROBLEM", 0, 19], ["protein modification processes", "TREATMENT", 66, 96], ["infection", "OBSERVATION", 10, 19], ["intestine", "ANATOMY", 113, 122]]], ["Thus, it is possible that the lack of clear acetylation motif in this study could be due to alteration in the genes participating in ubiquitous acetylation process by T. gondii infection.DiscussionGO enrichment and KEGG pathway analyses showed that the proteins with differentially acetylated peptides (PDAPs) were significantly enriched in metabolic processes, such as redox processes and peroxisomes (Fig. 3).", [["peroxisomes", "ANATOMY", 390, 401], ["T. gondii infection", "DISEASE", 167, 186], ["T. gondii", "ORGANISM", 167, 176], ["PDAPs", "GENE_OR_GENE_PRODUCT", 303, 308], ["peroxisomes", "CELLULAR_COMPONENT", 390, 401], ["T. gondii", "SPECIES", 167, 176], ["T. gondii", "SPECIES", 167, 176], ["clear acetylation motif", "PROBLEM", 38, 61], ["this study", "TEST", 65, 75], ["ubiquitous acetylation process", "PROBLEM", 133, 163], ["T. gondii infection", "PROBLEM", 167, 186], ["KEGG pathway analyses", "TEST", 215, 236], ["the proteins", "TEST", 249, 261], ["differentially acetylated peptides", "PROBLEM", 267, 301], ["gondii infection", "OBSERVATION", 170, 186], ["metabolic processes", "OBSERVATION", 341, 360]]], ["This is rather anticipated because infection by T. gondii is associated with considerable metabolic changes of the infected host (Zhou et al. 2015, 2016b).", [["infection", "DISEASE", 35, 44], ["T. gondii", "DISEASE", 48, 57], ["T. gondii", "ORGANISM", 48, 57], ["T. gondii", "SPECIES", 48, 57], ["T. gondii", "SPECIES", 48, 57], ["infection", "PROBLEM", 35, 44], ["T. gondii", "PROBLEM", 48, 57], ["infected", "OBSERVATION_MODIFIER", 115, 123]]], ["Previous proteomic studies have shown that a large number of protein lysine acetylation events occur in the mitochondria (Gibson 2005; Jardim et al. 2018; Peinado et al. 2014).", [["mitochondria", "ANATOMY", 108, 120], ["lysine", "CHEMICAL", 69, 75], ["lysine", "CHEMICAL", 69, 75], ["mitochondria", "CELLULAR_COMPONENT", 108, 120], ["Previous proteomic studies", "TEST", 0, 26], ["protein lysine acetylation events", "PROBLEM", 61, 94], ["large", "OBSERVATION_MODIFIER", 45, 50], ["protein lysine acetylation", "OBSERVATION", 61, 87]]], ["As shown in Fig. 4b, mitochondrion was enriched by the proteins with downregulated acetylated peptides.", [["mitochondrion", "ANATOMY", 21, 34], ["mitochondrion", "CELLULAR_COMPONENT", 21, 34], ["downregulated acetylated peptides", "TREATMENT", 69, 102], ["acetylated peptides", "OBSERVATION", 83, 102]]], ["In TCA cycle, malate dehydrogenase (MDH) and aconitate hydratase (ACO2) whose structural and functional stability had impacts on mitochondrial energy metabolism (Matasova and Popova 2008; Wang et al. 2009) were highly acetylated.", [["mitochondrial", "ANATOMY", 129, 142], ["TCA", "CHEMICAL", 3, 6], ["malate", "CHEMICAL", 14, 20], ["TCA", "CHEMICAL", 3, 6], ["malate", "CHEMICAL", 14, 20], ["aconitate", "CHEMICAL", 45, 54], ["TCA", "SIMPLE_CHEMICAL", 3, 6], ["malate dehydrogenase", "GENE_OR_GENE_PRODUCT", 14, 34], ["MDH", "GENE_OR_GENE_PRODUCT", 36, 39], ["aconitate hydratase", "GENE_OR_GENE_PRODUCT", 45, 64], ["ACO2", "SIMPLE_CHEMICAL", 66, 70], ["mitochondrial", "CELLULAR_COMPONENT", 129, 142], ["malate dehydrogenase", "PROTEIN", 14, 34], ["MDH", "PROTEIN", 36, 39], ["aconitate hydratase", "PROTEIN", 45, 64], ["ACO2", "PROTEIN", 66, 70], ["TCA cycle", "TEST", 3, 12], ["malate dehydrogenase (MDH)", "PROBLEM", 14, 40], ["aconitate hydratase (ACO2", "TEST", 45, 70], ["mitochondrial energy metabolism", "PROBLEM", 129, 160], ["functional stability", "OBSERVATION", 93, 113]]], ["In TCA cycle, citrate synthase (CS), isocitrate dehydrogenase (IDH), and oxoglutarate dehydrogenase complex (OGDC) are rate-limiting enzymes that play roles in regulating the TCA process.", [["citrate", "CHEMICAL", 14, 21], ["oxoglutarate", "CHEMICAL", 73, 85], ["TCA", "CHEMICAL", 3, 6], ["citrate", "CHEMICAL", 14, 21], ["isocitrate", "CHEMICAL", 37, 47], ["oxoglutarate", "CHEMICAL", 73, 85], ["TCA", "CHEMICAL", 175, 178], ["TCA", "SIMPLE_CHEMICAL", 3, 6], ["citrate synthase", "GENE_OR_GENE_PRODUCT", 14, 30], ["CS", "SIMPLE_CHEMICAL", 32, 34], ["isocitrate dehydrogenase", "GENE_OR_GENE_PRODUCT", 37, 61], ["IDH", "GENE_OR_GENE_PRODUCT", 63, 66], ["oxoglutarate dehydrogenase complex", "GENE_OR_GENE_PRODUCT", 73, 107], ["OGDC", "GENE_OR_GENE_PRODUCT", 109, 113], ["TCA", "SIMPLE_CHEMICAL", 175, 178], ["citrate synthase", "PROTEIN", 14, 30], ["CS", "PROTEIN", 32, 34], ["isocitrate dehydrogenase", "PROTEIN", 37, 61], ["IDH", "PROTEIN", 63, 66], ["oxoglutarate dehydrogenase complex", "PROTEIN", 73, 107], ["OGDC", "PROTEIN", 109, 113], ["rate-limiting enzymes", "PROTEIN", 119, 140], ["TCA cycle", "TEST", 3, 12], ["citrate synthase", "TREATMENT", 14, 30], ["isocitrate dehydrogenase (IDH)", "PROBLEM", 37, 67], ["oxoglutarate dehydrogenase complex", "PROBLEM", 73, 107]]], ["TCA cycle and oxidative phosphorylation (OxPhos) are crucial steps for ATP production.", [["TCA", "CHEMICAL", 0, 3], ["ATP", "CHEMICAL", 71, 74], ["TCA", "CHEMICAL", 0, 3], ["ATP", "CHEMICAL", 71, 74], ["TCA", "SIMPLE_CHEMICAL", 0, 3], ["OxPhos", "SIMPLE_CHEMICAL", 41, 47], ["ATP", "SIMPLE_CHEMICAL", 71, 74], ["TCA cycle", "TREATMENT", 0, 9], ["oxidative phosphorylation (OxPhos)", "TREATMENT", 14, 48], ["ATP production", "PROBLEM", 71, 85]]], ["In the present study, 44 proteins whose acetylated peptide abundances were downregulated in the infected small intestine were enriched in the OxPhos process (Fig. S2).", [["small intestine", "ANATOMY", 105, 120], ["small intestine", "ORGAN", 105, 120], ["OxPhos", "GENE_OR_GENE_PRODUCT", 142, 148], ["S2", "PROTEIN", 163, 165], ["the present study", "TEST", 3, 20], ["44 proteins whose acetylated peptide abundances", "PROBLEM", 22, 69], ["the infected small intestine", "PROBLEM", 92, 120], ["infected", "OBSERVATION", 96, 104], ["small intestine", "ANATOMY", 105, 120], ["OxPhos process", "OBSERVATION", 142, 156], ["Fig", "OBSERVATION_MODIFIER", 158, 161]]], ["The downregulated acetylation of OxPhos process and hypometabolic state seems to be bioenergetic tradeoffs strategy to promote host tissue tolerance to infection.DiscussionPeroxisome is an organelle involved in metabolic and stress responses (Cavallini et al. 2017; Mast et al. 2015).", [["tissue", "ANATOMY", 132, 138], ["organelle", "ANATOMY", 189, 198], ["infection", "DISEASE", 152, 161], ["OxPhos", "GENE_OR_GENE_PRODUCT", 33, 39], ["tissue", "TISSUE", 132, 138], ["organelle", "CELLULAR_COMPONENT", 189, 198], ["OxPhos", "PROTEIN", 33, 39], ["The downregulated acetylation of OxPhos process", "TREATMENT", 0, 47], ["hypometabolic state", "PROBLEM", 52, 71], ["bioenergetic tradeoffs strategy", "TREATMENT", 84, 115], ["infection", "PROBLEM", 152, 161], ["downregulated", "OBSERVATION_MODIFIER", 4, 17], ["acetylation of", "OBSERVATION", 18, 32], ["OxPhos process", "OBSERVATION", 33, 47], ["host tissue", "OBSERVATION_MODIFIER", 127, 138], ["infection", "OBSERVATION", 152, 161]]], ["It functions as a hub for immune metabolism, supporting cellular metabolites to control the development and activation of immune cells and regulating inflammatory pathways in different immune cells (Di Cara et al. 2019).", [["cellular", "ANATOMY", 56, 64], ["immune cells", "ANATOMY", 122, 134], ["immune cells", "ANATOMY", 185, 197], ["cellular", "CELL", 56, 64], ["immune cells", "CELL", 122, 134], ["immune cells", "CELL", 185, 197], ["immune cells", "CELL_TYPE", 122, 134], ["immune cells", "CELL_TYPE", 185, 197], ["immune metabolism", "PROBLEM", 26, 43], ["cellular metabolites", "TREATMENT", 56, 76], ["immune cells", "PROBLEM", 122, 134], ["regulating inflammatory pathways", "PROBLEM", 139, 171], ["immune cells", "OBSERVATION", 122, 134], ["inflammatory", "OBSERVATION_MODIFIER", 150, 162]]], ["The KEGG pathway enrichment analysis showed that, in T. gondii\u2013infected small intestine, 10 proteins with downregulated acetylated peptides were associated with peroxisomes (Fig. S3).", [["small intestine", "ANATOMY", 72, 87], ["peroxisomes", "ANATOMY", 161, 172], ["small intestine", "ORGAN", 72, 87], ["peroxisomes", "CELLULAR_COMPONENT", 161, 172], ["T. gondii\u2013infected", "SPECIES", 53, 71], ["The KEGG pathway enrichment analysis", "TEST", 0, 36], ["downregulated acetylated peptides", "PROBLEM", 106, 139], ["small intestine", "ANATOMY", 72, 87], ["acetylated peptides", "OBSERVATION", 120, 139]]], ["These proteins included hydroxysteroid dehydrogenase, catalase, isocitrate dehydrogenase, carnitine O-acetyltransferase, acyl-coenzyme A oxidase, superoxide dismutase, peroxiredoxin, nudix hydrolase 13, ATP binding cassette subfamily D member 3, and acyl-CoA synthetase long chain family member 4.", [["carnitine", "CHEMICAL", 90, 99], ["superoxide", "CHEMICAL", 146, 156], ["ATP", "CHEMICAL", 203, 206], ["hydroxysteroid", "CHEMICAL", 24, 38], ["isocitrate", "CHEMICAL", 64, 74], ["carnitine", "CHEMICAL", 90, 99], ["acyl", "CHEMICAL", 121, 125], ["superoxide", "CHEMICAL", 146, 156], ["ATP", "CHEMICAL", 203, 206], ["acyl-CoA", "CHEMICAL", 250, 258], ["hydroxysteroid dehydrogenase", "GENE_OR_GENE_PRODUCT", 24, 52], ["catalase", "GENE_OR_GENE_PRODUCT", 54, 62], ["isocitrate dehydrogenase", "GENE_OR_GENE_PRODUCT", 64, 88], ["carnitine O-acetyltransferase", "SIMPLE_CHEMICAL", 90, 119], ["acyl-coenzyme A oxidase", "GENE_OR_GENE_PRODUCT", 121, 144], ["superoxide dismutase", "GENE_OR_GENE_PRODUCT", 146, 166], ["peroxiredoxin", "GENE_OR_GENE_PRODUCT", 168, 181], ["nudix hydrolase 13", "GENE_OR_GENE_PRODUCT", 183, 201], ["ATP binding cassette subfamily D member 3", "GENE_OR_GENE_PRODUCT", 203, 244], ["acyl-CoA synthetase long chain family member 4", "GENE_OR_GENE_PRODUCT", 250, 296], ["hydroxysteroid dehydrogenase", "PROTEIN", 24, 52], ["catalase", "PROTEIN", 54, 62], ["isocitrate dehydrogenase", "PROTEIN", 64, 88], ["carnitine O-acetyltransferase", "PROTEIN", 90, 119], ["acyl-coenzyme A oxidase", "PROTEIN", 121, 144], ["superoxide dismutase", "PROTEIN", 146, 166], ["peroxiredoxin", "PROTEIN", 168, 181], ["nudix hydrolase 13", "PROTEIN", 183, 201], ["ATP binding cassette subfamily D member 3", "PROTEIN", 203, 244], ["acyl-CoA synthetase long chain family member 4", "PROTEIN", 250, 296], ["These proteins", "TEST", 0, 14], ["hydroxysteroid dehydrogenase", "TREATMENT", 24, 52], ["catalase", "TREATMENT", 54, 62], ["isocitrate dehydrogenase", "TREATMENT", 64, 88], ["carnitine O-acetyltransferase", "TREATMENT", 90, 119], ["acyl-coenzyme A oxidase", "TREATMENT", 121, 144], ["superoxide dismutase", "TREATMENT", 146, 166], ["peroxiredoxin, nudix hydrolase", "TREATMENT", 168, 198]]], ["Acyl coenzyme A oxidase has been shown to drive the peroxisome \u03b2-oxidation and to play an important role in inflammation control (Vamecq et al. 2018).", [["Acyl coenzyme A", "CHEMICAL", 0, 15], ["inflammation", "DISEASE", 108, 120], ["Acyl coenzyme A", "CHEMICAL", 0, 15], ["Acyl coenzyme A oxidase", "GENE_OR_GENE_PRODUCT", 0, 23], ["peroxisome \u03b2-oxidation", "GENE_OR_GENE_PRODUCT", 52, 74], ["Acyl coenzyme A oxidase", "PROTEIN", 0, 23], ["Acyl coenzyme A oxidase", "TREATMENT", 0, 23], ["the peroxisome \u03b2-oxidation", "TREATMENT", 48, 74], ["inflammation control", "TREATMENT", 108, 128]]], ["These results indicate the involvement of peroxisome in antiT. gondii immune responses.DiscussionT. gondii has been shown to influence the host cell cycle (Elsheikha et al. 2019) and subvert apoptosis signaling in host cells to promote its own survival (L\u00fcder and Gross 2005; He et al. 2016; Cong et al. 2017).", [["peroxisome", "ANATOMY", 42, 52], ["cell", "ANATOMY", 144, 148], ["cells", "ANATOMY", 219, 224], ["peroxisome", "CELLULAR_COMPONENT", 42, 52], ["antiT", "GENE_OR_GENE_PRODUCT", 56, 61], ["gondii", "ORGANISM", 63, 69], ["gondii", "ORGANISM", 100, 106], ["cell", "CELL", 144, 148], ["host cells", "CELL", 214, 224], ["antiT", "PROTEIN", 56, 61], ["host cells", "CELL_TYPE", 214, 224], ["gondii", "SPECIES", 63, 69], [". gondii", "SPECIES", 98, 106], ["gondii", "SPECIES", 63, 69], ["DiscussionT. gondii", "SPECIES", 87, 106], ["gondii", "PROBLEM", 100, 106], ["subvert apoptosis signaling in host cells", "PROBLEM", 183, 224], ["peroxisome", "OBSERVATION_MODIFIER", 42, 52]]], ["GO annotation analysis showed that most of the proteins with increased acetylated peptides are involved in promoting apoptosis (Fig. 4a).", [["annotation analysis", "TEST", 3, 22], ["the proteins", "PROBLEM", 43, 55], ["increased acetylated peptides", "PROBLEM", 61, 90], ["increased", "OBSERVATION_MODIFIER", 61, 70], ["acetylated peptides", "OBSERVATION", 71, 90], ["apoptosis", "OBSERVATION_MODIFIER", 117, 126]]], ["Interestingly, GO enrichment uncovered several PDAPs involved in mitochondrial matrix and mitochondrion.", [["mitochondrial matrix", "ANATOMY", 65, 85], ["mitochondrion", "ANATOMY", 90, 103], ["PDAPs", "GENE_OR_GENE_PRODUCT", 47, 52], ["mitochondrial matrix", "CELLULAR_COMPONENT", 65, 85], ["mitochondrion", "CELLULAR_COMPONENT", 90, 103], ["PDAPs", "PROTEIN", 47, 52], ["mitochondrial matrix", "OBSERVATION", 65, 85]]], ["Also, we have shown in this study that T. gondii through downregulation of the acetylation of OxPhos can affect mitochondrial metabolism.", [["mitochondrial", "ANATOMY", 112, 125], ["OxPhos", "CHEMICAL", 94, 100], ["T. gondii", "ORGANISM", 39, 48], ["OxPhos", "GENE_OR_GENE_PRODUCT", 94, 100], ["mitochondrial", "CELLULAR_COMPONENT", 112, 125], ["OxPhos", "PROTEIN", 94, 100], ["T. gondii", "SPECIES", 39, 48], ["T. gondii", "SPECIES", 39, 48], ["this study", "TEST", 23, 33], ["T. gondii", "PROBLEM", 39, 48], ["the acetylation of OxPhos", "TREATMENT", 75, 100], ["mitochondrial metabolism", "PROBLEM", 112, 136], ["mitochondrial metabolism", "OBSERVATION", 112, 136]]], ["The cytochrome c protein, which controls redox signaling in mitochondrial OxPhos, is released from the mitochondria into the cytosol to activate caspase proteases that trigger apoptotic changes (Hengartner 2000).", [["mitochondrial", "ANATOMY", 60, 73], ["mitochondria", "ANATOMY", 103, 115], ["cytosol", "ANATOMY", 125, 132], ["cytochrome c", "GENE_OR_GENE_PRODUCT", 4, 16], ["mitochondrial", "CELLULAR_COMPONENT", 60, 73], ["OxPhos", "GENE_OR_GENE_PRODUCT", 74, 80], ["mitochondria", "CELLULAR_COMPONENT", 103, 115], ["cytosol", "CELLULAR_COMPONENT", 125, 132], ["caspase", "GENE_OR_GENE_PRODUCT", 145, 152], ["cytochrome c protein", "PROTEIN", 4, 24], ["mitochondrial OxPhos", "PROTEIN", 60, 80], ["caspase proteases", "PROTEIN", 145, 162], ["The cytochrome c protein", "TEST", 0, 24], ["mitochondrial OxPhos", "TEST", 60, 80], ["caspase proteases", "TREATMENT", 145, 162], ["apoptotic changes", "PROBLEM", 176, 193], ["mitochondrial OxPhos", "OBSERVATION", 60, 80]]], ["These results suggest a clear impact of T. gondii\u2013induced alterations of protein acetylation on the bioenergetics and apoptotic processes in the cat intestine.", [["cat intestine", "ANATOMY", 145, 158], ["cat", "ORGANISM", 145, 148], ["intestine", "ORGAN", 149, 158], ["T. gondii\u2013induced alterations", "PROBLEM", 40, 69], ["protein acetylation", "TREATMENT", 73, 92], ["the bioenergetics", "TREATMENT", 96, 113], ["clear", "OBSERVATION_MODIFIER", 24, 29], ["protein acetylation", "OBSERVATION", 73, 92], ["apoptotic processes", "OBSERVATION", 118, 137], ["cat intestine", "ANATOMY", 145, 158]]], ["Sexual reproduction of T. gondii is a highly elaborate event, which involves parasite proliferation, differentiation and host cell destruction (Dubey et al. 1998).", [["cell", "ANATOMY", 126, 130], ["T. gondii", "DISEASE", 23, 32], ["T. gondii", "ORGANISM", 23, 32], ["host cell", "CELL", 121, 130], ["T. gondii", "SPECIES", 23, 32], ["T. gondii", "SPECIES", 23, 32], ["T. gondii", "PROBLEM", 23, 32], ["parasite proliferation", "PROBLEM", 77, 99], ["host cell destruction", "PROBLEM", 121, 142], ["parasite proliferation", "OBSERVATION", 77, 99], ["host cell destruction", "OBSERVATION", 121, 142]]], ["Following invasion of the feline small intestine, tachyzoites transform into a presexual merozoite that replicates and differentiates into male and female gametes, which ultimately form zygotes.", [["small intestine", "ANATOMY", 33, 48], ["tachyzoites", "ANATOMY", 50, 61], ["gametes", "ANATOMY", 155, 162], ["zygotes", "ANATOMY", 186, 193], ["feline", "ORGANISM", 26, 32], ["small intestine", "ORGAN", 33, 48], ["tachyzoites", "ORGANISM_SUBSTANCE", 50, 61], ["merozoite", "GENE_OR_GENE_PRODUCT", 89, 98], ["zygotes", "CELL", 186, 193], ["feline", "SPECIES", 26, 32], ["invasion of the feline small intestine", "PROBLEM", 10, 48], ["tachyzoites", "TREATMENT", 50, 61], ["a presexual merozoite", "TREATMENT", 77, 98], ["invasion", "OBSERVATION", 10, 18], ["intestine", "ANATOMY", 39, 48]]], ["Therefore, it is reasonable to anticipate a significant metabolic burden and an increased cellular destruction during T. gondii infection of the feline intestine.", [["cellular", "ANATOMY", 90, 98], ["intestine", "ANATOMY", 152, 161], ["T. gondii infection", "DISEASE", 118, 137], ["cellular", "CELL", 90, 98], ["T. gondii", "ORGANISM", 118, 127], ["feline", "ORGANISM", 145, 151], ["intestine", "ORGAN", 152, 161], ["T. gondii", "SPECIES", 118, 127], ["feline", "SPECIES", 145, 151], ["T. gondii", "SPECIES", 118, 127], ["a significant metabolic burden", "PROBLEM", 42, 72], ["an increased cellular destruction", "PROBLEM", 77, 110], ["T. gondii infection of the feline intestine", "PROBLEM", 118, 161], ["significant", "OBSERVATION_MODIFIER", 44, 55], ["metabolic burden", "OBSERVATION", 56, 72], ["increased", "OBSERVATION_MODIFIER", 80, 89], ["cellular destruction", "OBSERVATION", 90, 110], ["gondii infection", "OBSERVATION", 121, 137], ["feline intestine", "ANATOMY", 145, 161]]], ["To what extent the acetylated peptides that were found associated with apoptosis and mitochondrial metabolism in the present study can influence the intrinsic and extrinsic apoptotic pathways in the cat small intestine remains to be elucidated.DiscussionThe acetylated protein of T. gondii tachyzoites has been described previously (Wang et al. 2019).", [["mitochondrial", "ANATOMY", 85, 98], ["small intestine", "ANATOMY", 203, 218], ["mitochondrial", "CELLULAR_COMPONENT", 85, 98], ["cat", "ORGANISM", 199, 202], ["small intestine", "ORGAN", 203, 218], ["T. gondii", "ORGANISM", 280, 289], ["tachyzoites", "ORGANISM", 290, 301], ["acetylated protein", "PROTEIN", 258, 276], ["T. gondii", "SPECIES", 280, 289], ["T. gondii", "SPECIES", 280, 289], ["the acetylated peptides", "PROBLEM", 15, 38], ["apoptosis", "PROBLEM", 71, 80], ["mitochondrial metabolism", "PROBLEM", 85, 109], ["T. gondii tachyzoites", "PROBLEM", 280, 301], ["acetylated peptides", "OBSERVATION", 19, 38], ["mitochondrial metabolism", "OBSERVATION", 85, 109], ["extrinsic", "OBSERVATION_MODIFIER", 163, 172], ["apoptotic pathways", "OBSERVATION", 173, 191], ["intestine", "ANATOMY", 209, 218], ["gondii tachyzoites", "OBSERVATION", 283, 301]]], ["However, the acetylation status of T. gondii proteins during intestinal infection of cats was unknown until the present study, where we also identified 40 acetylated proteins of T. gondii.", [["intestinal", "ANATOMY", 61, 71], ["intestinal infection", "DISEASE", 61, 81], ["T. gondii", "ORGANISM", 35, 44], ["intestinal", "ORGAN", 61, 71], ["cats", "ORGANISM", 85, 89], ["T. gondii", "ORGANISM", 178, 187], ["T. gondii proteins", "PROTEIN", 35, 53], ["40 acetylated proteins", "PROTEIN", 152, 174], ["T. gondii", "SPECIES", 35, 44], ["cats", "SPECIES", 85, 89], ["T. gondii", "SPECIES", 178, 187], ["T. gondii", "SPECIES", 35, 44], ["T. gondii", "SPECIES", 178, 187], ["T. gondii proteins", "PROBLEM", 35, 53], ["intestinal infection of cats", "PROBLEM", 61, 89], ["the present study", "TEST", 108, 125], ["intestinal", "ANATOMY", 61, 71], ["infection", "OBSERVATION", 72, 81]]], ["The majority of the acetylated proteins of T. gondii belong to histone H2A, histone H2B, histone H3, and histone H4 families.", [["T. gondii", "ORGANISM", 43, 52], ["histone H2A", "GENE_OR_GENE_PRODUCT", 63, 74], ["histone H2B", "GENE_OR_GENE_PRODUCT", 76, 87], ["histone H3", "GENE_OR_GENE_PRODUCT", 89, 99], ["histone H4", "GENE_OR_GENE_PRODUCT", 105, 115], ["acetylated proteins", "PROTEIN", 20, 39], ["histone H2A", "PROTEIN", 63, 74], ["histone H2B", "PROTEIN", 76, 87], ["histone H3", "PROTEIN", 89, 99], ["histone H4 families", "PROTEIN", 105, 124], ["T. gondii", "SPECIES", 43, 52], ["T. gondii", "SPECIES", 43, 52], ["T. gondii", "PROBLEM", 43, 52], ["histone H2B", "TREATMENT", 76, 87], ["histone H3", "TREATMENT", 89, 99]]], ["Histone is an important component of chromatin and plays a key role in regulation of gene expression (Nardelli et al. 2013).", [["chromatin", "ANATOMY", 37, 46], ["Histone", "GENE_OR_GENE_PRODUCT", 0, 7], ["chromatin", "CELLULAR_COMPONENT", 37, 46], ["chromatin", "DNA", 37, 46], ["chromatin", "OBSERVATION", 37, 46]]], ["A previous report showed that shock protein 70 (HSP70) and heat shock protein 10 (HSP10) of T. gondii are acetylated proteins (Wang et al. 2019).", [["shock protein 70", "GENE_OR_GENE_PRODUCT", 30, 46], ["HSP70", "GENE_OR_GENE_PRODUCT", 48, 53], ["heat shock protein 10", "GENE_OR_GENE_PRODUCT", 59, 80], ["HSP10", "GENE_OR_GENE_PRODUCT", 82, 87], ["T. gondii", "ORGANISM", 92, 101], ["shock protein 70", "PROTEIN", 30, 46], ["HSP70", "PROTEIN", 48, 53], ["heat shock protein 10", "PROTEIN", 59, 80], ["HSP10", "PROTEIN", 82, 87], ["acetylated proteins", "PROTEIN", 106, 125], ["T. gondii", "SPECIES", 92, 101], ["T. gondii", "SPECIES", 92, 101], ["shock protein", "TEST", 30, 43], ["HSP70", "TEST", 48, 53], ["heat shock protein", "TEST", 59, 77], ["HSP10", "TEST", 82, 87], ["T. gondii", "PROBLEM", 92, 101], ["acetylated proteins", "PROBLEM", 106, 125]]], ["In the present study, HSP70 and HSP10 were also identified as acetylated proteins.", [["HSP70", "GENE_OR_GENE_PRODUCT", 22, 27], ["HSP10", "GENE_OR_GENE_PRODUCT", 32, 37], ["HSP70", "PROTEIN", 22, 27], ["HSP10", "PROTEIN", 32, 37], ["acetylated proteins", "PROTEIN", 62, 81], ["the present study", "TEST", 3, 20], ["HSP70", "TEST", 22, 27], ["HSP10", "TEST", 32, 37], ["acetylated proteins", "PROBLEM", 62, 81], ["acetylated proteins", "OBSERVATION", 62, 81]]], ["HSP70 is a virulence factor expressed during the transformation of T. gondii from tachyzoites to bradyzoites and plays a role in parasite replication and immune responses (Barenco et al. 2014).", [["tachyzoites", "ANATOMY", 82, 93], ["bradyzoites", "ANATOMY", 97, 108], ["HSP70", "GENE_OR_GENE_PRODUCT", 0, 5], ["T. gondii", "ORGANISM", 67, 76], ["tachyzoites", "ORGANISM_SUBSTANCE", 82, 93], ["HSP70", "PROTEIN", 0, 5], ["virulence factor", "PROTEIN", 11, 27], ["T. gondii", "SPECIES", 67, 76], ["T. gondii", "SPECIES", 67, 76], ["a virulence factor", "PROBLEM", 9, 27], ["T. gondii", "PROBLEM", 67, 76], ["tachyzoites", "PROBLEM", 82, 93], ["parasite replication", "TREATMENT", 129, 149]]], ["Also, we found one acetylated hypothetical protein TGME49_201640 whose function remains unknown and is only expressed in the oocyst and feline enterocyte stage.", [["oocyst", "ANATOMY", 125, 131], ["enterocyte", "ANATOMY", 143, 153], ["TGME49_201640", "GENE_OR_GENE_PRODUCT", 51, 64], ["acetylated hypothetical protein", "PROTEIN", 19, 50], ["TGME49_201640", "PROTEIN", 51, 64], ["feline", "SPECIES", 136, 142], ["oocyst", "OBSERVATION", 125, 131], ["feline enterocyte stage", "OBSERVATION", 136, 159]]], ["Bioinformatic analysis showed that this protein is a secretory protein.", [["secretory protein", "PROTEIN", 53, 70], ["Bioinformatic analysis", "TEST", 0, 22], ["this protein", "TEST", 35, 47]]], ["This suggests that the product of the TGME49_201640 gene might be discharged into host cells and contributes to the interaction between feline enterocyte and T. gondii.", [["cells", "ANATOMY", 87, 92], ["enterocyte", "ANATOMY", 143, 153], ["TGME49_201640", "GENE_OR_GENE_PRODUCT", 38, 51], ["host cells", "CELL", 82, 92], ["feline", "ORGANISM", 136, 142], ["enterocyte", "CELL", 143, 153], ["T. gondii", "ORGANISM", 158, 167], ["TGME49_201640 gene", "DNA", 38, 56], ["host cells", "CELL_TYPE", 82, 92], ["feline", "SPECIES", 136, 142], ["T. gondii", "SPECIES", 158, 167], ["T. gondii", "SPECIES", 158, 167], ["the interaction between feline enterocyte and T. gondii", "PROBLEM", 112, 167], ["enterocyte", "ANATOMY", 143, 153]]], ["The identified acetylated peptides listed in Table S3 may help us to elucidate new biological functions of T. gondii secretome in mediating the interaction between T. gondii and the small intestine of the feline definitive host.ConclusionThis study, for the first time, showed that T. gondii infection had significant effect on the acetylome of cat small intestine.", [["small intestine", "ANATOMY", 182, 197], ["small intestine", "ANATOMY", 349, 364], ["T. gondii infection", "DISEASE", 282, 301], ["Table S3", "GENE_OR_GENE_PRODUCT", 45, 53], ["T. gondii", "ORGANISM", 107, 116], ["T. gondii", "ORGANISM", 164, 173], ["small intestine", "ORGAN", 182, 197], ["feline", "ORGANISM", 205, 211], ["T. gondii", "ORGANISM", 282, 291], ["cat", "ORGANISM", 345, 348], ["small intestine", "ORGAN", 349, 364], ["T. gondii", "SPECIES", 107, 116], ["T. gondii", "SPECIES", 164, 173], ["T. gondii", "SPECIES", 282, 291], ["T. gondii", "SPECIES", 107, 116], ["T. gondii", "SPECIES", 164, 173], ["T. gondii", "SPECIES", 282, 291], ["acetylated peptides", "TREATMENT", 15, 34], ["T. gondii secretome", "PROBLEM", 107, 126], ["T. gondii", "TEST", 164, 173], ["This study", "TEST", 238, 248], ["T. gondii infection", "PROBLEM", 282, 301], ["acetylated peptides", "OBSERVATION", 15, 34], ["small intestine", "ANATOMY", 182, 197], ["infection", "OBSERVATION", 292, 301], ["intestine", "ANATOMY", 355, 364]]], ["High-resolution mass spectrometry\u2013based proteomics approach identified 2606 acetylation sites in 1357 acetylated proteins.", [["2606 acetylation sites", "DNA", 71, 93], ["1357 acetylated proteins", "PROTEIN", 97, 121], ["High-resolution mass spectrometry\u2013based proteomics approach", "TREATMENT", 0, 59], ["acetylation sites", "TREATMENT", 76, 93], ["acetylated proteins", "TREATMENT", 102, 121], ["resolution", "OBSERVATION_MODIFIER", 5, 15], ["mass", "OBSERVATION", 16, 20]]], ["Acetylated proteins altered by infection were found to belong to different cell compartments (cytoplasm, nucleus, mitochondria, extracellular component) and to participate in various metabolic pathways or cellular processes (glycolysis/gluconeogenesis, citrate cycle (TCA cycle) and peroxisome).", [["cell compartments", "ANATOMY", 75, 92], ["cytoplasm", "ANATOMY", 94, 103], ["nucleus", "ANATOMY", 105, 112], ["mitochondria", "ANATOMY", 114, 126], ["extracellular", "ANATOMY", 128, 141], ["cellular", "ANATOMY", 205, 213], ["peroxisome", "ANATOMY", 283, 293], ["infection", "DISEASE", 31, 40], ["citrate", "CHEMICAL", 253, 260], ["citrate", "CHEMICAL", 253, 260], ["cell", "CELL", 75, 79], ["cytoplasm", "ORGANISM_SUBSTANCE", 94, 103], ["nucleus", "CELLULAR_COMPONENT", 105, 112], ["mitochondria", "CELLULAR_COMPONENT", 114, 126], ["extracellular component", "CELLULAR_COMPONENT", 128, 151], ["cellular", "CELL", 205, 213], ["citrate", "SIMPLE_CHEMICAL", 253, 260], ["TCA", "SIMPLE_CHEMICAL", 268, 271], ["peroxisome", "CELLULAR_COMPONENT", 283, 293], ["Acetylated proteins", "PROTEIN", 0, 19], ["Acetylated proteins", "PROBLEM", 0, 19], ["infection", "PROBLEM", 31, 40], ["cellular processes", "PROBLEM", 205, 223], ["glycolysis/gluconeogenesis", "TREATMENT", 225, 251], ["citrate cycle (TCA cycle)", "TREATMENT", 253, 278], ["infection", "OBSERVATION", 31, 40], ["nucleus", "ANATOMY", 105, 112]]], ["We identified a list of novel acetylated proteins of T. gondii, including one hypothetical protein that is only expressed at the oocyst and feline enterocyte stage.", [["oocyst", "ANATOMY", 129, 135], ["enterocyte", "ANATOMY", 147, 157], ["T. gondii", "ORGANISM", 53, 62], ["acetylated proteins", "PROTEIN", 30, 49], ["T. gondii", "SPECIES", 53, 62], ["T. gondii", "SPECIES", 53, 62], ["novel acetylated proteins of T. gondii", "PROBLEM", 24, 62], ["one hypothetical protein", "PROBLEM", 74, 98], ["oocyst", "OBSERVATION", 129, 135], ["feline enterocyte stage", "OBSERVATION", 140, 163]]], ["Our data provided new and valuable resource to further investigations of the role of protein acetylation in the sexual reproduction of T. gondii in feline small intestine.", [["small intestine", "ANATOMY", 155, 170], ["T. gondii", "ORGANISM", 135, 144], ["feline", "ORGANISM", 148, 154], ["small intestine", "ORGAN", 155, 170], ["T. gondii", "SPECIES", 135, 144], ["feline", "SPECIES", 148, 154], ["T. gondii", "SPECIES", 135, 144], ["further investigations", "TEST", 47, 69], ["protein acetylation", "TREATMENT", 85, 104], ["intestine", "ANATOMY", 161, 170]]]], "a51a11b1d577a0e3ec272a54bc24f0b7f373cc69": [["This version will undergo additional copyediting, typesetting and review before it is published in its final form, but we are providing this version to give early visibility of the article.", [["this version", "TREATMENT", 136, 148]]], ["A letter to the editor on \"World Health Organization declares global emergency: A review of the 2019 novel coronavirus (COVID-19)\"Authors and affiliations:", [["coronavirus", "DISEASE", 107, 118]]]], "30d03a6bfb99b7abf5e8e7c41b7ba38531298a4f": [["cell mediated immunity (CMI).", [["cell", "ANATOMY", 0, 4], ["cell", "CELL", 0, 4]]], ["CMI may play an important role in protection of cats against FIPV, since induction of circulating antibodies to the S protein of FIPV contributes to disease pathogenesis by the induction of immune complexes and antibody dependent enhancement of the infectivity of FIPV for macrophages.", [["macrophages", "ANATOMY", 273, 284], ["FIPV", "CHEMICAL", 61, 65], ["FIPV", "CHEMICAL", 129, 133], ["cats", "ORGANISM", 48, 52], ["FIPV", "GENE_OR_GENE_PRODUCT", 61, 65], ["antibodies to the S protein", "GENE_OR_GENE_PRODUCT", 98, 125], ["FIPV", "GENE_OR_GENE_PRODUCT", 129, 133], ["FIPV", "GENE_OR_GENE_PRODUCT", 264, 268], ["macrophages", "CELL", 273, 284], ["circulating antibodies", "PROTEIN", 86, 108], ["S protein", "PROTEIN", 116, 125], ["FIPV", "PROTEIN", 129, 133], ["immune complexes", "PROTEIN", 190, 206], ["FIPV", "PROTEIN", 264, 268], ["macrophages", "CELL_TYPE", 273, 284], ["cats", "SPECIES", 48, 52], ["FIPV", "SPECIES", 61, 65], ["FIPV", "SPECIES", 264, 268], ["CMI", "PROBLEM", 0, 3], ["FIPV", "PROBLEM", 61, 65], ["circulating antibodies", "PROBLEM", 86, 108], ["FIPV", "PROBLEM", 129, 133], ["disease pathogenesis", "PROBLEM", 149, 169], ["immune complexes", "PROBLEM", 190, 206], ["antibody dependent enhancement", "PROBLEM", 211, 241], ["macrophages", "PROBLEM", 273, 284]]]], "PMC7116934": [["IntroductionHuman exhalation flows produced by respiratory activities can carry pathogens that are responsible for the transmission of airborne pathogens [1], [2].", [["respiratory", "ANATOMY", 47, 58], ["IntroductionHuman exhalation flows", "TREATMENT", 0, 34], ["pathogens", "PROBLEM", 80, 89], ["airborne pathogens", "PROBLEM", 135, 153]]], ["With current concerns about new, emerging respiratory viruses (e.g. avian A/H7N9 influenza, Middle East Respiratory Syndrome coronavirus \u2013 MERS-CoV), it is useful for infection control purposes to quantify the potential, relative risk posed by such exhaled pathogens.", [["respiratory viruses", "DISEASE", 42, 61], ["avian A/H7N9 influenza", "DISEASE", 68, 90], ["Middle East Respiratory Syndrome coronavirus", "DISEASE", 92, 136], ["infection", "DISEASE", 167, 176], ["avian A/H7N9 influenza", "ORGANISM", 68, 90], ["Middle East Respiratory Syndrome coronavirus", "ORGANISM", 92, 136], ["\u2013 MERS-CoV", "ORGANISM", 137, 147], ["H7N9 influenza", "SPECIES", 76, 90], ["A/H7N9 influenza, Middle East Respiratory Syndrome coronavirus \u2013 MERS-CoV", "SPECIES", 74, 147], ["emerging respiratory viruses", "PROBLEM", 33, 61], ["A/H7N9 influenza", "PROBLEM", 74, 90], ["Middle East Respiratory Syndrome", "PROBLEM", 92, 124], ["infection control purposes", "PROBLEM", 167, 193], ["such exhaled pathogens", "PROBLEM", 244, 266], ["respiratory viruses", "OBSERVATION", 42, 61]]], ["One component of this risk assessment is to estimate the fraction of the exhaled airflow that is re-inhaled during normal (nasal) breathing.", [["nasal", "ANATOMY", 123, 128], ["nasal", "ORGANISM_SUBDIVISION", 123, 128], ["this risk assessment", "TEST", 17, 37], ["the exhaled airflow", "PROBLEM", 69, 88], ["exhaled airflow", "OBSERVATION", 73, 88]]], ["This will impact upon risk assessment models that assume human exhaled aerosol as the main source for such exposures, with the fraction of re-inhaled exhaled air potentially not contributing to the final exhaled, airborne pathogen load.", [["human", "ORGANISM", 57, 62], ["human", "SPECIES", 57, 62], ["human", "SPECIES", 57, 62], ["risk assessment models", "TEST", 22, 44], ["human exhaled aerosol", "TREATMENT", 57, 78], ["re-inhaled exhaled air", "PROBLEM", 139, 161], ["the final exhaled, airborne pathogen load", "PROBLEM", 194, 235]]], ["This value has been previously reported by Laverge et al. [3] to be about 5% with a tracer gas experiment on the supine thermal manikin (steady condition), and by Zhu et al. [4] to be 17% by CFD simulation on the standing thermal manikin, but no experimental data of dynamic breathing processes has yet been performed, despite of the significant difference in the reported re-inhalation ratios.IntroductionTypical respiratory activities were characterized by Gupta et al. [5], [6].", [["respiratory", "ANATOMY", 414, 425], ["a tracer gas experiment", "PROBLEM", 82, 105], ["the standing thermal manikin", "TREATMENT", 209, 237], ["dynamic breathing processes", "PROBLEM", 267, 294], ["respiratory activities", "OBSERVATION", 414, 436]]], ["The breathing airflow has a maximum velocity of about 1\u20132 m/s, and can be approximated by a sinusoidal function.", [["The breathing airflow", "PROBLEM", 0, 21], ["a maximum velocity", "TEST", 26, 44], ["breathing airflow", "OBSERVATION", 4, 21], ["maximum", "OBSERVATION_MODIFIER", 28, 35], ["velocity", "OBSERVATION_MODIFIER", 36, 44], ["sinusoidal function", "OBSERVATION", 92, 111]]], ["Respiratory airflow can be influenced by human thermal plumes.", [["human", "ORGANISM", 41, 46], ["human", "SPECIES", 41, 46], ["human", "SPECIES", 41, 46], ["Respiratory airflow", "PROBLEM", 0, 19], ["airflow", "OBSERVATION", 12, 19]]], ["Schlieren optical systems have long been used to visualize the plume and its interaction with human respiratory activities [7], [8], [9].", [["human", "ORGANISM", 94, 99], ["human", "SPECIES", 94, 99], ["human", "SPECIES", 94, 99], ["Schlieren optical systems", "TREATMENT", 0, 25], ["human respiratory activities", "TEST", 94, 122]]], ["The human thermal plumes were quantified using hot-wire anemometers and Particle Image Velocimetry (PIV) techniques, and by Computational Fluid Dynamics (CFD) approaches [10], [11], [12], [13], [14].", [["human", "ORGANISM", 4, 9], ["[11]", "SIMPLE_CHEMICAL", 176, 180], ["[12], [13]", "SIMPLE_CHEMICAL", 182, 192], ["human", "SPECIES", 4, 9], ["human", "SPECIES", 4, 9], ["The human thermal plumes", "TREATMENT", 0, 24], ["hot-wire anemometers", "TREATMENT", 47, 67], ["Particle Image Velocimetry (PIV) techniques", "TREATMENT", 72, 115]]], ["The thermal plume of a standing person begins to turn into turbulent flow at the chest level when the Grashof number exceeds 109 and reaches a maximum velocity of 0.2 m/s above the head [7].", [["chest", "ANATOMY", 81, 86], ["head", "ANATOMY", 181, 185], ["chest", "ORGAN", 81, 86], ["person", "SPECIES", 32, 38], ["a maximum velocity", "TEST", 141, 159], ["thermal", "OBSERVATION_MODIFIER", 4, 11], ["plume", "OBSERVATION_MODIFIER", 12, 17], ["turbulent", "OBSERVATION_MODIFIER", 59, 68], ["flow", "OBSERVATION", 69, 73], ["chest", "ANATOMY", 81, 86], ["maximum", "OBSERVATION_MODIFIER", 143, 150], ["velocity", "OBSERVATION_MODIFIER", 151, 159], ["head", "ANATOMY", 181, 185]]], ["The maximum velocity at the breathing zone is about 0.1 m/s with a boundary thickness of around 0.1 m [10] for a standing occupant in quiescent air Factors that influence the thermal plume, e.g. supine or sitting postures, clothing insulation, walking of the occupant, have also been investigated [7], [15], [16], [17].IntroductionThe tracer-gas technique was often utilized for studying the inhalation zone during nasal breathing, which is distorted from a spherical configuration to a vertically elongated one due the presence of the thermal plume.", [["nasal", "ANATOMY", 415, 420], ["[15]", "SIMPLE_CHEMICAL", 302, 306], ["[16]", "SIMPLE_CHEMICAL", 308, 312], ["[17]", "SIMPLE_CHEMICAL", 314, 318], ["nasal", "ORGANISM_SUBDIVISION", 415, 420], ["The maximum velocity", "TEST", 0, 20], ["a boundary thickness", "TEST", 65, 85], ["quiescent air Factors", "PROBLEM", 134, 155], ["the thermal plume", "TREATMENT", 171, 188], ["clothing insulation", "TREATMENT", 223, 242], ["The tracer-gas technique", "TREATMENT", 331, 355], ["the inhalation zone", "TREATMENT", 388, 407], ["a vertically elongated one", "PROBLEM", 485, 511], ["the thermal plume", "PROBLEM", 532, 549], ["maximum", "OBSERVATION_MODIFIER", 4, 11], ["velocity", "OBSERVATION_MODIFIER", 12, 20], ["breathing", "ANATOMY", 28, 37], ["zone", "ANATOMY_MODIFIER", 38, 42], ["air Factors", "OBSERVATION", 144, 155], ["thermal", "OBSERVATION_MODIFIER", 175, 182], ["plume", "OBSERVATION_MODIFIER", 183, 188], ["nasal breathing", "ANATOMY", 415, 430], ["spherical configuration", "OBSERVATION", 458, 481], ["vertically", "OBSERVATION_MODIFIER", 487, 497], ["elongated", "OBSERVATION_MODIFIER", 498, 507], ["thermal", "OBSERVATION_MODIFIER", 536, 543], ["plume", "OBSERVATION", 544, 549]]], ["In the case of oral breathing in quiescent air, about one third of the inhaled air is entrained from around the mouth, and approximately two thirds is from below [12].", [["oral", "ANATOMY", 15, 19], ["mouth", "ANATOMY", 112, 117], ["oral", "ORGANISM_SUBDIVISION", 15, 19], ["mouth", "ORGANISM_SUBDIVISION", 112, 117], ["oral breathing in quiescent air", "PROBLEM", 15, 46], ["quiescent air", "OBSERVATION", 33, 46], ["air", "OBSERVATION", 79, 82], ["mouth", "ANATOMY", 112, 117]]], ["However, these measurements or simulations were mostly obtained under steady exhaling or inhaling conditions.", [["these measurements", "TEST", 9, 27]]], ["According to Lewis et al. [8], rising air accounts for only about 10% of inhaled air in each tidal nasal inspiration at rest.IntroductionThis study aims to experimentally investigate, qualitatively and quantitatively, the re-inhalation of exhaled flow during human normal breathing, both with and without the absence of thermal plumes.", [["nasal", "ANATOMY", 99, 104], ["nasal", "ORGANISM_SUBDIVISION", 99, 104], ["human", "ORGANISM", 259, 264], ["human", "SPECIES", 259, 264], ["human", "SPECIES", 259, 264], ["rising air accounts", "PROBLEM", 31, 50], ["This study", "TEST", 137, 147], ["exhaled flow", "TEST", 239, 251], ["air", "OBSERVATION", 81, 84], ["exhaled flow", "OBSERVATION", 239, 251]]], ["Unsteady nasal breathing and its interaction with the thermal plume will be also analysed.Breathing simulation ::: MethodsFor a 4-year-old female child, a typical respiratory frequency (RF) is 28 breaths per minute (bpm), with a tidal volume (TV) of 0.15 L [26], [27].", [["nasal", "ANATOMY", 9, 14], ["respiratory", "ANATOMY", 163, 174], ["nasal", "ORGAN", 9, 14], ["female", "ORGANISM", 139, 145], ["child", "ORGANISM", 146, 151], ["child", "SPECIES", 146, 151], ["Unsteady nasal breathing", "PROBLEM", 0, 24], ["the thermal plume", "TREATMENT", 50, 67], ["a tidal volume", "TEST", 227, 241], ["TV", "TEST", 243, 245]]], ["We also varied RF and TV to study their effects on the re-inhaled ratio of exhaled flow.Breathing simulation ::: MethodsThe breathing cycle can be approximated with a sinusoidal function,(1)qa(ta)=\u03c0\u22c5TV\u22c5RF60sin(\u03c0\u22c5RF30\u22c5ta),0\u2264ta\u2264ts,awhere the subscript a stands for air, qa is the volumetric flow rate with time ta, and ts,a=60/RF is the respiratory period.Breathing simulation ::: MethodsThe equivalent diameter of the nostril is 0.71 cm2, and the peak and mean flow rates of the typical case (RF = 28 bpm, TV = 0.15 L) are 0.22 L/s and 0.07 L/s, respectively, so the corresponding velocities are 2.8 m/s and 0.89 m/s, respectively.Breathing simulation ::: MethodsIt is known that the water-tank model can reproduce similar flows to that in air if it satisfies the similarity requirement, i.e. geometric similarity, kinematic similarity and dynamic similarity.", [["nostril", "ANATOMY", 417, 424], ["\u03c0\u22c5RF30\u22c5ta),0\u2264ta\u2264ts", "CHEMICAL", 210, 228], ["nostril", "ORGAN", 417, 424], ["TV", "TREATMENT", 22, 24], ["exhaled flow", "TEST", 75, 87], ["Methods", "TREATMENT", 113, 120], ["TV", "TEST", 199, 201], ["RF60sin", "TEST", 202, 209], ["the volumetric flow rate", "TEST", 274, 298], ["ts", "TEST", 317, 319], ["Methods", "TREATMENT", 379, 386], ["the peak", "TEST", 442, 450], ["mean flow rates", "TEST", 455, 470], ["RF", "TEST", 492, 494], ["bpm", "TEST", 500, 503], ["TV", "TEST", 505, 507], ["L/s", "TEST", 527, 530], ["L/s", "TEST", 540, 543], ["the corresponding velocities", "TEST", 562, 590], ["Methods", "TREATMENT", 655, 662], ["the water-tank model", "TREATMENT", 679, 699], ["the similarity requirement", "PROBLEM", 759, 785], ["geometric similarity", "TEST", 792, 812], ["exhaled flow", "OBSERVATION", 75, 87], ["respiratory period", "OBSERVATION", 335, 353], ["equivalent", "OBSERVATION_MODIFIER", 390, 400], ["diameter", "OBSERVATION_MODIFIER", 401, 409], ["nostril", "ANATOMY", 417, 424], ["0.71 cm2", "OBSERVATION_MODIFIER", 428, 436], ["peak", "OBSERVATION_MODIFIER", 446, 450], ["mean flow", "OBSERVATION", 455, 464], ["velocities", "OBSERVATION_MODIFIER", 580, 590], ["air", "OBSERVATION", 739, 742]]], ["According to Reynolds number equivalence between air and water(2)Rea=Ua\u22c5La\u03bda=Uw\u22c5Lw\u03bdw=Rewwhere the subscript w stands for water; Ua and Uw are characteristic velocities e.g. maximum velocity in the respiratory process; La and Lw are characteristic lengths, namely equivalent diameters of the nose outlets, where La = Lw here since a real full size model was used in the present water-tank experiment; the kinematic viscosity, \u03bda = 1.48 \u00d7 10\u22125 m2/s for 25 \u00b0C air; \u03bdw = 1.16 \u00d7 10\u22126 m2/s for 15 \u00b0C water and \u03bdw = 8.73 \u00d7 10\u22127 m2/s for 26 \u00b0C water.", [["nose", "ANATOMY", 291, 295], ["Ua", "TEST", 128, 130], ["velocities", "TEST", 157, 167], ["maximum velocity in the respiratory process", "PROBLEM", 173, 216], ["the kinematic viscosity", "TEST", 400, 423], ["\u03bda", "TEST", 425, 427], ["water", "TEST", 494, 499], ["velocities", "OBSERVATION_MODIFIER", 157, 167], ["maximum", "OBSERVATION_MODIFIER", 173, 180], ["velocity", "OBSERVATION_MODIFIER", 181, 189], ["respiratory process", "OBSERVATION", 197, 216], ["characteristic", "OBSERVATION_MODIFIER", 232, 246], ["lengths", "OBSERVATION_MODIFIER", 247, 254], ["equivalent", "OBSERVATION_MODIFIER", 263, 273], ["diameters", "OBSERVATION_MODIFIER", 274, 283], ["nose", "ANATOMY", 291, 295], ["outlets", "ANATOMY_MODIFIER", 296, 303], ["size", "OBSERVATION_MODIFIER", 342, 346], ["kinematic viscosity", "OBSERVATION", 404, 423]]], ["Thus, UwUa=La\u22c5\u03bdwLw\u22c5\u03bda=112.76 according to Equation (2).", [["La\u22c5\u03bdwLw\u22c5\u03bda", "TEST", 11, 21]]], ["The maximum Re is 1343 in a typical case.", [["maximum", "OBSERVATION_MODIFIER", 4, 11]]], ["Further, the time scale, namely the respiratory period, can be updated with the known length and velocity scales.(3)t\u00af=UataLa=UwtwLw(a),q\u00af=qa(ta)Ua\u22c5La2=qw(tw)Uw\u22c5Lw2(b)where, t\u00af and q\u00af are the normalized time and flow rate, respectively.Combining Equations (2), (3), we obtain(4)tw=(LwLa)2\u03bda\u03bdw\u22c5ta(a),qw(tw)=LwLa\u03bdw\u03bdaqa(ta)(b)", [["t\u00af", "PROTEIN", 174, 176], ["q\u00af", "PROTEIN", 181, 183], ["UataLa", "TEST", 119, 125], ["Ua\u22c5La2", "TEST", 145, 151], ["t\u00af", "TEST", 174, 176], ["flow rate", "TEST", 212, 221], ["LwLa", "TEST", 282, 286], ["respiratory", "ANATOMY", 36, 47]]]], "PMC7473596": [["IntroductionThe first known case of COVID-19 in the USA arrived from China on January 15, 2020 (Holshue et al. 2020).", [["COVID", "TEST", 36, 41]]], ["In the weeks that followed, deficiencies in testing allowed the virus that causes this disease to spread largely undetected (Perkins et al. 2020), with the number of reported cases growing to 429,319 by April 8, 2020 [39].", [["deficiencies in testing", "PROBLEM", 28, 51], ["the virus", "PROBLEM", 60, 69], ["this disease", "PROBLEM", 82, 94]]], ["These practices have tremendous economic and social consequences, however, which has precipitated growing desire to relax them [17].IntroductionA danger in relaxing the use of social distancing is that the virus could resurge in its absence (Prem et al. 2020).", [["the virus", "PROBLEM", 202, 211], ["tremendous", "OBSERVATION_MODIFIER", 21, 31], ["economic", "OBSERVATION_MODIFIER", 32, 40]]], ["A safe, effective, and widely used vaccine would obviate the need for social distancing, but there are many challenges associated with developing a vaccine against COVID-19 (Lurie et al. 2020) and one is not likely to be available until at least spring 2021 (Amanat and Krammer 2020).", [["vaccine", "TREATMENT", 35, 42], ["a vaccine", "TREATMENT", 146, 155], ["not likely", "UNCERTAINTY", 204, 214]]], ["Strategies for successfully controlling COVID-19 until then will depend on a suite of non-pharmaceutical interventions (Aledort et al. 2007), including some degree of social distancing but also diagnostic testing, contact tracing, and case isolation (Bedford et al. 2020).IntroductionIn models of pathogen transmission based on mass-action assumptions, non-pharmaceutical interventions all act in a similar way by reducing the transmission coefficient.", [["non-pharmaceutical interventions", "TREATMENT", 86, 118], ["diagnostic testing", "TEST", 194, 212], ["contact tracing", "TEST", 214, 229], ["pathogen transmission", "PROBLEM", 297, 318], ["mass", "PROBLEM", 328, 332], ["action assumptions", "TREATMENT", 333, 351], ["non-pharmaceutical interventions", "TREATMENT", 353, 385], ["pathogen", "OBSERVATION_MODIFIER", 297, 305], ["mass", "OBSERVATION", 328, 332]]]], "PMC3362556": [["IntroductionLower respiratory tract infections, commonly caused by viruses, are one of the leading causes of morbidity and mortality in children worldwide [1].", [["respiratory tract", "ANATOMY", 18, 35], ["respiratory tract infections", "DISEASE", 18, 46], ["IntroductionLower respiratory tract", "ORGANISM_SUBDIVISION", 0, 35], ["children", "ORGANISM", 136, 144], ["children", "SPECIES", 136, 144], ["IntroductionLower respiratory tract infections", "PROBLEM", 0, 46], ["viruses", "PROBLEM", 67, 74], ["morbidity", "PROBLEM", 109, 118], ["respiratory tract", "ANATOMY", 18, 35], ["infections", "OBSERVATION", 36, 46], ["viruses", "OBSERVATION", 67, 74]]], ["In the United States, approximately 30,000 children each year are hospitalized during their first year of life due to viral lower respiratory tract infections [2].", [["lower respiratory tract", "ANATOMY", 124, 147], ["lower respiratory tract infections", "DISEASE", 124, 158], ["children", "ORGANISM", 43, 51], ["children", "SPECIES", 43, 51], ["viral lower respiratory tract infections", "PROBLEM", 118, 158], ["lower", "ANATOMY_MODIFIER", 124, 129], ["respiratory tract", "ANATOMY", 130, 147]]], ["In developing countries, the problem is even larger, where up to 1.8 million children die each year due to acute respiratory illnesses [3].IntroductionUntil recently, most viral lower respiratory infections in children were attributed to respiratory syncytial virus (RSV), parainfluenzavirus, adenovirus, and influenza viruses [4], [5].", [["respiratory", "ANATOMY", 113, 124], ["respiratory", "ANATOMY", 184, 195], ["respiratory illnesses", "DISEASE", 113, 134], ["viral lower respiratory infections", "DISEASE", 172, 206], ["respiratory syncytial virus (RSV), parainfluenzavirus, adenovirus, and influenza viruses", "DISEASE", 238, 326], ["children", "ORGANISM", 77, 85], ["children", "ORGANISM", 210, 218], ["respiratory syncytial virus", "ORGANISM", 238, 265], ["RSV", "ORGANISM", 267, 270], ["adenovirus", "ORGANISM", 293, 303], ["influenza viruses", "ORGANISM", 309, 326], ["children", "SPECIES", 77, 85], ["children", "SPECIES", 210, 218], ["respiratory syncytial virus", "SPECIES", 238, 265], ["respiratory syncytial virus", "SPECIES", 238, 265], ["RSV", "SPECIES", 267, 270], ["adenovirus", "SPECIES", 293, 303], ["acute respiratory illnesses", "PROBLEM", 107, 134], ["IntroductionUntil", "TREATMENT", 139, 156], ["most viral lower respiratory infections in children", "PROBLEM", 167, 218], ["respiratory syncytial virus (RSV)", "PROBLEM", 238, 271], ["parainfluenzavirus", "PROBLEM", 273, 291], ["adenovirus", "PROBLEM", 293, 303], ["influenza viruses", "PROBLEM", 309, 326], ["larger", "OBSERVATION_MODIFIER", 45, 51], ["acute", "OBSERVATION_MODIFIER", 107, 112], ["respiratory illnesses", "OBSERVATION", 113, 134], ["viral", "OBSERVATION_MODIFIER", 172, 177], ["lower", "OBSERVATION_MODIFIER", 178, 183], ["respiratory infections", "OBSERVATION", 184, 206], ["respiratory", "ANATOMY", 238, 249], ["syncytial virus", "OBSERVATION", 250, 265]]], ["Yet, while the etiology of a majority of lower respiratory tract disease is thought to be viral, only around 40% of cases have an etiologically identifiable agent [6], [7], [8].", [["lower respiratory tract", "ANATOMY", 41, 64], ["respiratory tract disease", "DISEASE", 47, 72], ["lower", "ORGANISM", 41, 46], ["respiratory tract", "ORGANISM_SUBDIVISION", 47, 64], ["lower respiratory tract disease", "PROBLEM", 41, 72], ["viral", "PROBLEM", 90, 95], ["lower", "ANATOMY_MODIFIER", 41, 46], ["respiratory tract", "ANATOMY", 47, 64], ["thought to be", "UNCERTAINTY", 76, 89], ["viral", "OBSERVATION", 90, 95]]], ["Over the last 10 years, advances in molecular detection and genomic amplification have led to the discovery of many new viruses including: human metapneumovirus (hMPV) [9]; human coronaviruses: NL63 [10] and HKU1 [11]; SARS-CoV [12], KI and WU polyomaviruses [13], [14]; and human bocavirus (HBoV) [15].IntroductionHerein we examine a novel respiratory virus, HBoV; a parvovirus first described in 2005 by Allander et al. that has been found to be associated with respiratory tract disease and gastroenteritis in children [15].", [["respiratory tract", "ANATOMY", 464, 481], ["human metapneumovirus", "DISEASE", 139, 160], ["respiratory virus, HBoV", "DISEASE", 341, 364], ["parvovirus", "DISEASE", 368, 378], ["respiratory tract disease", "DISEASE", 464, 489], ["gastroenteritis", "DISEASE", 494, 509], ["human metapneumovirus", "ORGANISM", 139, 160], ["hMPV) [9]", "ORGANISM", 162, 171], ["human", "ORGANISM", 173, 178], ["coronaviruses", "ORGANISM", 179, 192], ["NL63", "GENE_OR_GENE_PRODUCT", 194, 198], ["HKU1 [11", "ORGANISM", 208, 216], ["SARS-CoV", "ORGANISM", 219, 227], ["WU polyomaviruses", "ORGANISM", 241, 258], ["[14]", "ORGANISM", 265, 269], ["human", "ORGANISM", 275, 280], ["bocavirus", "ORGANISM", 281, 290], ["HBoV", "ORGANISM", 292, 296], ["HBoV", "ORGANISM", 360, 364], ["parvovirus", "ORGANISM", 368, 378], ["tract", "ORGANISM_SUBDIVISION", 476, 481], ["children", "ORGANISM", 513, 521], ["human", "SPECIES", 139, 144], ["metapneumovirus", "SPECIES", 145, 160], ["human", "SPECIES", 173, 178], ["human", "SPECIES", 275, 280], ["children", "SPECIES", 513, 521], ["human metapneumovirus", "SPECIES", 139, 160], ["hMPV", "SPECIES", 162, 166], ["human coronaviruses", "SPECIES", 173, 192], ["SARS-CoV", "SPECIES", 219, 227], ["WU polyomaviruses", "SPECIES", 241, 258], ["human", "SPECIES", 275, 280], ["molecular detection", "TEST", 36, 55], ["genomic amplification", "PROBLEM", 60, 81], ["many new viruses", "PROBLEM", 111, 127], ["human metapneumovirus (hMPV)", "TREATMENT", 139, 167], ["HKU1", "TEST", 208, 212], ["SARS", "TEST", 219, 223], ["KI", "TEST", 234, 236], ["WU polyomaviruses", "TEST", 241, 258], ["human bocavirus (HBoV)", "TEST", 275, 297], ["a novel respiratory virus", "PROBLEM", 333, 358], ["HBoV", "PROBLEM", 360, 364], ["a parvovirus", "PROBLEM", 366, 378], ["respiratory tract disease", "PROBLEM", 464, 489], ["gastroenteritis", "PROBLEM", 494, 509], ["found to be associated with", "UNCERTAINTY", 436, 463], ["respiratory tract disease", "OBSERVATION", 464, 489], ["gastroenteritis", "OBSERVATION", 494, 509]]], ["Up to 4 different types of HBoV have been isolated, with HBoV1 infecting primarily respiratory epithelium and HBoV2-4 infecting the gastrointestinal tract [16], [17], [18].", [["respiratory epithelium", "ANATOMY", 83, 105], ["gastrointestinal tract", "ANATOMY", 132, 154], ["HBoV", "ORGANISM", 27, 31], ["HBoV1", "GENE_OR_GENE_PRODUCT", 57, 62], ["epithelium", "TISSUE", 95, 105], ["HBoV2-4", "CELL", 110, 117], ["gastrointestinal tract", "PATHOLOGICAL_FORMATION", 132, 154], ["HBoV", "SPECIES", 27, 31], ["HBoV", "PROBLEM", 27, 31], ["respiratory epithelium", "TEST", 83, 105], ["HBoV2", "TEST", 110, 115], ["HBoV", "OBSERVATION", 27, 31], ["respiratory epithelium", "OBSERVATION", 83, 105], ["gastrointestinal tract", "ANATOMY", 132, 154]]], ["Clinical features associated with the detection of HBoV1 infection include fever, rhinorrhea, cough, wheezing, and gastroenteritis [16], [17], [18], [19], [20].IntroductionIn the United States, HBoV viral DNA was detected by PCR in 5.2% of nasopharyngeal swabs from children in New Haven, CT with respiratory tract disease who tested negative for RSV, influenza A and B virus, parainfluenza viruses 1\u20133, and adenoviruses, and 0% of asymptomatic control subjects, suggesting a possible causal role for the virus in respiratory tract disease [19].", [["nasopharyngeal swabs", "ANATOMY", 240, 260], ["respiratory tract", "ANATOMY", 297, 314], ["respiratory tract", "ANATOMY", 514, 531], ["HBoV1 infection", "DISEASE", 51, 66], ["fever", "DISEASE", 75, 80], ["rhinorrhea", "DISEASE", 82, 92], ["cough", "DISEASE", 94, 99], ["wheezing", "DISEASE", 101, 109], ["gastroenteritis", "DISEASE", 115, 130], ["respiratory tract disease", "DISEASE", 297, 322], ["influenza A", "DISEASE", 352, 363], ["parainfluenza viruses", "DISEASE", 377, 398], ["respiratory tract disease", "DISEASE", 514, 539], ["HBoV1", "GENE_OR_GENE_PRODUCT", 51, 56], ["[17], [18], [19]", "SIMPLE_CHEMICAL", 137, 153], ["HBoV", "ORGANISM", 194, 198], ["DNA", "CELLULAR_COMPONENT", 205, 208], ["nasopharyngeal swabs", "CANCER", 240, 260], ["children", "ORGANISM", 266, 274], ["tract", "ORGANISM_SUBDIVISION", 309, 314], ["RSV", "ORGANISM", 347, 350], ["influenza A and B virus", "ORGANISM", 352, 375], ["parainfluenza viruses 1\u20133", "ORGANISM", 377, 402], ["adenoviruses", "ORGANISM", 408, 420], ["respiratory tract", "ORGANISM", 514, 531], ["HBoV viral DNA", "DNA", 194, 208], ["children", "SPECIES", 266, 274], ["B virus", "SPECIES", 368, 375], ["parainfluenza", "SPECIES", 377, 390], ["HBoV", "SPECIES", 194, 198], ["RSV", "SPECIES", 347, 350], ["influenza A", "SPECIES", 352, 363], ["B virus", "SPECIES", 368, 375], ["HBoV1 infection", "PROBLEM", 51, 66], ["fever", "PROBLEM", 75, 80], ["rhinorrhea", "PROBLEM", 82, 92], ["cough", "PROBLEM", 94, 99], ["wheezing", "PROBLEM", 101, 109], ["gastroenteritis", "PROBLEM", 115, 130], ["HBoV viral DNA", "PROBLEM", 194, 208], ["PCR", "TEST", 225, 228], ["nasopharyngeal swabs", "TREATMENT", 240, 260], ["CT", "TEST", 289, 291], ["respiratory tract disease", "PROBLEM", 297, 322], ["RSV", "PROBLEM", 347, 350], ["influenza", "PROBLEM", 352, 361], ["B virus", "PROBLEM", 368, 375], ["parainfluenza viruses", "PROBLEM", 377, 398], ["adenoviruses", "TREATMENT", 408, 420], ["asymptomatic control subjects", "PROBLEM", 432, 461], ["the virus in respiratory tract disease", "PROBLEM", 501, 539], ["infection", "OBSERVATION", 57, 66], ["respiratory tract", "ANATOMY", 297, 314], ["respiratory tract", "ANATOMY", 514, 531]]], ["An additional seroepidemiology study in New Haven, CT found that >90% of children had antibody to HBoV by the age of 4 years, suggesting exposure to HBoV is nearly universal in early childhood [21].", [["HBoV", "DISEASE", 98, 102], ["HBoV", "DISEASE", 149, 153], ["children", "ORGANISM", 73, 81], ["HBoV", "ORGANISM", 98, 102], ["HBoV", "ORGANISM", 149, 153], ["children", "SPECIES", 73, 81], ["HBoV", "SPECIES", 98, 102], ["HBoV", "SPECIES", 149, 153], ["An additional seroepidemiology study", "TEST", 0, 36], ["CT", "TEST", 51, 53], ["antibody", "PROBLEM", 86, 94], ["HBoV", "PROBLEM", 98, 102], ["HBoV", "PROBLEM", 149, 153], ["HBoV", "OBSERVATION", 149, 153]]], ["Yet, little is known about HBoV in the developing world.IntroductionIn this study we sought to determine whether HBoV infection was present in a Caribbean population, in an attempt to elucidate possible differences in HBoV epidemiology in tropical resource poor settings.", [["HBoV infection", "DISEASE", 113, 127], ["HBoV", "DISEASE", 218, 222], ["HBoV", "ORGANISM", 27, 31], ["HBoV", "ORGANISM", 113, 117], ["HBoV", "ORGANISM", 218, 222], ["HBoV", "SPECIES", 27, 31], ["HBoV", "SPECIES", 113, 117], ["HBoV", "SPECIES", 218, 222], ["HBoV", "PROBLEM", 27, 31], ["this study", "TEST", 71, 81], ["HBoV infection", "PROBLEM", 113, 127], ["infection", "OBSERVATION", 118, 127]]], ["Using a recently developed ELISA for HBoV [21], we examined hospitalized and non-hospitalized children ages 0\u201318 years presenting for care at the University Hospital of the West Indies, in Kingston, Jamaica between June 23 and August 10, 2009.", [["HBoV", "ORGANISM", 37, 41], ["children", "ORGANISM", 94, 102], ["children", "SPECIES", 94, 102], ["HBoV", "SPECIES", 37, 41], ["HBoV", "PROBLEM", 37, 41]]], ["The purpose of the study was to generate estimates of exposure to HBoV in the Caribbean and to compare hospitalized and non-hospitalized children of differing ages in an attempt to identify sub-populations that might be at risk for increased HBoV exposure.Detection of HBoV-specific antibodies in human serum by HBoV Virus Like Particle\u2013based ELISA ::: Materials and MethodsAn ELISA developed by Kahn et al. was used to detect HBoV-specific antibodies, a detailed description of which can be found elsewhere [21].", [["serum", "ANATOMY", 303, 308], ["HBoV", "DISEASE", 66, 70], ["HBoV", "DISEASE", 242, 246], ["HBoV", "ORGANISM", 66, 70], ["children", "ORGANISM", 137, 145], ["HBoV", "ORGANISM", 242, 246], ["HBoV", "ORGANISM", 269, 273], ["human", "ORGANISM", 297, 302], ["serum", "ORGANISM_SUBSTANCE", 303, 308], ["HBoV Virus", "ORGANISM", 312, 322], ["HBoV", "ORGANISM", 427, 431], ["HBoV-specific antibodies", "PROTEIN", 269, 293], ["HBoV-specific antibodies", "PROTEIN", 427, 451], ["children", "SPECIES", 137, 145], ["human", "SPECIES", 297, 302], ["HBoV", "SPECIES", 66, 70], ["HBoV", "SPECIES", 242, 246], ["HBoV", "SPECIES", 269, 273], ["human", "SPECIES", 297, 302], ["HBoV Virus", "SPECIES", 312, 322], ["HBoV", "SPECIES", 427, 431], ["the study", "TEST", 15, 24], ["HBoV", "PROBLEM", 66, 70], ["sub-populations", "PROBLEM", 190, 205], ["increased HBoV exposure", "PROBLEM", 232, 255], ["HBoV", "TEST", 269, 273], ["specific antibodies", "TEST", 274, 293], ["human serum", "TEST", 297, 308], ["MethodsAn ELISA", "TREATMENT", 367, 382], ["HBoV", "PROBLEM", 427, 431], ["increased", "OBSERVATION_MODIFIER", 232, 241], ["HBoV exposure", "OBSERVATION", 242, 255], ["HBoV", "OBSERVATION", 269, 273]]], ["Briefly, the ELISA uses virus like particles (VLPs) composed of the VP2 gene of HBoV.", [["VLPs", "ORGANISM", 46, 50], ["VP2", "GENE_OR_GENE_PRODUCT", 68, 71], ["HBoV", "ORGANISM", 80, 84], ["VP2 gene", "DNA", 68, 76], ["virus like particles (VLPs", "TREATMENT", 24, 50], ["HBoV", "PROBLEM", 80, 84], ["HBoV", "OBSERVATION", 80, 84]]], ["The VLPs created by Kahn et al. have shown high reactivity with human antibodies to HBoV, and therefore are optimal for use in ELISAs.", [["VLPs", "ORGANISM", 4, 8], ["human", "ORGANISM", 64, 69], ["HBoV", "ORGANISM", 84, 88], ["human antibodies", "PROTEIN", 64, 80], ["human", "SPECIES", 64, 69], ["human", "SPECIES", 64, 69], ["HBoV", "SPECIES", 84, 88], ["The VLPs", "TREATMENT", 0, 8], ["high reactivity", "PROBLEM", 43, 58], ["human antibodies", "TREATMENT", 64, 80], ["HBoV", "PROBLEM", 84, 88], ["high reactivity", "OBSERVATION_MODIFIER", 43, 58]]], ["HBoV VLPs were obtained from Dr. Peter Tattersall at Yale University School of Medicine.Detection of HBoV-specific antibodies in human serum by HBoV Virus Like Particle\u2013based ELISA ::: Materials and MethodsThe Kahn et al. ELISA protocol was optimized for use with the given study samples.", [["serum", "ANATOMY", 135, 140], ["HBoV", "ORGANISM", 0, 4], ["HBoV", "ORGANISM", 101, 105], ["human", "ORGANISM", 129, 134], ["serum", "ORGANISM_SUBSTANCE", 135, 140], ["HBoV Virus", "ORGANISM", 144, 154], ["HBoV-specific antibodies", "PROTEIN", 101, 125], ["human", "SPECIES", 129, 134], ["HBoV", "SPECIES", 0, 4], ["HBoV", "SPECIES", 101, 105], ["human", "SPECIES", 129, 134], ["HBoV Virus", "SPECIES", 144, 154], ["HBoV VLPs", "PROBLEM", 0, 9], ["HBoV", "TEST", 101, 105], ["specific antibodies", "TEST", 106, 125], ["human serum", "TEST", 129, 140], ["ELISA protocol", "TREATMENT", 222, 236], ["study samples", "TEST", 274, 287], ["HBoV", "OBSERVATION", 101, 105]]], ["First, samples were run at various dilutions to determine the adequate dilution to use in the assay.", [["samples", "ANATOMY", 7, 14]]], ["A dilution of 1\u223640 was chosen for its optimal reactivity with HBoV VLPs in the given ELISA.", [["HBoV", "ORGANISM", 62, 66], ["HBoV", "SPECIES", 62, 66], ["A dilution", "TEST", 0, 10], ["HBoV VLPs", "TREATMENT", 62, 71]]], ["Next, positive and negative controls were identified and compared to samples with known HBoV infection.", [["samples", "ANATOMY", 69, 76], ["HBoV infection", "DISEASE", 88, 102], ["HBoV", "ORGANISM", 88, 92], ["HBoV", "SPECIES", 88, 92], ["known HBoV infection", "PROBLEM", 82, 102], ["negative", "OBSERVATION", 19, 27], ["HBoV infection", "OBSERVATION", 88, 102]]], ["The identified positive and negative controls were used in each assay.", [["positive", "OBSERVATION_MODIFIER", 15, 23]]], ["Finally, all 287 samples were run at a 1\u223640 dilution and read on an optical reader at an optical density of 450 nm.Detection of HBoV-specific antibodies in human serum by HBoV Virus Like Particle\u2013based ELISA ::: Materials and MethodsIn order to determine a cut-off point to classify samples as seropositive or seronegative all OD450 ELISA values were taken and operationally separated into 2 groups by means of a cutoff of 0.150, as previously published by Kahn et al.[21] Next, the mean and standard deviation of all values OD450<0.150 were calculated.", [["samples", "ANATOMY", 17, 24], ["serum", "ANATOMY", 162, 167], ["samples", "ANATOMY", 283, 290], ["HBoV", "ORGANISM", 128, 132], ["human", "ORGANISM", 156, 161], ["serum", "ORGANISM_SUBSTANCE", 162, 167], ["HBoV Virus", "ORGANISM", 171, 181], ["HBoV-specific antibodies", "PROTEIN", 128, 152], ["human", "SPECIES", 156, 161], ["HBoV", "SPECIES", 128, 132], ["human", "SPECIES", 156, 161], ["HBoV Virus", "SPECIES", 171, 181], ["HBoV", "TEST", 128, 132], ["specific antibodies", "TEST", 133, 152], ["human serum", "TEST", 156, 167], ["Methods", "TREATMENT", 226, 233], ["seropositive or seronegative", "PROBLEM", 294, 322], ["ELISA values", "TEST", 333, 345], ["the mean", "TEST", 479, 487], ["450 nm", "OBSERVATION_MODIFIER", 108, 114], ["HBoV", "OBSERVATION", 128, 132]]], ["The cut off point to classify samples as seropositive or seronegative was calculated as the mean of all OD450<0.150 plus three standard deviations.", [["samples", "ANATOMY", 30, 37], ["samples", "CANCER", 30, 37], ["seropositive or seronegative", "PROBLEM", 41, 69]]], ["For this calculation, negative OD450 values were set to zero.", [["OD450", "DNA", 31, 36], ["this calculation", "TEST", 4, 20]]], ["Based on these calculations, a serum specimen negative for HBoV was defined as having an OD450\u22640.234 (at dilution of 1\u223640).Statistical Analysis ::: Materials and MethodsData were analyzed with the use of SPSS 18.0.", [["serum specimen", "ANATOMY", 31, 45], ["serum", "ORGANISM_SUBSTANCE", 31, 36], ["HBoV", "ORGANISM", 59, 63], ["HBoV", "SPECIES", 59, 63], ["these calculations", "TEST", 9, 27], ["a serum specimen", "TEST", 29, 45], ["HBoV", "PROBLEM", 59, 63], ["MethodsData", "TEST", 162, 173], ["SPSS", "TEST", 204, 208]]], ["Standard errors for proportions were calculated using standard statistical analysis.", [["standard statistical analysis", "TEST", 54, 83]]], ["Subjects with and without serologic evidence of past HBoV infection were compared with respect to hospitalization status and age group using chi-squared tests for categorical variables and t-tests for continuous variables.", [["HBoV infection", "DISEASE", 53, 67], ["Subjects", "ORGANISM", 0, 8], ["HBoV", "ORGANISM", 53, 57], ["HBoV", "SPECIES", 53, 57], ["past HBoV infection", "PROBLEM", 48, 67], ["chi-squared tests", "TEST", 141, 158], ["categorical variables", "TEST", 163, 184], ["t-tests", "TEST", 189, 196], ["continuous variables", "PROBLEM", 201, 221], ["infection", "OBSERVATION", 58, 67]]], ["Multivariate logistic regression was used to determine significance in a final model.", [["Multivariate logistic regression", "PROBLEM", 0, 32]]], ["For all tests, a two-tailed critical alpha of 0.05 defined statistical significance.Results287 blood samples were collected from pediatric patients aged 0\u201318 years at the University Hospital of the West Indies in Kingston, Jamaica.", [["blood samples", "ANATOMY", 95, 108], ["blood samples", "ORGANISM_SUBSTANCE", 95, 108], ["patients", "ORGANISM", 139, 147], ["patients", "SPECIES", 139, 147], ["all tests", "TEST", 4, 13], ["blood samples", "TEST", 95, 108]]], ["The patients had a mean age of 50.13\u00b150.96 months (range of 0\u2013236 months).", [["patients", "ORGANISM", 4, 12], ["patients", "SPECIES", 4, 12]]], ["134 (46.7%) of the children were male and 153 (53.3%) were female.ResultsOverall, 220 (76.7%) of the 287 serum specimens were seropositive for HBoV antibody.", [["serum specimens", "ANATOMY", 105, 120], ["children", "ORGANISM", 19, 27], ["serum", "ORGANISM_SUBSTANCE", 105, 110], ["specimens", "CANCER", 111, 120], ["HBoV", "ORGANISM", 143, 147], ["HBoV antibody", "PROTEIN", 143, 156], ["children", "SPECIES", 19, 27], ["HBoV", "SPECIES", 143, 147], ["ResultsOverall", "TEST", 66, 80], ["serum specimens", "TEST", 105, 120], ["HBoV antibody", "TEST", 143, 156]]], ["Proportion of seropositivity varied by age group (Figure 1).", [["seropositivity", "PROBLEM", 14, 28], ["seropositivity", "OBSERVATION", 14, 28]]], ["Although 80% of newborns at birth were seropositive for HBoV, this proportion decreased to 50% by six months of age.", [["HBoV", "DISEASE", 56, 60], ["newborns", "ORGANISM", 16, 24], ["HBoV", "ORGANISM", 56, 60], ["HBoV", "SPECIES", 56, 60], ["HBoV", "PROBLEM", 56, 60]]], ["After six months of age the proportion of seropositive subjects rapidly rebounded, so that by the age of 24 months >80% of children were seropositive.", [["children", "ORGANISM", 123, 131], ["children", "SPECIES", 123, 131], ["seropositive subjects", "PROBLEM", 42, 63], ["seropositive", "PROBLEM", 137, 149], ["seropositive", "OBSERVATION", 42, 54], ["rapidly", "OBSERVATION_MODIFIER", 64, 71], ["rebounded", "OBSERVATION_MODIFIER", 72, 81]]], ["Age was a significant predictor of HBoV exposure in all children (P<0.001), with HBoV seropositive children being older (average age 30.3\u00b117.3 months) than HBoV seronegative children (average age 17.8\u00b112.7 months)ResultsIn order to determine if hospitalization was associated with HBoV exposure we characterized sub-groups of 84 hospitalized children from the inpatient pediatrics wards and compared them to 118 non-hospitalized children from the well child clinics (all of whom had never previously been hospitalized).", [["HBoV seronegative", "DISEASE", 156, 173], ["HBoV", "ORGANISM", 35, 39], ["children", "ORGANISM", 56, 64], ["HBoV", "ORGANISM", 81, 85], ["children", "ORGANISM", 99, 107], ["HBoV", "ORGANISM", 156, 160], ["children", "ORGANISM", 174, 182], ["HBoV", "ORGANISM", 281, 285], ["children", "ORGANISM", 342, 350], ["children", "ORGANISM", 429, 437], ["children", "SPECIES", 56, 64], ["children", "SPECIES", 99, 107], ["children", "SPECIES", 174, 182], ["children", "SPECIES", 342, 350], ["children", "SPECIES", 429, 437], ["HBoV", "SPECIES", 35, 39], ["HBoV", "SPECIES", 281, 285], ["HBoV exposure", "PROBLEM", 35, 48], ["HBoV exposure", "PROBLEM", 281, 294], ["HBoV exposure", "OBSERVATION", 35, 48]]], ["For these comparisons all children from the sub-specialty clinics, neonatal intensive care, pediatric trauma, and special care were excluded on the basis of our inability to determine their previous hospitalization history; and all neonates (<1 month) were also excluded under the premise that a majority of positive values in this age group would represent maternal antibody, not previous HBoV exposure.ResultsHospitalization proved to be significantly associated with HBoV exposure with 71/84 (84.5%) hospitalized children versus 79/118 (66.9%) of non-hospitalized children testing seropositive to HBoV (P=0.005).", [["trauma", "DISEASE", 102, 108], ["HBoV", "DISEASE", 600, 604], ["children", "ORGANISM", 26, 34], ["neonates", "ORGANISM", 232, 240], ["HBoV", "ORGANISM", 390, 394], ["HBoV", "ORGANISM", 470, 474], ["children", "ORGANISM", 516, 524], ["children", "ORGANISM", 567, 575], ["HBoV", "ORGANISM", 600, 604], ["maternal antibody", "PROTEIN", 358, 375], ["children", "SPECIES", 26, 34], ["children", "SPECIES", 516, 524], ["children", "SPECIES", 567, 575], ["HBoV", "SPECIES", 390, 394], ["HBoV", "SPECIES", 470, 474], ["HBoV", "SPECIES", 600, 604], ["positive values", "PROBLEM", 308, 323], ["maternal antibody", "PROBLEM", 358, 375], ["previous HBoV exposure", "PROBLEM", 381, 403], ["HBoV exposure", "PROBLEM", 470, 483], ["HBoV", "TEST", 600, 604], ["HBoV exposure", "OBSERVATION", 390, 403], ["HBoV", "OBSERVATION", 470, 474]]], ["However, hospitalized children were significantly older with an average age of 53.2\u00b140.7 months versus 26.2\u00b116.9 months for non-hospitalized children (P<0.001).", [["children", "ORGANISM", 22, 30], ["children", "ORGANISM", 141, 149], ["children", "SPECIES", 22, 30], ["children", "SPECIES", 141, 149]]], ["In a multivariate analysis the age of the subjects proved to be the only statistically significant finding.DiscussionSeroepidemiology studies have been conducted in many developed countries to screen for the presence of HBoV, and the virus appears to have a worldwide distribution [19], [24], [25], [26], [27], [28].", [["HBoV", "ORGANISM", 220, 224], ["[25]", "SIMPLE_CHEMICAL", 293, 297], ["HBoV", "SPECIES", 220, 224], ["a multivariate analysis", "TEST", 3, 26], ["Seroepidemiology studies", "TEST", 117, 141], ["HBoV", "PROBLEM", 220, 224], ["the virus", "PROBLEM", 230, 239], ["HBoV", "OBSERVATION", 220, 224]]], ["To date there are very few reports on HBoV from the developing world [29], [30].", [["HBoV", "ORGANISM", 38, 42], ["HBoV", "PROBLEM", 38, 42]]], ["This study is the first seroepidemiology study to show that HBoV antibodies are present in a Caribbean population, with findings that greater than 80% of Jamaican children are exposed to HBoV by the age of 24 months.DiscussionThe seroepidemiology findings show a high rate of HBoV antibody in the first month of life, with a decline to a nadir around 6 months and a rebound in seropositivity around 24 months.", [["HBoV", "DISEASE", 187, 191], ["HBoV", "ORGANISM", 60, 64], ["Jamaican", "ORGANISM", 154, 162], ["children", "ORGANISM", 163, 171], ["HBoV", "ORGANISM", 187, 191], ["HBoV", "ORGANISM", 276, 280], ["HBoV antibodies", "PROTEIN", 60, 75], ["HBoV antibody", "PROTEIN", 276, 289], ["children", "SPECIES", 163, 171], ["HBoV", "SPECIES", 60, 64], ["HBoV", "SPECIES", 187, 191], ["HBoV", "SPECIES", 276, 280], ["This study", "TEST", 0, 10], ["the first seroepidemiology study", "TEST", 14, 46], ["HBoV antibodies", "PROBLEM", 60, 75], ["HBoV", "PROBLEM", 187, 191], ["The seroepidemiology findings", "TEST", 226, 255], ["a high rate of HBoV antibody", "PROBLEM", 261, 289], ["a rebound in seropositivity", "PROBLEM", 364, 391], ["HBoV antibody", "OBSERVATION", 276, 289], ["rebound", "OBSERVATION_MODIFIER", 366, 373]]], ["The decline of antibody in infants less than 6 months of age represents waning maternally acquired antibody, as observed in other respiratory viruses such as RSV and human metapneumovirus [31].", [["infants", "ORGANISM", 27, 34], ["RSV", "ORGANISM", 158, 161], ["human metapneumovirus", "ORGANISM", 166, 187], ["infants", "SPECIES", 27, 34], ["RSV", "SPECIES", 158, 161], ["human", "SPECIES", 166, 171], ["metapneumovirus", "SPECIES", 172, 187], ["RSV", "SPECIES", 158, 161], ["human metapneumovirus", "SPECIES", 166, 187], ["The decline of antibody", "PROBLEM", 0, 23], ["waning maternally acquired antibody", "PROBLEM", 72, 107], ["other respiratory viruses", "PROBLEM", 124, 149], ["RSV", "PROBLEM", 158, 161], ["human metapneumovirus", "PROBLEM", 166, 187], ["decline", "OBSERVATION_MODIFIER", 4, 11], ["respiratory viruses", "OBSERVATION", 130, 149]]], ["This decline overlaps with exposure to HBoV during infancy and early childhood.DiscussionAge was the sole predictor associated with the presence of HBoV antibody in the study population.", [["HBoV", "DISEASE", 39, 43], ["HBoV", "ORGANISM", 39, 43], ["HBoV", "ORGANISM", 148, 152], ["HBoV antibody", "PROTEIN", 148, 161], ["HBoV", "SPECIES", 39, 43], ["HBoV", "SPECIES", 148, 152], ["HBoV", "PROBLEM", 39, 43], ["HBoV antibody", "PROBLEM", 148, 161], ["HBoV", "OBSERVATION", 39, 43], ["HBoV antibody", "OBSERVATION", 148, 161]]], ["HBoV exposure is common in the population and therefore children have increasing likelihood of exposure as their age increases.", [["HBoV", "DISEASE", 0, 4], ["HBoV", "ORGANISM", 0, 4], ["children", "ORGANISM", 56, 64], ["children", "SPECIES", 56, 64], ["HBoV exposure", "PROBLEM", 0, 13]]], ["We enrolled both healthy and hospitalized children in an effort to both characterize the difference between exposure in these populations and to adequately estimate HBoV seroepidemiology in the overall population.", [["children", "ORGANISM", 42, 50], ["HBoV", "ORGANISM", 165, 169], ["children", "SPECIES", 42, 50], ["HBoV", "SPECIES", 165, 169]]], ["Since HBoV seroepidemiology in subspecialty clinics or hospitalized patients may not be representative of an overall seropositivity rate of the population, we enrolled healthy children in a prospective manner.", [["HBoV", "ORGANISM", 6, 10], ["patients", "ORGANISM", 68, 76], ["children", "ORGANISM", 176, 184], ["patients", "SPECIES", 68, 76], ["children", "SPECIES", 176, 184], ["HBoV", "SPECIES", 6, 10]]], ["While seroepidemiology in healthy vs hospitalized children was different, with more hospitalized children being exposed to HBoV than healthy children, this was found to be directly related to the age of the populations.", [["HBoV", "DISEASE", 123, 127], ["children", "ORGANISM", 50, 58], ["children", "ORGANISM", 97, 105], ["HBoV", "ORGANISM", 123, 127], ["children", "ORGANISM", 141, 149], ["children", "SPECIES", 50, 58], ["children", "SPECIES", 97, 105], ["children", "SPECIES", 141, 149], ["HBoV", "SPECIES", 123, 127]]], ["Therefore, since the difference in the hospitalized and healthy children was due to age we feel comfortable in including all the children in the study in the overall estimation of the seroepidemiolgoy of the population.DiscussionWhile HBoV seroepidemiology and prevalence studies have shown evidence for widespread exposure to the virus, the causative role of HBoV in respiratory tract disease is still under investigation.", [["respiratory tract", "ANATOMY", 368, 385], ["HBoV", "DISEASE", 360, 364], ["respiratory tract disease", "DISEASE", 368, 393], ["children", "ORGANISM", 64, 72], ["children", "ORGANISM", 129, 137], ["HBoV", "ORGANISM", 360, 364], ["respiratory tract", "ORGANISM_SUBDIVISION", 368, 385], ["children", "SPECIES", 64, 72], ["children", "SPECIES", 129, 137], ["HBoV", "SPECIES", 360, 364], ["the study", "TEST", 141, 150], ["HBoV seroepidemiology", "TEST", 235, 256], ["prevalence studies", "TEST", 261, 279], ["the virus", "PROBLEM", 327, 336], ["HBoV in respiratory tract disease", "PROBLEM", 360, 393], ["HBoV", "OBSERVATION", 360, 364], ["respiratory tract", "ANATOMY", 368, 385]]], ["Definitive evidence is difficult to obtain without an in vitro culture system and animal model.", [["an in vitro culture system", "TEST", 51, 77]]], ["While there has been one recent successful report of propagation of HBoV in cell culture, this technique has proven difficult to replicate [32].", [["cell culture", "ANATOMY", 76, 88], ["HBoV", "DISEASE", 68, 72], ["HBoV", "ORGANISM", 68, 72], ["cell", "CELL", 76, 80], ["HBoV", "SPECIES", 68, 72], ["HBoV in cell culture", "PROBLEM", 68, 88], ["this technique", "TREATMENT", 90, 104], ["HBoV", "OBSERVATION", 68, 72]]], ["In the absence of definitive evidence, comparative studies have been used to suggest a causative role of HBoV in acute infection.", [["HBoV", "DISEASE", 105, 109], ["acute infection", "DISEASE", 113, 128], ["HBoV", "ORGANISM", 105, 109], ["HBoV", "SPECIES", 105, 109], ["comparative studies", "TEST", 39, 58], ["HBoV", "PROBLEM", 105, 109], ["acute infection", "PROBLEM", 113, 128], ["HBoV", "OBSERVATION", 105, 109], ["acute", "OBSERVATION_MODIFIER", 113, 118], ["infection", "OBSERVATION", 119, 128]]], ["However, these studies are complicated by the fact that HBoV is often co-detected with other respiratory viruses, which makes it difficult to draw conclusions about its pathogenicity.DiscussionOne study by Allander et al. showed that 5% of symptomatic patients with acute wheezing tested positive for HBoV DNA by PCR in the absence of 12 other viruses known to cause respiratory disease [33].", [["respiratory", "ANATOMY", 367, 378], ["HBoV", "DISEASE", 56, 60], ["respiratory viruses", "DISEASE", 93, 112], ["wheezing", "DISEASE", 272, 280], ["respiratory disease", "DISEASE", 367, 386], ["HBoV", "ORGANISM", 56, 60], ["patients", "ORGANISM", 252, 260], ["HBoV", "ORGANISM", 301, 305], ["DNA", "CELLULAR_COMPONENT", 306, 309], ["HBoV DNA", "DNA", 301, 309], ["patients", "SPECIES", 252, 260], ["HBoV", "SPECIES", 56, 60], ["HBoV", "SPECIES", 301, 305], ["these studies", "TEST", 9, 22], ["HBoV", "PROBLEM", 56, 60], ["other respiratory viruses", "PROBLEM", 87, 112], ["acute wheezing", "PROBLEM", 266, 280], ["HBoV DNA", "PROBLEM", 301, 309], ["PCR", "TEST", 313, 316], ["12 other viruses", "PROBLEM", 335, 351], ["respiratory disease", "PROBLEM", 367, 386], ["HBoV", "OBSERVATION", 56, 60], ["respiratory viruses", "OBSERVATION", 93, 112], ["acute", "OBSERVATION_MODIFIER", 266, 271], ["wheezing", "OBSERVATION", 272, 280], ["respiratory disease", "OBSERVATION", 367, 386]]], ["This suggests a possible causative role for HBoV in acute wheezing.", [["HBoV", "DISEASE", 44, 48], ["wheezing", "DISEASE", 58, 66], ["HBoV", "ORGANISM", 44, 48], ["HBoV", "SPECIES", 44, 48], ["HBoV", "PROBLEM", 44, 48], ["acute wheezing", "PROBLEM", 52, 66], ["suggests a possible", "UNCERTAINTY", 5, 24], ["HBoV", "OBSERVATION", 44, 48], ["acute", "OBSERVATION_MODIFIER", 52, 57], ["wheezing", "OBSERVATION", 58, 66]]], ["Three other studies, by Kesebir, Fry and Maggi, have also tried to address whether HBoV infection was associated with respiratory tract symptoms.", [["respiratory tract", "ANATOMY", 118, 135], ["HBoV infection", "DISEASE", 83, 97], ["respiratory tract symptoms", "DISEASE", 118, 144], ["HBoV", "ORGANISM", 83, 87], ["respiratory tract", "ORGANISM_SUBDIVISION", 118, 135], ["HBoV", "SPECIES", 83, 87], ["Three other studies", "TEST", 0, 19], ["HBoV infection", "PROBLEM", 83, 97], ["respiratory tract symptoms", "PROBLEM", 118, 144], ["infection", "OBSERVATION", 88, 97]]], ["These studies reported that HBoV DNA was more frequently found in patients with acute respiratory tract symptoms than asymptomatic controls [19], [30], [34].DiscussionLimitations of our study included lack of serial sampling, lack of detection of viral DNA by PCR, and our inability to verify our ELISA findings with a neutralization assay.", [["respiratory tract", "ANATOMY", 86, 103], ["acute respiratory tract symptoms", "DISEASE", 80, 112], ["HBoV", "ORGANISM", 28, 32], ["DNA", "CELLULAR_COMPONENT", 33, 36], ["patients", "ORGANISM", 66, 74], ["tract", "ORGANISM_SUBDIVISION", 98, 103], ["DNA", "CELLULAR_COMPONENT", 253, 256], ["HBoV DNA", "DNA", 28, 36], ["viral DNA", "DNA", 247, 256], ["patients", "SPECIES", 66, 74], ["HBoV", "SPECIES", 28, 32], ["These studies", "TEST", 0, 13], ["HBoV DNA", "PROBLEM", 28, 36], ["acute respiratory tract symptoms", "PROBLEM", 80, 112], ["asymptomatic controls", "PROBLEM", 118, 139], ["our study", "TEST", 182, 191], ["serial sampling", "TEST", 209, 224], ["viral DNA", "PROBLEM", 247, 256], ["PCR", "TEST", 260, 263], ["a neutralization assay", "TEST", 317, 339], ["acute", "OBSERVATION_MODIFIER", 80, 85], ["respiratory tract", "ANATOMY", 86, 103]]], ["Currently, one of the major obstacles to studying the epidemiology and biology of HBoV is the lack of reagents, specifically infectious virus and monospecific anti-HBoV antibodies [32].", [["HBoV", "DISEASE", 82, 86], ["HBoV", "ORGANISM", 82, 86], ["infectious virus", "ORGANISM", 125, 141], ["monospecific anti-HBoV antibodies", "PROTEIN", 146, 179], ["HBoV", "SPECIES", 82, 86], ["anti-HBoV", "SPECIES", 159, 168], ["HBoV", "PROBLEM", 82, 86], ["infectious virus", "PROBLEM", 125, 141], ["monospecific anti-HBoV antibodies", "TEST", 146, 179]]], ["Therefore, we were unable to verify our ELISA with a neutralization assay.", [["a neutralization assay", "TEST", 51, 73]]], ["Instead, we used accepted statistical methods for correct cut-off values in ELISAs [21].", [["statistical methods", "TREATMENT", 26, 45], ["ELISAs", "TEST", 76, 82]]], ["Regrettably, our study was performed prior to the discovery that HBoV has specific subtypes.", [["HBoV", "DISEASE", 65, 69], ["HBoV", "ORGANISM", 65, 69], ["HBoV", "SPECIES", 65, 69], ["our study", "TEST", 13, 22], ["HBoV", "PROBLEM", 65, 69]]], ["The ELISA used is not specific to individual HBoV subtypes but rather to HBoV-specific antibodies in general, making the findings not a statement specifically on HBoV1, but of all HBoV subtypes.DiscussionIn conclusion, this is the first study of HBoV seroepidemiology in a Caribbean population.", [["HBoV seroepidemiology", "DISEASE", 246, 267], ["HBoV", "ORGANISM", 45, 49], ["HBoV", "ORGANISM", 73, 77], ["HBoV1", "GENE_OR_GENE_PRODUCT", 162, 167], ["HBoV", "ORGANISM", 180, 184], ["HBoV", "ORGANISM", 246, 250], ["HBoV-specific antibodies", "PROTEIN", 73, 97], ["HBoV", "SPECIES", 45, 49], ["HBoV", "SPECIES", 73, 77], ["HBoV", "SPECIES", 246, 250], ["individual HBoV subtypes", "PROBLEM", 34, 58], ["HBoV", "TEST", 73, 77], ["all HBoV subtypes", "PROBLEM", 176, 193], ["HBoV subtypes", "OBSERVATION", 180, 193]]], ["We showed that HBoV is a common virus infecting children within the first few years of life.", [["HBoV", "DISEASE", 15, 19], ["HBoV", "ORGANISM", 15, 19], ["children", "ORGANISM", 48, 56], ["children", "SPECIES", 48, 56], ["HBoV", "SPECIES", 15, 19], ["HBoV", "PROBLEM", 15, 19], ["HBoV", "OBSERVATION", 15, 19]]], ["Our findings of HBoV seroepidemiology in Jamaica are similar to reports from other areas of the world, reinforcing the notion that HBoV has a worldwide distribution.", [["HBoV", "DISEASE", 131, 135], ["HBoV", "ORGANISM", 16, 20], ["HBoV", "ORGANISM", 131, 135], ["HBoV", "SPECIES", 16, 20], ["HBoV", "SPECIES", 131, 135], ["HBoV seroepidemiology", "PROBLEM", 16, 37], ["HBoV", "PROBLEM", 131, 135], ["HBoV", "OBSERVATION", 16, 20], ["HBoV", "OBSERVATION", 131, 135]]]], "PMC7118627": [["PreventionAccording to clinical manifestations of patients who infected with COVID-19, it can be classified as \u201cwet, heat, congestion\u201d, in their lungs.", [["lungs", "ANATOMY", 145, 150], ["COVID-19", "CHEMICAL", 77, 85], ["congestion", "DISEASE", 123, 133], ["COVID-19", "CHEMICAL", 77, 85], ["patients", "ORGANISM", 50, 58], ["lungs", "ORGAN", 145, 150], ["patients", "SPECIES", 50, 58], ["COVID", "TREATMENT", 77, 82], ["congestion", "PROBLEM", 123, 133], ["congestion", "OBSERVATION", 123, 133], ["lungs", "ANATOMY", 145, 150]]], ["In Traditional Chinese Medicine, we believe that lungs are delicate, so the disease first affects lungs\u2019 function.Prevention\u201cWet\u201d refers to the factor with sticky and heavy turbidity that can cause a long course of disease and damage the function of the body.", [["lungs", "ANATOMY", 49, 54], ["lungs", "ANATOMY", 98, 103], ["body", "ANATOMY", 254, 258], ["lungs", "ORGAN", 49, 54], ["lungs", "ORGAN", 98, 103], ["body", "ORGANISM_SUBDIVISION", 254, 258], ["the disease", "PROBLEM", 72, 83], ["sticky and heavy turbidity", "PROBLEM", 156, 182], ["disease", "PROBLEM", 215, 222], ["lungs", "ANATOMY", 49, 54], ["disease", "OBSERVATION", 76, 83], ["lungs", "ANATOMY", 98, 103], ["body", "ANATOMY", 254, 258]]], ["\u201cHot\u201d refers to the factor with hot, dry, and rising turbidity that can cause disease.", [["rising turbidity", "PROBLEM", 46, 62], ["disease", "PROBLEM", 78, 85]]], ["\u201cCongestion\u201d is a causative factor that can congest blood circulation and cause symptoms such as pain.PreventionTraditional Chinese medicine believes that Qi is the basic substance that constitutes the human body and maintains basic functions.", [["blood", "ANATOMY", 52, 57], ["body", "ANATOMY", 208, 212], ["pain", "DISEASE", 97, 101], ["blood", "ORGANISM_SUBSTANCE", 52, 57], ["human", "ORGANISM", 202, 207], ["body", "ORGANISM_SUBDIVISION", 208, 212], ["human", "SPECIES", 202, 207], ["human", "SPECIES", 202, 207], ["Congestion", "PROBLEM", 1, 11], ["a causative factor", "PROBLEM", 16, 34], ["blood circulation", "PROBLEM", 52, 69], ["symptoms", "PROBLEM", 80, 88], ["pain", "PROBLEM", 97, 101], ["Congestion", "OBSERVATION", 1, 11]]], ["We divide Qi into the healthy Qi and the pathogenic Qi.", [["Qi", "PROTEIN", 10, 12]]], ["The healthy Qi refers to substances that maintain the normal operation of our body.", [["body", "ANATOMY", 78, 82], ["body", "ORGANISM_SUBDIVISION", 78, 82], ["body", "ANATOMY", 78, 82]]], ["The pathogenic Qi refers to substances that can harm the health of our body.PreventionTherefore, the aim of preventive treatment of TCM is to protect lungs.", [["body", "ANATOMY", 71, 75], ["lungs", "ANATOMY", 150, 155], ["TCM", "CHEMICAL", 132, 135], ["body", "ORGANISM_SUBDIVISION", 71, 75], ["lungs", "ORGAN", 150, 155], ["preventive treatment of TCM", "TREATMENT", 108, 135], ["lungs", "ANATOMY", 150, 155]]], ["Yupingfeng San, a kind of preventative patent medicine, is chosen because of the nature of the lungs' diseases, listed in Table 1.", [["lungs", "ANATOMY", 95, 100], ["lungs' diseases", "DISEASE", 95, 110], ["lungs", "ORGAN", 95, 100], ["preventative patent medicine", "TREATMENT", 26, 54], ["the lungs' diseases", "PROBLEM", 91, 110], ["patent", "OBSERVATION", 39, 45], ["lungs", "ANATOMY", 95, 100]]], ["Yupingfeng San is an ancient herbal medicine in TCM and used to protect lung Qi and avoid pathogenic Qi.", [["lung", "ANATOMY", 72, 76], ["lung", "ORGAN", 72, 76], ["an ancient herbal medicine", "TREATMENT", 18, 44], ["lung", "ANATOMY", 72, 76]]], ["In this medicine, there are three herbs: Astragalus, Fangfeng and Atractylodes.", [["Astragalus", "TREATMENT", 41, 51], ["Atractylodes", "TREATMENT", 66, 78], ["Astragalus", "ANATOMY", 41, 51], ["Atractylodes", "OBSERVATION", 66, 78]]], ["Astragalus can improve lung Qi and can reduce phlegm.", [["lung", "ANATOMY", 23, 27], ["Astragalus", "CHEMICAL", 0, 10], ["phlegm", "DISEASE", 46, 52], ["Astragalus", "SIMPLE_CHEMICAL", 0, 10], ["lung", "ORGAN", 23, 27], ["phlegm", "PROBLEM", 46, 52], ["lung", "ANATOMY", 23, 27], ["Qi", "OBSERVATION", 28, 30], ["phlegm", "OBSERVATION", 46, 52]]], ["Fangfeng can relieve the pathogenic Qi, remove dampness and relieve pain.", [["Fangfeng", "CHEMICAL", 0, 8], ["pain", "DISEASE", 68, 72], ["Fangfeng", "SIMPLE_CHEMICAL", 0, 8], ["Fangfeng", "TREATMENT", 0, 8], ["the pathogenic Qi", "PROBLEM", 21, 38], ["dampness", "PROBLEM", 47, 55], ["pain", "PROBLEM", 68, 72]]], ["Atractylodes enhances the spleen Qi, which can affect our digestion and absorption.", [["spleen", "ANATOMY", 26, 32], ["Atractylodes", "CHEMICAL", 0, 12], ["Atractylodes", "SIMPLE_CHEMICAL", 0, 12], ["spleen", "ORGAN", 26, 32], ["Atractylodes", "TREATMENT", 0, 12], ["spleen", "ANATOMY", 26, 32]]], ["Previous studies has shown that Yupingfeng San could regulate the body's immune function.PreventionThese medicinal herbs should be mixed and boiled together with 1000ml pure water for about 15 minutes after boiling to get about 600ml tincture.", [["body", "ANATOMY", 66, 70], ["body", "ORGANISM_SUBDIVISION", 66, 70], ["Previous studies", "TEST", 0, 16], ["These medicinal herbs", "TREATMENT", 99, 120]]], ["Each tincture may be subdivided into three doses and taken orally 200ml once, three times a day.Treatment of mild infectionPatients with mild infection often has fever, sweat, headache, thirst, cough, sore throat, red tongue tip, thin white or pale yellow coating and floating pulse.", [["sweat", "ANATOMY", 169, 174], ["tongue", "ANATOMY", 218, 224], ["infection", "DISEASE", 114, 123], ["infection", "DISEASE", 142, 151], ["fever", "DISEASE", 162, 167], ["headache", "DISEASE", 176, 184], ["thirst", "DISEASE", 186, 192], ["cough", "DISEASE", 194, 199], ["sore throat", "DISEASE", 201, 212], ["Patients", "ORGANISM", 123, 131], ["sweat", "ORGANISM_SUBDIVISION", 169, 174], ["throat", "ORGANISM_SUBDIVISION", 206, 212], ["tongue", "ORGANISM_SUBDIVISION", 218, 224], ["Patients", "SPECIES", 123, 131], ["Each tincture", "TREATMENT", 0, 13], ["mild infection", "PROBLEM", 109, 123], ["mild infection", "PROBLEM", 137, 151], ["fever", "PROBLEM", 162, 167], ["sweat", "PROBLEM", 169, 174], ["headache", "PROBLEM", 176, 184], ["thirst", "PROBLEM", 186, 192], ["cough", "PROBLEM", 194, 199], ["sore throat", "PROBLEM", 201, 212], ["red tongue tip", "PROBLEM", 214, 228], ["thin white or pale yellow coating and floating pulse", "PROBLEM", 230, 282], ["mild", "OBSERVATION_MODIFIER", 109, 113], ["infection", "OBSERVATION", 114, 123], ["mild", "OBSERVATION_MODIFIER", 137, 141], ["infection", "OBSERVATION", 142, 151], ["sore throat", "ANATOMY", 201, 212], ["tongue", "ANATOMY", 218, 224], ["tip", "ANATOMY_MODIFIER", 225, 228], ["thin", "OBSERVATION_MODIFIER", 230, 234], ["white", "OBSERVATION_MODIFIER", 235, 240], ["pale", "OBSERVATION_MODIFIER", 244, 248], ["yellow coating", "OBSERVATION", 249, 263], ["floating pulse", "OBSERVATION", 268, 282]]], ["We base on above symptoms to diagnose if a patient is a mild one.", [["patient", "ORGANISM", 43, 50], ["patient", "SPECIES", 43, 50], ["above symptoms", "PROBLEM", 11, 25], ["a mild one", "PROBLEM", 54, 64], ["mild", "OBSERVATION_MODIFIER", 56, 60]]], ["According to theories of Traditional Chinese Medical, pathogenic Qi hurts lung Qi.", [["lung", "ANATOMY", 74, 78], ["lung", "ORGAN", 74, 78], ["lung", "ANATOMY", 74, 78]]], ["If the lung Qi does not work properly, it will cause lung heat and dampness and some typical symptoms, including fever, cough, sore throat and fatigue.", [["lung", "ANATOMY", 7, 11], ["lung", "ANATOMY", 53, 57], ["lung heat and dampness", "DISEASE", 53, 75], ["fever", "DISEASE", 113, 118], ["cough", "DISEASE", 120, 125], ["sore throat", "DISEASE", 127, 138], ["fatigue", "DISEASE", 143, 150], ["lung", "ORGAN", 7, 11], ["lung", "ORGAN", 53, 57], ["lung heat", "PROBLEM", 53, 62], ["dampness", "PROBLEM", 67, 75], ["some typical symptoms", "PROBLEM", 80, 101], ["fever", "PROBLEM", 113, 118], ["cough", "PROBLEM", 120, 125], ["sore throat", "PROBLEM", 127, 138], ["fatigue", "PROBLEM", 143, 150], ["lung", "ANATOMY", 7, 11], ["Qi", "OBSERVATION", 12, 14], ["lung", "ANATOMY", 53, 57], ["dampness", "OBSERVATION", 67, 75], ["cough", "OBSERVATION", 120, 125], ["sore throat", "ANATOMY", 127, 138], ["fatigue", "OBSERVATION", 143, 150]]], ["So we used the method of \u201cclearing lung heat and dampness\u201d to treat it.", [["lung", "ANATOMY", 35, 39], ["lung", "ORGAN", 35, 39], ["the method", "TREATMENT", 11, 21], ["\u201cclearing lung heat", "TREATMENT", 25, 44], ["dampness", "PROBLEM", 49, 57], ["lung", "ANATOMY", 35, 39], ["dampness", "OBSERVATION", 49, 57]]], ["The main function of these two prescriptions is to clear lung heat, expel phlegm, relieve cough, regulate the patient's lungs and restore normal lung function.", [["lung", "ANATOMY", 57, 61], ["lungs", "ANATOMY", 120, 125], ["lung", "ANATOMY", 145, 149], ["phlegm", "DISEASE", 74, 80], ["cough", "DISEASE", 90, 95], ["lung", "ORGAN", 57, 61], ["phlegm", "ORGANISM_SUBDIVISION", 74, 80], ["patient", "ORGANISM", 110, 117], ["lungs", "ORGAN", 120, 125], ["lung", "ORGAN", 145, 149], ["patient", "SPECIES", 110, 117], ["expel phlegm", "PROBLEM", 68, 80], ["cough", "PROBLEM", 90, 95], ["main", "OBSERVATION_MODIFIER", 4, 8], ["lung", "ANATOMY", 57, 61], ["cough", "OBSERVATION", 90, 95], ["lungs", "ANATOMY", 120, 125], ["normal", "OBSERVATION", 138, 144], ["lung", "ANATOMY", 145, 149]]], ["Clinically, we chose Yinqiao san for patients who had high fever and Sangju yin for patients who had severe cough.Treatment of mild infectionThese medicinal herbs should be mixed and boiled together with 1000ml pure water for about 15 minutes after boiling to get about 600ml tincture.", [["fever", "DISEASE", 59, 64], ["cough", "DISEASE", 108, 113], ["infection", "DISEASE", 132, 141], ["patients", "ORGANISM", 37, 45], ["patients", "ORGANISM", 84, 92], ["patients", "SPECIES", 37, 45], ["patients", "SPECIES", 84, 92], ["high fever", "PROBLEM", 54, 64], ["severe cough", "PROBLEM", 101, 113], ["mild infection", "PROBLEM", 127, 141], ["These medicinal herbs", "TREATMENT", 141, 162], ["severe", "OBSERVATION_MODIFIER", 101, 107], ["cough", "OBSERVATION", 108, 113], ["mild", "OBSERVATION_MODIFIER", 127, 131], ["infection", "OBSERVATION", 132, 141]]], ["Each tincture may be subdivided into three doses and taken 200ml orally once, three times a day.Treatment of mild infectionFrom some studies, we found that Yinqiao san may have antibacterial and antiviral functions, and can be used to enhance the immune function of upper respiratory tract [6].", [["upper respiratory tract", "ANATOMY", 266, 289], ["Yinqiao san", "CHEMICAL", 156, 167], ["upper respiratory", "ORGANISM_SUBDIVISION", 266, 283], ["tract", "ORGANISM_SUBDIVISION", 284, 289], ["Each tincture", "TREATMENT", 0, 13], ["mild infectionFrom some studies", "PROBLEM", 109, 140], ["antibacterial and antiviral functions", "PROBLEM", 177, 214], ["mild", "OBSERVATION_MODIFIER", 109, 113], ["antiviral functions", "OBSERVATION", 195, 214], ["upper", "ANATOMY_MODIFIER", 266, 271], ["respiratory tract", "ANATOMY", 272, 289]]], ["These two prescriptions can be used to treat patients with mild infection of COVID-19.Treatment of severe infectionIn the early course of treatment for COVID-19, if the infection cannot be controlled, worse respiratory failure, multiple organ failure, and death will occur, then serious infection should be considered.", [["respiratory", "ANATOMY", 207, 218], ["organ", "ANATOMY", 237, 242], ["infection", "DISEASE", 64, 73], ["infection", "DISEASE", 106, 115], ["infection", "DISEASE", 169, 178], ["respiratory failure", "DISEASE", 207, 226], ["organ failure", "DISEASE", 237, 250], ["death", "DISEASE", 256, 261], ["infection", "DISEASE", 287, 296], ["COVID-19", "CHEMICAL", 77, 85], ["patients", "ORGANISM", 45, 53], ["organ", "ORGAN", 237, 242], ["patients", "SPECIES", 45, 53], ["mild infection of COVID", "PROBLEM", 59, 82], ["severe infection", "PROBLEM", 99, 115], ["treatment", "TREATMENT", 138, 147], ["COVID", "TEST", 152, 157], ["the infection", "PROBLEM", 165, 178], ["worse respiratory failure", "PROBLEM", 201, 226], ["multiple organ failure", "PROBLEM", 228, 250], ["death", "PROBLEM", 256, 261], ["serious infection", "PROBLEM", 279, 296], ["mild", "OBSERVATION_MODIFIER", 59, 63], ["infection", "OBSERVATION", 64, 73], ["severe", "OBSERVATION_MODIFIER", 99, 105], ["infection", "OBSERVATION", 106, 115], ["infection", "OBSERVATION", 169, 178], ["respiratory failure", "OBSERVATION", 207, 226], ["multiple", "OBSERVATION_MODIFIER", 228, 236], ["organ", "ANATOMY", 237, 242], ["failure", "OBSERVATION", 243, 250]]], ["These infectious patients have following main manifestations: high fever, cough, phlegm, difficult breathing, sweating, chest tightness, fatigue, nausea, bloating, red or dark red tongue, yellow coating and slippery or weak pulse.", [["chest", "ANATOMY", 120, 125], ["tongue", "ANATOMY", 180, 186], ["fever", "DISEASE", 67, 72], ["cough", "DISEASE", 74, 79], ["phlegm", "DISEASE", 81, 87], ["sweating", "DISEASE", 110, 118], ["chest tightness", "DISEASE", 120, 135], ["fatigue", "DISEASE", 137, 144], ["nausea", "DISEASE", 146, 152], ["bloating", "DISEASE", 154, 162], ["patients", "ORGANISM", 17, 25], ["tongue", "ORGANISM_SUBDIVISION", 180, 186], ["patients", "SPECIES", 17, 25], ["high fever", "PROBLEM", 62, 72], ["cough", "PROBLEM", 74, 79], ["phlegm", "PROBLEM", 81, 87], ["difficult breathing", "PROBLEM", 89, 108], ["sweating", "PROBLEM", 110, 118], ["chest tightness", "PROBLEM", 120, 135], ["fatigue", "PROBLEM", 137, 144], ["nausea", "PROBLEM", 146, 152], ["bloating", "PROBLEM", 154, 162], ["red or dark red tongue", "PROBLEM", 164, 186], ["yellow coating and slippery or weak pulse", "PROBLEM", 188, 229], ["infectious", "OBSERVATION", 6, 16], ["high", "OBSERVATION_MODIFIER", 62, 66], ["fever", "OBSERVATION", 67, 72], ["phlegm", "ANATOMY", 81, 87], ["chest", "ANATOMY", 120, 125], ["bloating", "OBSERVATION", 154, 162], ["tongue", "ANATOMY", 180, 186], ["yellow coating", "OBSERVATION", 188, 202]]], ["We base on the above symptoms to diagnose if patients are severe ones.Treatment of severe infectionAccording to TCM, if early treatments are not effective, patients are improperly treated, or the pathogenic Qi is too strong, the healthy Qi (especially the lung Qi) will be damaged severely and lungs will not work.", [["lung", "ANATOMY", 256, 260], ["lungs", "ANATOMY", 294, 299], ["TCM", "DISEASE", 112, 115], ["patients", "ORGANISM", 45, 53], ["patients", "ORGANISM", 156, 164], ["lung", "ORGAN", 256, 260], ["lungs", "ORGAN", 294, 299], ["patients", "SPECIES", 45, 53], ["patients", "SPECIES", 156, 164], ["the above symptoms", "PROBLEM", 11, 29], ["severe ones", "PROBLEM", 58, 69], ["severe infectionAccording to TCM", "PROBLEM", 83, 115], ["early treatments", "TREATMENT", 120, 136], ["the pathogenic Qi", "PROBLEM", 192, 209], ["severe", "OBSERVATION_MODIFIER", 58, 64], ["severe", "OBSERVATION_MODIFIER", 83, 89], ["infectionAccording", "OBSERVATION", 90, 108], ["too strong", "OBSERVATION_MODIFIER", 213, 223], ["lung", "ANATOMY", 256, 260], ["lungs", "ANATOMY", 294, 299]]], ["Therefore, more and more sputum will be produced and patients cannot breathe anymore.", [["sputum", "ANATOMY", 25, 31], ["patients", "ORGANISM", 53, 61], ["patients", "SPECIES", 53, 61]]], ["Maxingshigan tang(decoction) and Baihegujin tang are shown in Table 3and could be used to benefit the healthy Qi, expel the pathogenic Qi and help the lung to expel sputum and get air.Treatment of severe infectionThese medicinal herbs should be boiled together with 1000ml pure water for about 30 minutes after boiling to get about 600ml tincture.", [["lung", "ANATOMY", 151, 155], ["sputum", "ANATOMY", 165, 171], ["Maxingshigan tang", "CHEMICAL", 0, 17], ["infection", "DISEASE", 204, 213], ["lung", "ORGAN", 151, 155], ["sputum", "ORGANISM_SUBSTANCE", 165, 171], ["Maxingshigan tang(decoction", "TREATMENT", 0, 27], ["Baihegujin tang", "TREATMENT", 33, 48], ["severe infection", "PROBLEM", 197, 213], ["These medicinal herbs", "TREATMENT", 213, 234], ["lung", "ANATOMY", 151, 155], ["severe", "OBSERVATION_MODIFIER", 197, 203], ["infection", "OBSERVATION", 204, 213]]], ["Each tincture may be subdivided into three doses and taken orally 200ml once, three times a day.Treatment of severe infectionMaxinshigan tang is mainly used to clear lung fever and reduce phlegm.", [["lung", "ANATOMY", 166, 170], ["infection", "DISEASE", 116, 125], ["lung fever", "DISEASE", 166, 176], ["phlegm", "DISEASE", 188, 194], ["lung", "ORGAN", 166, 170], ["Each tincture", "TREATMENT", 0, 13], ["severe infection", "PROBLEM", 109, 125], ["Maxinshigan tang", "TREATMENT", 125, 141], ["clear lung fever", "PROBLEM", 160, 176], ["reduce phlegm", "PROBLEM", 181, 194], ["severe", "OBSERVATION_MODIFIER", 109, 115], ["infection", "OBSERVATION", 116, 125], ["lung", "ANATOMY", 166, 170], ["fever", "OBSERVATION", 171, 176], ["phlegm", "OBSERVATION", 188, 194]]], ["Baihegujin tang can invigorate the lung Qi.", [["lung", "ANATOMY", 35, 39], ["Baihegujin", "CHEMICAL", 0, 10], ["lung", "ORGAN", 35, 39], ["Baihegujin tang", "TREATMENT", 0, 15], ["lung", "ANATOMY", 35, 39]]], ["We should mix the two prescriptions together when severe infection happens to benefit the healthy Qi and expel the pathogenic Qi.DiscussionIn 2003, a lot of descriptions of Traditional Chinese Medicine were used to prevent and treat SARS([7,8]).", [["infection", "DISEASE", 57, 66], ["SARS", "DISEASE", 233, 237], ["severe infection", "PROBLEM", 50, 66], ["Traditional Chinese Medicine", "TREATMENT", 173, 201], ["SARS", "PROBLEM", 233, 237], ["severe", "OBSERVATION_MODIFIER", 50, 56], ["infection", "OBSERVATION", 57, 66]]], ["In 2009, National Administration of Traditional Chinese Medicine of China issued a Traditional Chinese Medicine program for treatment of H1N1 infection [9].", [["H1N1 infection", "DISEASE", 137, 151], ["a Traditional Chinese Medicine program", "TREATMENT", 81, 119], ["H1N1 infection", "PROBLEM", 137, 151], ["H1N1", "OBSERVATION", 137, 141]]], ["Based on these experiences, we believe that Traditional Chinese Medicine is effective for COVID-19, so we use it during the outbreak of COVID-19, and it works very well clinically.DiscussionThere is no effective treatment for COVID-19 until now.", [["Traditional Chinese Medicine", "TREATMENT", 44, 72], ["COVID", "TEST", 90, 95], ["COVID", "TREATMENT", 136, 141], ["COVID", "TEST", 226, 231], ["no effective", "UNCERTAINTY", 199, 211]]], ["However, during the treatment of Covid-19 in China, we found that the intervention of traditional Chinese medicine can reduce the severe symptoms of patients.", [["patients", "ORGANISM", 149, 157], ["patients", "SPECIES", 149, 157], ["Covid", "TEST", 33, 38], ["traditional Chinese medicine", "TREATMENT", 86, 114], ["the severe symptoms", "PROBLEM", 126, 145], ["severe", "OBSERVATION_MODIFIER", 130, 136]]], ["The empirical therapy of Traditional Chinese Medicine is been widely used in Chinese hospitals now, and this therapy might be useful for people all around the world.", [["people", "ORGANISM", 137, 143], ["people", "SPECIES", 137, 143], ["The empirical therapy", "TREATMENT", 0, 21], ["Traditional Chinese Medicine", "TREATMENT", 25, 53], ["this therapy", "TREATMENT", 104, 116]]]]}